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Abstract 
 
Oestrogen receptors (ER) have classically been described as ligand-inducible nuclear 
transcription factors. The pleiotrophic effects of ER function have a predominant role 
in the direct regulation of the growth, differentiation and development of tissues of 
the human reproductive system. There are two ER subtypes, ERα and ERβ which 
differ in their specificity for ligand and the consequent actions they orchestrate. 
Moreover, the latter exists in multiple splice variants of which ERβ is the only fully 
functional homologue. Research into the underlying differences in subtype responses 
to ligand has involved examination of the intranuclear dynamics of individual 
receptor subtypes. Studies into the mobility of ER in response to ligand have 
exclusively focused on studies of full length ERα and ERβ independently in 
transfected cell lines. The studies described in this thesis have investigated the 
kinetics of ER using Fluorescence Recovery After Photobleaching (FRAP) in 
infected cell lines which lends itself to more precise expression of the subtype of 
interest. The morphological impact of natural oestrogenic and synthetic ligands on 
ERs was examined and the influence on the intranuclear dynamics assessed. Further 
to this, the effect of co-expression of different ER subtype combinations was 
examined. 
 
Studies on the intranuclear mobility of ER have confirmed and extended the findings 
of others. Previous work on the development of ER agonists and antagonists has 
been to target specific overexpressing ER subtypes in a physiological setting. In this 
study, we demonstrated for the first time an overwhelming ERβ-selective effect in 
slowing the rate of mobility within the nucleus, suggesting the study of intranuclear 
dynamics is an important parameter for the examination of efficacy of a compound. 
Differential responses to ligand based on co-infected partnerships indicate that 
heterodimerisation has a profound effect in augmenting ligand-dependent regulation 
and activity. 
 
  iv 
Several studies have claimed a dominant functional role for splicing variants of the 
full length ERs. In the current study we have focused on ERβ5, a truncated variant of 
ERβ with impaired ligand-binding capacity. Based on the widespread expression of 
ERβ5 that was determined in the normal endometrium, cell-based assays were 
implemented to explore the mode of activation and function of the ERβ5. To date, 
there have been no published reports on the intranuclear response of ERβ5 to ligand. 
In the current study, the mobility of ERβ5 tagged to yellow fluorescent protein (YFP) 
(ERβ5-YFP) was not influenced by incubation of cells with ligand (17β oestradiol-
E2) independently but co-infection with unlabelled ERα resulted in a decrease in the 
mobility pattern of the ERβ5-YFP protein. Further to this, the co-expression of ERβ5 
and ERα in cells incubated with E2 resulted in enhanced transcriptional activity. The 
induction of an oestrogen response element (ERE)-luciferase reporter resulted in an 
increase in expression of luciferase beyond that in cells infected with ERα alone. 
Taken together, these results suggest a role for ERβ5 as an active dimer partner in 
influencing E2-dependent gene expression in the human endometrium. 
 
While the canonical mode of nuclear receptor activation is ligand-mediated, a role 
for growth factor (GF)-driven tyrosine signalling cascades in the phosphorylation of 
ER has been described as a ligand-independent mechanism of activation. In the 
current study, a direct role for epidermal growth factor (EGF) in mediating 
phosphorylation of ERα was shown. Activation of the extracellular signal-regulated 
kinase (ERK)1/2 mitogen-activated protein kinase (MAPK) pathway was also 
demonstrated in response to EGF treatment, suggesting a likely mechanism through 
which EGF can act to phosphorylate ER. To determine the mechanics of the 
responses to GF within the cell, FRAP analyses revealed an impact of EGF in 
slowing down the mobility of ERα, ERβ, ERβ2 and ERβ5 in a temporal manner. The 
latter results could therefore hold promise for studies into alternative modes of 
activation of truncated splice variants lacking a function ligand-binding domain.  
 
In conclusion, this study has demonstrated important differences in intranuclear 
dynamics and transactivation of ER subtypes and splice variants when independently 
  v 
or co-expressed in response to natural and synthetic compounds. The influence of 
EGF on splice variants with impaired ligand binding function has raised questions 
about an alternative mode of activation of these isoforms and thus, reaffirming a 
functional role for these ERs in human physiology. 
  vi 
Presentations relating to this thesis 
 
Fertility 2009 (Jan 2009, Edinburgh) Short Paper Session: Establishing a role for 
the oestrogen receptor beta 5 (ERβ5) splice variant in human endometrium: potential 
impact on oestrogen signalling. 
  
Simpson Symposium 2008 (Aug 2008, Edinburgh) Poster Session: Expression of 
the oestrogen receptor beta 5 (ERβ5) splice variant in human endometrium. 
 
Society for Reproduction and Fertility (June 2008, Edinburgh) Student Oral 
Communication Prize Session:  Expression of the oestrogen receptor beta 5 (ERβ5) 
splice variant in human endometrium: potential impact on oestrogen signalling. 
 
British Endocrinology Society (Apr 2008, Harrogate, England) Oral 
Communication: Dynamic responses of oestrogen receptors revealed by fluorescent 
recovery after photobleaching (FRAP). 
 
  vii 
Abbreviations 
 
4HT  4’-hydroxy-tamoxifen 
AIB-1  Amplified in breast cancer-1 
AD1  Activation domain 1 
AD2  Activation domain 2 
AF-1  Activation function 1 
AF-2  Activation function 2 
AR  Androgen receptor 
cAMP  Cyclic adenosine monophosphate 
CBP  CREB binding protein 
CDK  Cyclin dependent kinase 
COX-2 Cyclooxygenase-2 
CREB  cAMP response element-binding 
DBD  DNA binding domain 
DNA  Deoxyribonucleic acid 
DPN™ Diarylpropionitrile 
E1  Oestrone 
E2  17β oestradiol 
EGF  Epidermal growth factor 
EGFR  Epidermal growth factor receptor 
eNOS  Endothelial nitric oxide synthase 
ER  Oestrogen receptor 
ERE  Oestrogen response element 
ERK  Extracellular signal-regulated kinase 
ERKO  Oestrogen receptor knockout 
ERα   Oestrogen receptor alpha 
ERβ  Oestrogen receptor beta 
FRAP  Fluorescence recovery after photobleaching 
GRIP  Glucocorticoid receptor interacting protein 1 
GTP  Guanosine-5’-triphosphate 
  viii 
HAT  Histone acetyltransferase 
HDAC  Histone deacetylase 
HER  Human epidermal growth factor receptor 
HRT  Hormone replacement therapy 
hsp  Heat shock protein  
IGF  Insulin-like growth factor 
IGFR  Insulin-like growth factor receptor 
LBD  Ligand binding domain 
MAPK  Mitogen activated protein kinase 
mRNA  Messenger ribonucleic acid 
NCoR  Nuclear corepressor 
NR  Nuclear receptor 
PDGF  Platelet derived growth factor 
PPT™  Propyl pyrazole triol 
PR  Progesterone receptor 
RAR  Retinoic acid receptor 
RNA  Ribonucleic acid 
SERM  Selective oestrogen receptor modulator 
SHR  Steroid hormone receptor 
SMRT  Silencing mediator for retinoid and thyroid hormone receptors 
SRC  Steroid receptor coactivator 
TR  Thyroid receptor 
TRAP  Thyroid hormone receptor activating protein 








  ix 
Table of Contents 
Declaration ................................................................................................................... i 
Acknowledgements ..................................................................................................... ii 
Abstract ...................................................................................................................... iii 
Presentations relating to this thesis ......................................................................... vi 
Abbreviations ........................................................................................................... vii 
Table of Contents ...................................................................................................... ix 
List of figures .......................................................................................................... xvii 
List of tables ........................................................................................................... xxiv 
1 Literature Review............................................................................................... 2 
1.1 Oestrogens in reproductive health and disease ............................................ 2 
1.2 Biosynthesis of oestrogens ........................................................................... 3 
1.3 Oestrogen receptors (ERs) ........................................................................... 4 
1.4 Structural organisation of oestrogen receptors ............................................. 6 
1.4.1 The A/B domain ................................................................................... 9 
1.4.2 The DNA-binding (C) domain ............................................................. 9 
1.4.3 The D (hinge) domain ........................................................................ 10 
1.4.4 The ligand-binding (E/F) domain....................................................... 10 
1.5 Oestrogen receptor alpha (ERα) ................................................................. 11 
1.5.1 ERα splice variants............................................................................. 12 
1.6 Oestrogen receptor beta (ERβ) ................................................................... 13 
1.6.1 ERβ splice variants ............................................................................. 14 
1.7 Mechanisms of oestrogen receptor dependent gene activation .................. 16 
1.7.1 Ligand-dependent gene activation ..................................................... 18 
1.7.2 ERE-independent gene activation ...................................................... 18 
1.7.3 Non-genomic gene activation ............................................................ 19 
1.7.4 Ligand-independent gene activation .................................................. 20 
1.8 ER dimerisation .......................................................................................... 21 
1.9 ER transcriptional coregulators .................................................................. 22 
1.9.1 ER coactivators .................................................................................. 23 
1.9.2 ER corepressors .................................................................................. 25 
  x 
1.10 ER Ligands ................................................................................................. 26 
1.10.1 ER Selective agonists ......................................................................... 28 
1.10.2 Anti-oestrogens .................................................................................. 28 
1.10.3 Selective Oestrogen Receptor Modulators (SERMs) ......................... 29 
1.11 Growth Factors ........................................................................................... 30 
1.11.1 GF-mediated Phosphorylation of ER subtypes: The MAPK signalling 
cascade  ............................................................................................................ 31 
1.11.2 GF-mediated Phosphorylation of ER subtypes: The target sites ....... 33 
1.11.3 Evidence for an interplay between growth factor and oestrogen 
receptor signalling cascades ............................................................................... 36 
1.12 Functional analysis of ERs: gene knockout studies ................................... 36 
1.13 Oestrogens, oestrogen receptors and human endometrial function ........... 38 
1.13.1 Oestrogen expression in the human endometrium ............................. 40 
1.14 Aims of the thesis ....................................................................................... 40 
2 General materials and methods ...................................................................... 43 
2.1 Cell Culture ................................................................................................ 43 
2.1.1 MDA human caucasian breast adenocarcinoma cells ........................ 43 
2.1.2 Ishikawa uterine adenocarcinoma cells .............................................. 43 
2.1.3 hTERT endometrial epithelial cells (hTERT) .................................... 43 
2.2 Human Tissue ............................................................................................ 44 
2.2.1 Human Endometrial Samples ............................................................. 44 
2.2.2 Tissue processing ............................................................................... 44 
2.3 Ligands ....................................................................................................... 45 
2.3.1 Oestrogenic Ligands........................................................................... 45 
2.3.1.1 Natural Oestrogenic Ligand ........................................................... 45 
2.3.1.2 Synthetic Ligands ........................................................................... 45 
2.3.2 Growth Factors ................................................................................... 45 
2.3.3 Inhibitors ............................................................................................ 45 
2.4 Immunohistochemistry ............................................................................... 46 
2.4.1 IHC of endometrial tissue sections .................................................... 46 
2.4.1.1 Tissue processing (sectioning) ....................................................... 47 
  xi 
2.4.1.2 Dewaxing of tissue ......................................................................... 47 
2.4.2 Antigen retrieval................................................................................. 47 
2.4.3 Blocking to promote specific signal amplification ............................ 48 
2.4.3.1 Methanol Peroxidase Block ........................................................... 48 
2.4.3.2 Serum Block ................................................................................... 48 
2.4.3.3 Avidin-Biotin Block ....................................................................... 48 
2.4.4 Primary Antibodies ............................................................................ 48 
2.4.5 Secondary Antibodies ........................................................................ 49 
2.4.6 Antigen detection, counterstaining and mounting ............................. 49 
2.4.7 Immunofluorescence .......................................................................... 49 
2.4.8 Image Analysis ................................................................................... 52 
2.5 Ribonucleic Acid (RNA) Analysis............................................................. 52 
2.5.1 RNA extraction from cell lines and human tissue ............................. 52 
2.5.2 RNA Quantification (Nanodrop®) ..................................................... 52 
2.5.3 Qualitative Polymerase Chain Reaction (PCR) ................................. 53 
2.5.3.1 Reverse transcription of RNA using oligo dTs .............................. 53 
2.5.4 Quantitative-Real Time-PCR (Taqman® Method) ............................. 54 
2.5.4.1 Reverse transcription of RNA using random hexamers ................. 55 
2.5.4.2 Preparation of Taqman® reaction mix using the universal probe 
library™  ........................................................................................................ 55 
2.5.4.3 Quantitative real time Taqman® PCR ............................................ 56 
2.5.4.4 Analysis of computational output .................................................. 57 
2.5.4.5 Primer/probe Validation ................................................................. 58 
2.6 Protein Extraction and Quantification ........................................................ 59 
2.6.1 Total protein extraction from cell lines and human tissue ................. 59 
2.6.2 Nuclear protein extraction from cell lines .......................................... 60 
2.6.3 Protein Quantification (Lowry method) ............................................. 60 
2.7 Western Blotting ........................................................................................ 61 
2.7.1 Sample preparation............................................................................. 61 
2.7.2 NuPage® Polyacrylamide Gel Electrophoresis ................................. 61 
2.7.3 Protein transfer ................................................................................... 61 
  xii 
2.7.4 Antibodies (and peptides) .................................................................. 62 
2.7.5 Protein expression assessment (LI-COR™ Instruments) .................. 64 
2.8 Fluorescent Recovery After Photobleaching (FRAP) ................................ 64 
2.8.1 Background ........................................................................................ 64 
2.8.2 Live Cell Maintenance ....................................................................... 66 
2.8.3 Transient Transfection (Controls) ...................................................... 66 
2.8.4 Cell Infection ...................................................................................... 66 
2.8.5 The Process ........................................................................................ 67 
2.8.6 Instrumentation Setup ........................................................................ 68 
2.8.7 Quantitative Interpretation ................................................................. 68 
2.9 Luciferase Gene Reporter Assay ................................................................ 72 
2.9.1 Bright-Glo™ Luciferase Assay System (Promega) ........................... 72 
2.10 Commonly used Buffer Solutions .............................................................. 73 
3 Agonist and antagonist influences on the dynamics of ER subtypes ........... 76 
3.1 Introduction ................................................................................................ 76 
3.1.1 Aims of this chapter ........................................................................... 77 
3.2 Materials and Methods ............................................................................... 78 
3.2.1 Cells ................................................................................................... 78 
3.2.2 Taqman® qRT-PCR ............................................................................ 78 
3.2.3 Adenoviral Infection .......................................................................... 78 
3.2.4 Western Immunoblotting ................................................................... 79 
3.2.5 Cell Treatments .................................................................................. 79 
3.2.6 Fluorescence Recovery After Photobleaching (FRAP) ..................... 79 
3.2.7 Luciferase Gene Reporter Assay ........................................................ 80 
3.3 Results ........................................................................................................ 80 
3.3.1 Characterisation of Cell lines ............................................................. 80 
3.3.1.1 Expression of mRNAs in cell lines ................................................ 80 
3.3.1.2 Multiplicity of Infection determination; single infections ............. 81 
3.3.1.3 Optimal MOI determination; multiple infection ............................ 82 
3.3.1.4 Expression of mRNAs in cells infected with viral constructs........ 83 
3.3.1.5 Protein expression .......................................................................... 89 
  xiii 
3.3.2 Intranuclear dynamics of ER homodimers ......................................... 91 
3.3.2.1 Agonist Response ........................................................................... 91 
3.3.2.1.1 MDA cells ................................................................................ 92 
3.3.2.1.2 Ishikawa cells ......................................................................... 101 
3.3.2.1.3 hTERT cells ........................................................................... 108 
3.3.2.2 Impact of anti-oestrogen on receptor dynamics ........................... 115 
3.3.2.2.1 Ishikawa cells ......................................................................... 115 
3.3.3 Intranuclear dynamics of ER heterodimers ...................................... 120 
3.3.3.1 Agonist Response ......................................................................... 120 
3.3.4 Analysis of reporter gene activation in response to ER activity ...... 127 
3.3.4.1 Homodimeric Response ............................................................... 127 
3.3.4.2 Heterodimeric Response .............................................................. 129 
3.4 Discussion ................................................................................................ 131 
3.4.1 Differential ER subtype nuclear distribution and expression patterns ... 
  .......................................................................................................... 132 
3.4.2 Changes in intranuclear dynamics are cell context dependent......... 132 
3.4.3 Incubation with anti-oestrogenic ligand influences ER sub-nuclear 
mobility  .......................................................................................................... 134 
3.4.4 Impact of co-infecting two ER subtypes on intra-nuclear dynamics 137 
3.4.5 The ability of natural and synthetic ligands to transactivate ER 
subtypes alone and in combination at an Oestrogen Response Element (ERE) .... 
  .......................................................................................................... 140 
3.5 Conclusions .............................................................................................. 143 
4 Role of ERβ5 in the human endometrium ................................................... 146 
4.1 Introduction .............................................................................................. 146 
4.1.1 Aims of the chapter .......................................................................... 147 
4.2 Materials and Methods ............................................................................. 148 
4.2.1 Taqman® qRT-PCR .......................................................................... 148 
4.2.2 Collection of endometrial tissue ...................................................... 148 
4.2.3 Immunohistochemistry ..................................................................... 149 
4.2.3.1 Non Fluorescent Immunhistochemistry  ...................................... 149 
  xiv 
4.2.3.2 Immunofluorescence .................................................................... 149 
4.2.4 Western Immunoblotting ................................................................. 150 
4.2.5 Cell treatments ................................................................................. 151 
4.2.6 FRAP ................................................................................................ 151 
4.2.7 Luciferase Gene Reporter Assay ...................................................... 152 
4.3 Results ...................................................................................................... 152 
4.3.1 ERβ5 expression pattern in the endometrium .................................. 152 
4.3.1.1 ER mRNA expression across the menstrual cycle ....................... 152 
4.3.1.2 Immunolocalisation of Endometrial ERβ5 in endometrium across 
the cycle  ...................................................................................................... 154 
4.3.1.3 Co-localisation of ERβ5 and ERα in endometrial tissue ............. 156 
4.3.1.4 Co-localisation of ERβ5 and ERβ ................................................ 157 
4.3.1.5 Co-localisation of ERβ5 and ERβ2 .............................................. 159 
4.3.2 Western analysis of ERβ5 in Ishikawa cells .................................... 160 
4.3.3 Intranuclear dynamics of ERβ5 protein ........................................... 161 
4.3.3.1 ERβ5 response to incubation with agonists in Ishikawa cells ..... 161 
4.3.3.2 ERβ5 Response to agonists in hTERT cells ................................. 163 
4.3.3.3 ERβ5 Response to antagonist in Ishikawa cells ........................... 165 
4.3.3.4 ERβ5 Response to antagonist in hTERT cells ............................. 166 
4.3.4 Intranuclear dynamics of ERβ5 in combination with ERα .............. 168 
4.3.4.1 E2-mediated response on ERβ5-YFP and ERα in Ishikawa cells 168 
4.3.4.2 E2-mediated response of ERβ5-YFP and ERα in hTERT cells ... 169 
4.3.5 Analysis of reporter gene activation in response to ER activity ...... 171 
4.3.5.1 Comparison of YFP labelled versus unlabelled ERβ5 constructs 171 
4.3.5.2 Role of agonists and antagonists on the functional capacity of ERs 
in Ishikawa cells ........................................................................................... 173 
4.3.5.3 E2-mediated transcriptional response of ERα and ERβ5 after single 
or co-expression of receptors ....................................................................... 174 
4.4 Discussion ................................................................................................ 176 
4.4.1 Protein expression of ERβ5 in the human endometrium ................. 176 
  xv 
4.4.2 ERβ5 intranuclear mobility is not influenced by oestrogenic ligand 
but is responsive to anti-oestrogenic treatment ................................................ 178 
4.4.3 Oestrogen exposure alters the intranuclear dynamics of endometrial 
cells co-infected with ERβ5-YFP and ERα in vitro ......................................... 179 
4.4.4 Oestrogen exposure effects the transcriptional capacity of endometrial 
cells co-infected with ERβ5 and ERα in vitro ................................................. 180 
4.5 Conclusion ............................................................................................... 181 
5 Alternative modes of activation .................................................................... 184 
5.1 Introduction .............................................................................................. 184 
5.1.1 Aims of the chapter .......................................................................... 187 
5.2 Materials and Methods ............................................................................. 188 
5.2.1 Taqman® qRT-PCR .......................................................................... 188 
5.2.2 Collection of endometrial tissue ...................................................... 188 
5.2.3 Immunohistochemistry ..................................................................... 188 
5.2.3.1 Non Fluorescent Immunohistochemistry (DAB) ......................... 188 
5.2.4 Western Immunoblotting ................................................................. 189 
5.2.5 Cell treatments ................................................................................. 190 
5.2.6 FRAP ................................................................................................ 190 
5.2.7 Luciferase Gene Reporter Assay ...................................................... 191 
5.3 Results ...................................................................................................... 191 
5.3.1 The EGFR family of proteins are expressed in the human 
endometrium .................................................................................................... 191 
5.3.2 RNA and protein expression of EGFR in cell lines ......................... 192 
5.3.3 EGF functions through activation of the MAPK pathway in 
endometrial cells .............................................................................................. 193 
5.3.4 ERα is phosphorylated at the Ser118 residue in response to EGF-
mediated signalling. ......................................................................................... 195 
5.3.5 Intranuclear dynamics of ERs in response to incubation with EGF 197 
5.3.6 EGF induces ligand-independent transactivation of ERs at the ERE. ... 
  .......................................................................................................... 202 
  xvi 
5.3.7 Impact of proteasome-dependent degradation on ER intranuclear 
dynamics  .......................................................................................................... 205 
5.3.8 ER activity is regulated by proteasomal function ............................ 211 
5.4 Discussion ................................................................................................ 214 
5.4.1 The EGF family of receptors are expressed in the human 
endometrium .................................................................................................... 214 
5.4.2 EGF treatment has an impact on the intranuclear dynamics of ER 
subtypes in endometrial cells in vitro............................................................... 216 
5.4.3 EGF treatment has an effect on the transcriptional activity of ERs in 
vitro  .......................................................................................................... 217 
5.4.4 Inhibition of the 26S proteome relayed effects on the intranuclear 
dynamics of ERs in vitro in endometrial cells ................................................. 218 
5.4.5 MG132-induced disruption of the ubiquitin protease pathway had an 
effect on activation of the ERE reporter gene .................................................. 219 
5.4.6 Conclusions ...................................................................................... 220 
6 Final Discussion .............................................................................................. 222 
6.1 Relationship between nuclear dynamics of ER and transcriptional output.... 
  .................................................................................................................. 223 
6.2 A role for truncated ERβ splice variants .................................................. 228 
6.3 Influence of growth factor signalling on ER functionality ...................... 230 
6.4 General Conclusions ................................................................................ 231 
References ............................................................................................................... 233 
 
  xvii 
List of figures 
Figure 1.1 Overview of biological function of oestrogens. ......................................... 3 
Figure 1.2 Oestrogen biosynthesis. .............................................................................. 4 
Figure 1.3 Nuclear receptor classification system. ...................................................... 5 
Figure 1.4 NR classification according to expression pattern and function. ............... 6 
Figure 1.5 Structural organisation of the nuclear receptor superfamily....................... 7 
Figure 1.6 Schematic overview of ERα and ERβ structural architecture. ................... 8 
Figure 1.7 Schematic models illustrating the unique conformations adopted by the 
ER ligand-binding domain (LBD) in response to ligand. .......................................... 11 
Figure 1.8 Structure of ERα isoforms. ....................................................................... 13 
Figure 1.9 Structure of ERβ isoforms. ....................................................................... 16 
Figure 1.10 Overview of the distinct regulatory pathways of ER actions ................. 17 
Figure 1.11 Schematic overview of ERα/ERβ homo- and hetero-dimerisation 
patterns. ...................................................................................................................... 22 
Figure 1.12 Opposing actions of co-regulator activity. ............................................. 23 
Figure 1.13 E2 binding enables activation at the ERE............................................... 27 
Figure 1.14 Schematic overview of ER agonist, antagonist and SERM activity. ...... 27 
Figure 1.15 Comparison of anti-oestrogen and selective oestrogen receptor 
modulator activity. ..................................................................................................... 30 
Figure 1.16 Schematic overview of the MAPK (ERK1/2) tyrosine signalling cascade 
and its regulation. ....................................................................................................... 33 
Figure 1.17 Overview of ERα residues that are targets for phosphorylation and the 
signalling pathways that control them........................................................................ 34 
Figure 1.18 Schematic overview of the differentially regulated phases of the 
menstrual cycle........................................................................................................... 39 
Figure 2.1 Schematic overview of immunohistochemistry process........................... 46 
Figure 2.2 Overview of qRT-PCR experimental setup .............................................. 54 
Figure 2.3 Validation of primer/probe mix used in Taqman® reactions. .................. 58 
Figure 2.4 Validation of gene of interest primer/probe usage relative to 18S 
primer/probe control mix. .......................................................................................... 59 
Figure 2.5 Overview of the concept of a FRAP experiment. ..................................... 65 
  xviii 
Figure 2.6 FRAP normalisation methodology ........................................................... 71 
Figure 3.1 Comparison of mRNA expression of endogenous ERα, ERβ and ERβ2 in 
Ishikawa and hTERT  cell lines relative to the MDA cell line. ................................. 81 
Figure 3.2 Observational evaluation of MDA cells infected with yellow fluorescent 
labelled adenoviral ER constructs. ............................................................................. 82 
Figure 3.3 Observational evaluation of MDA cells infected with two YFP-tagged ER 
constructs. .................................................................................................................. 83 
Figure 3.4 ER mRNA expression in MDA cells. ....................................................... 85 
Figure 3.5 ER mRNA expression in Ishikawa cells. .................................................. 86 
Figure 3.6 ER mRNA expression in hTERT cells. .................................................... 87 
Figure 3.7 Western blot analysis of ERα and YFP-labelled protein expression in 
MDA cells. ................................................................................................................. 90 
Figure 3.8 Western analysis of ERβ protein expression in MDA cells. .................... 91 
Figure 3.9 Qualitative FRAP assessment. .................................................................. 93 
Figure 3.10 Quantitative analysis of intra-nuclear kinetics of ERα-infected MDA 
cells. ........................................................................................................................... 95 
Figure 3.11 Qualitative FRAP assessment of ERβ infected MDA cells. .............. 97 
Figure 3.12 Quantitative analysis of intra-nuclear kinetics of ERβ-infected MDA 
cells. ........................................................................................................................... 98 
Figure 3.13 Qualitative FRAP assessment of ERβ2 infected MDA cells. ............ 99 
Figure 3.14 Quantitative analysis of intra-nuclear kinetics of ERβ2-infected MDA 
cells. ......................................................................................................................... 100 
Figure 3.15 Control FRAP experiments in Ishikawa cells. ...................................... 101 
Figure 3.16 Qualitative FRAP assessment of ERα infected Ishikawa cells. ............ 102 
Figure 3.17 Quantitative analysis of intra-nuclear kinetics of ERα-infected Ishikawa 
cells. ......................................................................................................................... 103 
Figure 3.18 Qualitative FRAP assessment of ERβ infected Ishikawa cells. ............ 104 
Figure 3.19 Quantitative analysis of intra-nuclear kinetics of ERβ-infected Ishikawa 
cells. ......................................................................................................................... 105 
Figure 3.20 Qualitative FRAP assessment of ERβ2 infected Ishikawa cells. .......... 106 
  xix 
Figure 3.21 Quantitative analysis of intra-nuclear kinetics of ERβ2-infected Ishikawa 
cells. ......................................................................................................................... 107 
Figure 3.22 Control FRAP experiments in hTERT  cells. ....................................... 108 
Figure 3.23 Qualitative FRAP assessment of ERα infected into hTERT  cells. ...... 109 
Figure 3.24 Quantitative analysis of intra-nuclear kinetics of ERα-infected hTERT  
cells. ......................................................................................................................... 110 
Figure 3.25 Qualitative FRAP assessment of ERβ infected hTERT cells. .............. 111 
Figure 3.26 Quantitative analysis of intra-nuclear kinetics of ERβ-infected hTERT 
cells. ......................................................................................................................... 112 
Figure 3.27 Qualitative FRAP assessment of ERβ2 infected hTERT cells. ............ 113 
Figure 3.28 Quantitative analysis of intra-nuclear kinetics of ERβ2-infected hTERT  
cells. ......................................................................................................................... 114 
Figure 3.29 Qualitative FRAP assessment of ERα infected Ishikawa cells. ............ 115 
Figure 3.30 Quantitative analysis of intra-nuclear kinetics of ERα-infected Ishikawa 
cells. ......................................................................................................................... 116 
Figure 3.31 Qualitative FRAP assessment of ERβ infected Ishikawa cells. ............ 117 
Figure 3.32 Quantitative analysis of intra-nuclear kinetics of ERβ-infected Ishikawa 
cells. ......................................................................................................................... 117 
Figure 3.33 Qualitative FRAP assessment of ERβ2 infected Ishikawa cells. .......... 118 
Figure 3.34 Quantitative analysis of intra-nuclear kinetics of ERβ2-infected Ishikawa 
cells. ......................................................................................................................... 119 
Figure 3.35 Qualitative FRAP assessment of dual infected MDA cells. ............ 121 
Figure 3.36 Quantitative analysis of intra-nuclear kinetics of dual infected MDA 
cells.  .......................................................................................................... 122 
Figure 3.37 Qualitative FRAP assessment of dual infected MDA cells. ............ 123 
Figure 3.38 Quantitative analysis of intra-nuclear kinetics of dual infected MDA 
cells.  .......................................................................................................... 124 
Figure 3.39 Qualitative FRAP assessment of dual infected MDA cells. ............ 125 
Figure 3.40 Quantitative analysis of intra-nuclear kinetics of dual infected MDA 
cells.  .......................................................................................................... 126 
  xx 
Figure 3.41 Impact of natural and synthetic agonists with ERs on luciferase 
reporter activity in MDA cells. ................................................................................ 128 
Figure 3.42 Impact of natural and synthetic agonists with two ERs on luciferase 
reporter activity in MDA cells. ................................................................................ 130 
Figure 4.1 Expression of mRNAs encoding ER subtypes ERα and ERβ and the splice 
variants ERβ2 and ERβ5 in normal endometrium during the proliferative and 
secretory (luteal) phases of the menstrual cycle. ..................................................... 153 
Figure 4.2 Validation of anti-ERβ antibodies used for histological evaluation of 
human endometrial tissue. ........................................................................................ 154 
Figure 4.3 ERβ5 immunoexpression in the endometrium. ...................................... 155 
Figure 4.4 High power view of ERβ5 expression in human endometrium. ............. 156 
Figure 4.5 Co-expression of ERβ5 (green) and ERα (red) in normal endometrial 
tissue from stages across the menstrual cycle. ......................................................... 157 
Figure 4.6 Co-expression of ERβ1 (red) and ERβ5 (green) in normal endometrial 
tissue from stages across the menstrual cycle. ......................................................... 158 
Figure 4.7 Co-expression of ERβ2 (red) and ERβ5 (green) in normal endometrial 
tissue from stages across the menstrual cycle. ......................................................... 159 
Figure 4.8 Determination of ERβ5 protein levels in the Ishikawa cell line. ............ 160 
Figure 4.9 Qualitative FRAP assessment of ERβ5 infected Ishikawa cells. ............ 161 
Figure 4.10 Quantitative analysis of intra-nuclear kinetics of ERβ5-infected Ishikawa 
cells. ......................................................................................................................... 162 
Figure 4.11 Qualitative FRAP assessment of ERβ5 infected hTERT cells. Cells were 
treated with a DMSO vehicle control, E2 10-8M, PPT 10-8M or DPN 10-8M for 60 
minutes. .................................................................................................................... 163 
Figure 4.12 Quantitative analysis of intra-nuclear kinetics of ERβ5-infected hTERT  
cells. ......................................................................................................................... 164 
Figure 4.13 Qualitative FRAP assessment of ERβ5 infected Ishikawa cells. .......... 165 
Figure 4.14 Quantitative analysis of intra-nuclear kinetics of ERβ5-infected Ishikawa 
cells. ......................................................................................................................... 166 
Figure 4.15 Qualitative FRAP assessment of ERβ5 infected hTERT cells. Cells were 
treated with a DMSO vehicle control, E2 10-8M and ICI 10-8M. ............................ 167 
  xxi 
Figure 4.16 Quantitative analysis of intra-nuclear kinetics of ERβ5-infected hTERT 
cells. ......................................................................................................................... 167 
Figure 4.17 Qualitative FRAP assessment of ERβ5-YFP and ERα infected Ishikawa 
cells. ......................................................................................................................... 168 
Figure 4.18 Quantitative analysis of intra-nuclear kinetics of ERβ5-YFP and 
untagged ERα infected Ishikawa cells. .................................................................... 169 
Figure 4.19  Qualitative FRAP assessment of ERβ5-YFP and ERα infected hTERT 
cells. ......................................................................................................................... 170 
Figure 4.20 Quantitative analysis of intra-nuclear kinetics of ERβ5-YFP and 
untagged ERα infected hTERT cells. ....................................................................... 170 
Figure 4.21 Comparison of tagged versus untagged constructs in MDA cells. ....... 172 
Figure 4.22 Impact of natural and synthetic agonists with ERs on luciferase reporter 
activity in Ishikawa cells. ......................................................................................... 174 
Figure 4.23 Comparison of impact of E2 on luciferase activity in Ishikawa (A) and 
hTERT (B) cell contexts. ......................................................................................... 175 
Figure 5.1 EGF receptor (EGFR) family immunoexpression in the human 
endometrium. ........................................................................................................... 192 
Figure 5.2 Comparison of mRNA expression of endogenous EGFR in Ishikawa and 
hTERT cell lines relative to the MDA cell line. ...................................................... 193 
Figure 5.3 Determination of EGFR protein levels in the cell lines. ......................... 193 
Figure 5.4 Western analysis of MAPK and phospho-MAPK proteins in Ishikawa 
cells. ......................................................................................................................... 194 
Figure 5.5 Quantification of Western blots p44 (ERK1) (A) and p42 (ERK2) (B) 
after EGF stimulation for 10, 20 and 30 minute intervals. ...................................... 195 
Figure 5.6 Western analysis of ERα and phosphorylated ERα at the Serine residue 
118 protein in Ishikawa cells.................................................................................... 196 
Figure 5.7 Quantification of Western blot for the Ser118 phosphorylation of ERα-
YFP in Ishikawa cells. ............................................................................................. 197 
Figure 5.8 Qualitative FRAP assessment of ERα-YFP infected Ishikawa cells. Cells 
were treated with a dH2O vehicle control and EGF 10-7M over a range of time-points 
(10, 20, 30, 60 and 90 minutes). ............................................................................... 198 
  xxii 
Figure 5.9 Quantitative analysis of intra-nuclear kinetics of ERα-YFP infected 
Ishikawa cells. .......................................................................................................... 198 
Figure 5.10 Qualitative FRAP assessment of ERβ-YFP infected Ishikawa cells. ... 199 
Figure 5.11 Quantitative analysis of intra-nuclear kinetics of ERβ-YFP infected 
Ishikawa cells. .......................................................................................................... 199 
Figure 5.12 Qualitative FRAP assessment of ERβ5-YFP infected Ishikawa cells. . 200 
Figure 5.13 Quantitative analysis of intra-nuclear kinetics of ERβ5-YFP infected 
Ishikawa cells. .......................................................................................................... 200 
Figure 5.14 Qualitative FRAP assessment of ERβ5-YFP and ERα infected Ishikawa 
cells. ......................................................................................................................... 201 
Figure 5.15 Quantitative analysis of intra-nuclear kinetics of ERβ5-YFP and 
untagged ERα in Ishikawa cells. .............................................................................. 202 
Figure 5.16 Impact of growth factor (EGF) with ERs on luciferase reporter activity in 
Ishikawa cells. .......................................................................................................... 203 
Figure 5.17 Impact of growth factor (EGF) with ERs on luciferase reporter activity in 
hTERT  cells. ........................................................................................................... 204 
Figure 5.18 Qualitative FRAP assessment of ERα-YFP infected hTERT  cells. .... 206 
Figure 5.19 Quantitative analysis of intra-nuclear kinetics of ERα-YFP infected 
hTERT  cells. ........................................................................................................... 206 
Figure 5.20 Qualitative FRAP assessment of ERβ-YFP infected hTERT cells. ..... 207 
Figure 5.21 Quantitative analysis of intra-nuclear kinetics of ERβ-YFP infected 
hTERT  cells. ........................................................................................................... 207 
Figure 5.22 Qualitative FRAP assessment of ERβ5-YFP infected hTERT cells. ... 209 
Figure 5.23 Quantitative analysis of intra-nuclear kinetics of ERβ5-YFP infected 
hTERT  cells. ........................................................................................................... 209 
Figure 5.24 Qualitative FRAP assessment of ERβ5-YFP and ERα infected hTERT 
cells. ......................................................................................................................... 210 
Figure 5.25 Quantitative analysis of intra-nuclear kinetics of ERβ5-YFP and 
untagged ERα infected hTERT  cells. ...................................................................... 210 
Figure 5.26 Impact of transcriptional inhibitor (MG132) with ERs on luciferase 
reporter activity in Ishikawa cells. ........................................................................... 212 
  xxiii 
Figure 5.27 Impact of transcriptional inhibitor (MG132) with ERs on luciferase 
reporter activity in hTERT  cells. ............................................................................. 213 
Figure 6.1 Morphological comparison of fluorescently-labelled ERα and ERβ in 
MDA cells between vehicle control versus E2-stimulated conditions..................... 222
Figure 6.2 Summary of relationship between mobility and luciferase reporter activity 
in the current study. .................................................................................................. 228
  xxiv 
List of tables 
 
Table 1.1 ER coactivator listing of coregulators that enhance functional activity. ... 25 
Table 1.2 ER corepressors that decrease oestrogen stimulatory function. ................. 26 
Table 1.3 Overview of ER knockout mice model phenotypes................................... 38 
Table 2.1 Summary of primary antibodies used for immunohistochemistry ............. 50 
Table 2.2 Summary of secondary antibodies used for immunohistochemistry ......... 51 
Table 2.3 Primer and Probe Sequences (UPL) used in qRT-PCR ............................. 56 
Table 2.4 Primary antibodies used for Western blotting............................................ 63 
Table 2.5 Secondary antibodies used for Western blotting........................................ 64 
Table 2.6 Concentrations of Adenoviral Constructs used .......................................... 67 
Table 3.1 Average threshold cycle (Ct) values determined by the ABI 7900 sequence 
detection system (Applied Biosystems). .................................................................... 89 
Table 3.2 Comparison of intranuclear mobility responses to ligand treatment in 
MDA, Ishikawa and hTERT lines. ........................................................................... 137 
Table 4.1 Summary of primary and secondary antibodies and the fluorescent labels 
used for immunofluorescence .................................................................................. 150 
Table 4.2 Primary antibodies used for Western blotting.......................................... 151 
Table 5.1 Summary of primary and secondary antibodies used for DAB 
immunodetection. ..................................................................................................... 189 








Chapter 1     Literature Review 2 
1 Literature Review 
1.1 Oestrogens in reproductive health and disease 
Oestrogens are sex steroids that play an essential role in regulating formation and 
function of the reproductive system and also have an impact on the cardiovascular 
system, the immune system, the skeleton, the breast and the brain (reviewed in Deroo 
and Korach, 2006). Oestrogens have been implicated in development of reproductive 
disorders including endometriosis and cancer (Fig. 1.1). Sex steroids are lipophilic 
ligands that readily cross cell membranes and alter gene expression by binding to 
receptors that function as ligand-activated transcription factors. Two oestrogen 
receptors (ERs), ERα and ERβ have been identified (section 1.5 and 1.6). Oestrogens 
play key roles in development of the mammary gland and endometrium (Klinge, 
2000) and in the stimulation of bone growth and its maintenance (Manolagas and 
Kousteni, 2001). A deficiency in circulatory levels of oestrogen is associated with an 
increased risk of osteoporosis in postmenopausal and ageing populations worldwide 
(Riggs and Melton, 1995) arising from increased osteoclast-mediated resorption of 
the bone (Albright et al., 1941, Riggs et al., 1998). The use of oestrogen in hormone 
replacement therapy (HRT) in postmenopausal women has been linked to a reduced 
risk in the development of coronary heart disease (Campos et al., 1993). Oestrogens 
act as cardioprotectants by increasing clearance of low-density lipoprotein 
cholesterol while increasing formation of high density lipoproteins and triglycerides 
(Guetta and Cannon, 1996, Campos et al., 1997). They have also been implicated in 
the up-regulation of the atheroprotective prostacyclin PGI2 through the activation of 
cyclooxygenase 2 (COX-2) in mice (Egan et al., 2004).  
 
Conversely oestrogen exposure has also been implicated in the development of some 
cancers. For example, the use of oestrogen-only HRT increases the risk of 
developing endometrial cancer (Shapiro et al., 1985, Beral et al., 2005). The 
menopausal transition (climacteric), a time when oestrogens may be elevated has 
been proposed as a possible ‘window of risk’ for the development of the disease later 
in life (Hale et al., 2002). 
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Figure 1.1 Overview of biological function of oestrogens.  
The physiological relevance of oestrogenic function is exemplified in the bone, breast 
and reproductive tissues. 
1.2 Biosynthesis of oestrogens 
In pre-menopausal, non-pregnant women, the ovaries are the primary source of 
circulating oestrogen (Simpson et al., 1999) (section 1.10). Oestrogen is the end-
product of step-wise biosynthesis from cholesterol that is regulated by a series of 
cytochrome P450s (Mitrunen and Hirvonen, 2003) and hydroxysteroid 
dehydrogenases (3β and 17β) (summarised in Fig. 1.2). Cleavage of the cholesterol 
side-chain yields the C21 steroid pregnenolone that in turn is reduced to progesterone 
or androstenedione (Omura and Morohashi, 1995). The critical step in oestrogen 
biosynthesis (aromatisation) is accomplished by the action of the aromatase complex, 
an essential component of which is the aromatase cytochrome P450 enzyme 
(P450arom) (Simpson and Davis, 2001), either directly to produce oestrone (E1) or 
indirectly via the aromatisation of  testosterone. Clinical studies implicate a role for 
the aromatase enzyme in the development of the reproductive organs and regulation 
of gonadotrophins (Fisher et al., 1998) and overexpression of aromatase has been 
implicated in the pathogenesis of breast cancers (reviewed in Kristensen and 
Borresen-Dale, 2000). 
Chapter 1     Literature Review 4 
 
Figure 1.2 Oestrogen biosynthesis.  
The sequential production of the C18 oestrogenic steroids (oestrone and oestradiol) 
from the C19 androgen precursors (androstenedione and testosterone) is catalysed by 
a series of aromatase and hydroxysteroid dehydrogenases. 3β-HSD denotes 3β-
hydroxysteroid dehydrogenase, 17β-HSD 17β-hydroxysteroid dehydrogenase, 17-
KSR 17-ketosteroid reductase, DHEA dehydroepiandrosterone, P-450 cytochrome P-
450, SCC side-chain–cleavage enzyme, CYP17 17β-hydroxylase, CYP21 21-
hydroxylase, CYP11 11β-hydroxylase, E1 oestrone and E2 oestradiol. Adapted from 
Clemons and Goss, 2001.  
1.3 Oestrogen receptors  
Critical evidence that ERs existed in oestrogen target tissues such as the uterus 
originated from the demonstration of high affinity binding sites for 17-tritiated 
oestradiol in the rat uterus (Jenson and Jacobson 1962). The first ER gene was cloned 
in 1986 (Green et al., 1986b, Greene et al., 1986) and together with the androgen, 
glucocorticoid and mineralocorticoid receptors was one of the founder members of a 
superfamily of ligand activated transcription factors that channel the actions of 
steroid hormone as well as retinoids and thyroid hormones (Katzenellenbogen and 
Katzenellenbogen, 1996, Escriva et al., 2000). The nuclear receptor superfamily is 
regarded as one of the most significant groups of transcriptional regulators in 
eukaryotes playing a key role regulating the expression of hormone-responsive genes 
(Tsai and O'Malley, 1994a, Robinson-Rechavi et al., 2003). Based on phylogenetic 
analysis of vertebrates it has been proposed that this family evolved from a common 
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ancestral gene that most closely resembles the sequence of an ER (Thornton, 2001). 
The pioneering studies that isolated the sex steroid receptors led to subsequent 
isolation of a large number of related proteins to the extent that the superfamily now 
also includes a number of proteins currently classified as ‘orphan’ receptors because 
they have no known ligand (Mangelsdorf et al., 1995, Giguere, 1999). Grouping of 
steroid hormone receptors (SHRs) into four subtypes (I-IV) was proposed based on 
the nature of the binding of family members to deoxyribonucleic acid (DNA) 
(Mangelsdorf et al., 1995). This is illustrated in Fig. 1.3. The binding of oestrogen 
receptors to direct palindromic repeat sequences known as EREs is covered in detail 
in section 1.4.2. 
 
 
Figure 1.3 Nuclear receptor classification system. 
Type I receptors are ligand-inducible receptors that bind palindromic DNA half-
sites. Type II receptors constitutively bind DNA at direct repeat sequences. Type III 
receptors have undefined ligands (‘orphan receptors’) and bind as homodimers at 
direct repeats. Type IV orphan receptors bind DNA as monomers (adapted from 
Mangelsdorf et al., 1995). 
 
More recently, cluster analysis based on patterns of expression of SHRs in mouse 
tissues and information relating to their impact on gene expression has been used to 
classify the receptors into five functional groups. Notably in this scheme ERs are 
assigned to group IB together with the receptors for androgens (androgen receptor, 
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AR) and progestins (progesterone receptor, PR) that each play a key role in 
formation and function of reproductive tissues (Bookout et al., 2006) (Fig. 1.4). 
 
 
Figure 1.4 Nuclear receptor classification according to expression pattern and 
function. 
This analysis revealed a higher-order network linking nuclear receptor function to 
reproduction, development, central, and basal metabolic functions, dietary-lipid 
metabolism, and energy homeostasis. Taken from Bookout et al., 2006. 
1.4 Structural organisation of oestrogen receptors 
In common with other members of the SHR superfamily, oestrogen receptors are 
composed of five distinct structure/function domains (Fig. 1.5). These are: an N-
terminal A/B domain, a DNA-binding (C) domain (DBD), an interacting hinge (D) 
region and a ligand-binding (E/F) domain (LBD) (Griekspoor et al., 2007). 
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Figure 1.5 Structural organisation of the nuclear receptor superfamily.  
The N-terminal A/B domain comprises the first of two activation function domains 
(AF-1), the C domain is responsible for receptor tethering to the DNA, the D domain 
is a hinge region that has been shown to encompass a carboxyl terminal extension 
(CTE) for optimal DNA binding of the androgen receptor, the E domain facilitates 
binding of ligand and is the location of the constitutive AF-2 sequence, the 
functionality of the C-terminal F domain is largely unknown. Adapted from Olefsky, 
2001.  
 
The functional activity of the different domains of the oestrogen receptors has been 
deciphered by studies in vitro, receptor modelling and domain swapping (Klinge, 
2001, Metzger et al., 1995, Tanenbaum et al., 1998) and are covered in more detail 
in the subsequent subsections (1.4.1 to 1.4.4 inclusively). 
 
ERα and ERβ are transcribed from two genes, ESR1 and ESR2, found on different 
autosomes, and both receptor proteins are encoded by 8 exons. The relationship 
between the exons and the domains they each encode is summarised below (Fig. 
1.6A). Although ERα and ERβ share a common structural architecture and both are 
able to bind oestrogenic ligands, the two ER proteins differ in their patterns of 
expression (Saunders et al., 1997, Saunders et al., 2000, Saunders et al., 2001, 
Saunders and Critchley, 2002) and function (Enmark et al., 1997).  
 
Human ERα and ERβ share a high degree of homology at the DBD (96%) 
(Mosselman et al., 1996) and consequently have been shown to similarly bind cis-
acting ERE sites (Pettersson and Gustafsson, 2001a). Differences in their sequence 
homology at the LBD (~59% homology) (Fig. 1.6B), the smaller (20%) ligand-
binding cavity of ERβ (Brzozowski et al., 1997, Pike et al., 1999) and the individual 
characteristic repertoires of coregulators (Warnmark et al., 2001, An et al., 2001) 
account for the differential response of the two ERs to certain ligands (including 
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xenoestrogens and phytoestrogens) and the LBD is the target domain for 
pharmacological exploitation in the development of novel ER selective therapeutics 





Figure 1.6 Schematic overview of ERα and ERβ structural architecture.  
A. The top exon structure is aligned to the functional domains encoded by each exon. 
The function of each domain is outlined below the structural outline; B. Comparative 
analysis of ERα and ERβ functional domain homology (Adapted from Schiff, 2002). 
 
Alternative splicing of the pre-messenger ribonucleic acid (mRNA) wild type ERs 
has rendered numerous additional isoform variants that have broadened the diversity 
of the proteome and may also have an impact on the activities of their full-length 
counterparts. The human ERα isoforms are largely lacking the full complement of 
coding exons (Poola et al., 2000) (section 1.5.1) while many of the defined human 
ERβ variants arise from differing sequences at the C terminus (exon 8) (Moore et al., 
1998, Poola et al., 2002) (section 1.6.1).  
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1.4.1 The A/B domain 
The N-terminus of the oestrogen receptors is the least conserved between the steroid 
receptor family members. For example the amino acid sequences of human ERα and 
ERβ only have ~16% identity (Schiff, 2002). This region contains the first of two 
acidic transactivational function domains called the activation-function 1 (AF-1). 
Ligand-dependent phosphorylation of ERα by mitogen activated protein kinase 
signalling pathways at serine residues 104, 106 and 118 has been shown to potentiate 
AF-1 activity (Ali et al., 1993, Le Goff et al., 1994a) (section 1.7.4 and 1.10.1). The 
AF-1 of ERα has been demonstrated to be receptive to coactivator recruitment of 
steroid receptor coactivator 1 (SRC-1) (Onate et al., 1998) and glucocorticoid 
receptor-interacting protein-1 (GRIP1), members of the p160 family of coactivators 
(Webb et al., 1998) (section 1.9.1). Studies examining the function of ERα AF-1 in 
chinese hamster ovary cells suggest that AF-1 synergises with AF-2 at the C-terminal 
of the protein under the influence of SRC-1 to enhance agonist-mediated activity 
(McInerney and Katzenellenbogen, 1996). Domain swapping experiments involving 
alteration of the A/B domains between ERα and ERβ determined an improved 
transcriptional activity profile of ERβ chimera when fused to the A/B domain of ERα 
in human endometrial cancer (HEC-1) and human breast cancer (MDA-231) cells. 
Furthermore the ERβ chimeric cells demonstrated an anti-oestrogen agonist response 
with 4-hydroxy-tamoxifen that is not observed with ERβ alone, implicating the A/B 
domain of ERα for these specific responses (McInerney et al., 1998). Subsequently, a 
study investigating the co-expression of ERα and ERβ in MDA-MB-231 cells 
established the dominant negative effects of ERβ in a heterodimer with ERα in 
response to anti-oestrogen stimulation are AF-1 dependent (Gougelet et al., 2007).  
1.4.2 The DNA-binding (C) domain 
The DBD of SHRs is highly conserved and shares ~97% homology between human 
ERα and ERβ (Enmark et al., 1997). The DBD is composed of two cysteine-rich zinc 
finger domains, two α-helices, a number of sequence elements designated P, D, T 
and A boxes and a COOH tail involved in sequence recognition and dimerisation 
(Umesono and Evans, 1989, Klinge, 2001, Pike et al., 1999). The zinc finger 
Chapter 1     Literature Review 10 
sequences, EGCKAF in finger one and CPATNQC of the second finger are 
specifically involved in promoter sequence recognition at the ERE and dimerisation 
of the ERs respectively (Forman and Samuels, 1990, Pettersson and Gustafsson, 
2001b) (section 1.8). Molecular modelling of DBDs from type I nuclear receptors 
bound to DNA has revealed specific binding at a palindromic sequences comprising 
two consensus half sites (Luisi et al., 1991, Schwabe et al., 1993) that is regulated by 
P box activity (Germain et al., 2006) in contrast to type II NRs that constitutively 
bind at direct repeats of their specific promoter sites (Tsai and O'Malley, 1994b).  
1.4.3 The D (hinge) domain 
Domain D is a flexible hinge region that harbours a nuclear localisation signal in 
SHRs and precludes steric hindrance by activated DBD and LBD conformational 
changes. This region is poorly conserved amongst SHR family members (Robinson-
Rechavi et al., 2003).  
1.4.4 The ligand-binding (E/F) domain  
In addition to determining ligand binding and specificity, the LBD has roles in 
nuclear localisation, dimerisation, chaperone binding and coregulator recruitment 
through the second of the activation function domains AF-2 (Griekspoor et al., 
2007). Crystallography studies have determined the secondary structure of the 
carboxyl-terminal LBD as an α-helical ‘sandwich’ that encompasses twelve α-helices 
(Helix 1-12) with a short β-turn (s1-s2) (Bourguet et al., 1995, Tanenbaum et al., 
1998). Helix 12 behaves as a ‘molecular switch’ that can form multiple response 
conformations that can dictate the type(s) of co-regulatory proteins recruited to the 
receptor-ligand complex (Fig. 1.7). For example, following binding of an agonist, the 
helix 12 adopts a stable structure in which it locks the ligand into a cavity, exposes 
specific sequences on the protein in the AF-2 domain and enables binding of 
coactivators (Fig 1.7A and B).  Conversely, x-ray crystallography structural studies 
have revealed antagonist binding to the ERα and ERβ results in an ‘inhibitory’ 
orientation of helix 12 that prohibits AF-2 activity and hinders the recruitment of 
coregulators (Fig. 1.7C) (reviewed in Pike, 2006). The AF-2 is composed of residues 
from helices 3, 4, 5 and 12 that form a shallow hydrophobic cleft (Henttu et al., 
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1997, Wurtz et al., 1996) that recognises and accommodates the LxxLL motif (NR 
box; L = leucine, x = any amino acid) of co-regulator proteins such as members of 
the p160 family of proteins (Heery et al., 1997, Kalkhoven et al., 1998). The 
sequence homology between the LBD of ERα and ERβ is ~53% which is 
accountable for the selectivity of different natural oestrogens and selective oestrogen 
receptor modulators (SERMS) for these subtypes (Enmark et al., 1997) (section 
1.10.3). The F domain is highly variable among NRs and the function remains 
unknown (Robinson-Rechavi et al., 2003). 
 
 
Figure 1.7 Schematic models illustrating the unique conformations adopted by the 
ER ligand-binding domain (LBD) in response to ligand. 
A. The binding of an agonist (e.g. E2) facilitates the ‘on’ conformation of helix 12 
(green cylinder) and active state of AF-2; B. Adoption of the agonist-mediated 
conformation enables coactivator interaction of the LxxLL sequence motif (purple 
cylinder) at the hydrophobic AF-2 groove; C. Antagonist (e.g. raloxifene) binding at 
the LBD displaces helix 12 and occludes the coactivator binding groove. Taken from 
Pike, 2006. 
1.5 Oestrogen receptor alpha (ERα) 
ERα was originally cloned and characterised from the MCF-7 breast cancer cell line 
(Walter et al., 1985, Green et al., 1986a). The gene was identified as a 14-kb DNA 
sequence comprising eight exons localised to human chromosome 6q25.1 
(Ponglikitmongkol et al., 1988, Reid et al., 2002). This gene (ESR1) encodes a 
protein of ~66kDa with 595 amino acids with a high binding affinity for oestradiol 
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(KD ~ 0.4nM) (Green et al., 1986b). ERα protein conforms to the signature modular 
structure of the NR superfamily (section 1.4) and is transcribed from at least three 
different promoter sites (Green et al., 1986b, Keaveney et al., 1991, Grandien, 1996). 
ERα is widely expressed, notably within in female reproductive tissues and the 
breast, the growth of which is regulated by oestradiol. ERα protein has been 
immunolocalised to the uterine vascular smooth muscle cells (tunica media) (Perrot-
Applanat et al., 1988), the granulosa cells of mature antral follicles and the surface 
epithelium of the ovary (Saunders et al., 2000), the stromal and epithelial 
compartments of the mammary gland (Pelletier and El-Alfy, 2000) and to stromal 
and epithelial compartments of the endometrium with decreasing levels of mRNA 
and protein detected in the functional endometrial layer coincident with advancement 
of the menstrual cycle (Critchley, 2000, Saunders and Critchley, 2002). 
1.5.1 ERα splice variants 
Two splicing variants of the full-length human ERα protein have been described 
(Fig. 1.8). ERα-46 is a protein with a molecular weight of 46kDa and is transcribed 
from an mRNA splice variant of the ERα gene that lacks sequences encoded by exon 
1. As a result the protein lacks the first 173 amino acids of the A/B domain (Flouriot 
et al., 2000). Expression of ERα-46 in vitro suggested a role for the protein as a 
dominant inhibitor of the ERα-66 splice variant. ERα-46 has been shown to actively 
and preferentially heterodimerise with its full length homologue and has been 
detected in osteoblasts and vascular endothelial cells (Denger et al., 2001b, Russell et 
al., 2000).  It has been proposed that the ERα-46 isoform is subject to post-
translational modification by palmitoylation after which it becomes membrane-
associated, activates endothelial nitric oxide synthase (eNOS) production and 
channels E2-mediated signals to the endothelium (Li et al., 2003).  
 
A second splicing variant of ERα generated by a promoter sequence in the first intron 
of the full-length receptor is ERα-36. This isoform was cloned from HEK293 cells 
and is devoid of both transactivation functions; AF-1 and AF-2 but has retained 
DNA-binding function and dimerisation capability (Wang et al., 2005). Like ERα-46 
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it has been suggested that the ERα-36 variant can mediate membrane-initiated 
oestrogen signalling (Li et al., 2003, Wang et al., 2005). 
 
Figure 1.8 Structure of ERα isoforms.  
The primary functional domains; AF-1, DBD and LBD (AF-2 within) are outlined. 
The short length splice variants ERα-46 and ERα-36 are devoid of the N-terminal 
A/B structural domain. (Adapted from Heldring et al., 2007). 
1.6 Oestrogen receptor beta (ERβ) 
The cloning of a second oestrogen receptor, usually known as ERβ, from the rat 
prostate in 1996 (Kuiper et al., 1996) and its localisation to the granulosa cells of the 
rat ovary was followed by the identification of a homologous protein in human 
(Mosselman et al., 1996). The human gene (ESR2) was subsequently localised to 
14q23.2 (Enmark et al., 1997). The full length human ERβ protein is 58kDa in size 
but a second ‘short type’ receptor that lacks the first 54 amino acids of its full length 
counterpart and is 53kDa arising from internal ribosomal entry has been described 
(Denger et al., 2001a). Expression of ERβ protein in female reproductive tissues has 
been localised to the granulosa cells of the follicles within the ovary (Saunders et al., 
2000), stromal and epithelial compartments of breast tissue (Pelletier and El-Alfy, 
2000) and the stroma, epithelium and exclusively the endothelial cells of the 
endometrium (Critchley et al., 2001). In addition, ERβ protein expression has been 
determined in a wide range of human tissues including the lungs, kidney, heart and 
most regions of the brain (except hippocampus that exclusively expresses ERα) 
(Taylor and Al-Azzawi, 2000) as well as in cancers such as breast cancer tissue 
(Saunders et al., 2002) suggesting a potential role for this isoform in the mediation of 
oestrogenic transcriptional activity both in reproductive and non-reproductive tissues. 
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1.6.1 ERβ splice variants 
Multiple C-terminal truncated protein isoforms of human ERβ (ERβ2-5) that diverge 
at amino acid 469 of the wild type receptor have been determined that result from the 
alternative splicing of the last exons (exon 8 and 9) (Fig 1.9A) (reviewed in Scobie et 
al., 2002, Leung et al., 2006, Zhao et al., 2008).  
 
ERβ2/ERβcx encodes a protein composed of 495 amino acids including a signature 
26 amino acid sequence in place of the last 61 amino acids of ERβ at its carboxyl 
terminal domain (Moore et al., 1998). Similarly to ERβ, the use of alternative ATG 
sites within the ERβ2 coding sequence results in long and short forms of the splice 
variant with protein weights of 55kDa and 51kDa respectively (Ogawa et al., 1998c). 
Crystallography studies have revealed that this protein has an incomplete AF-2 
domain and disoriented Helix 12 that is consistent with studies that suggest this 
variant does not activate reporter genes in response to incubation with oestrogenic 
ligands (Leung et al., 2006, Ogawa et al., 1998c). However, ERβ2 is reportedly 
capable of forming heterodimers (preferentially with ERα) (Ogawa et al., 1998c, 
Zhao et al., 2007). Unlike ERβ2, the molecular models demonstrate that ERβ4 and 
ERβ5 are completely devoid of Helix 12 (Leung et al., 2006) (Fig. 1. 9B) and in vitro 
studies have reported formation of mixed dimers with full length ERs (Poola et al., 
2005a). ERβ4 has a unique sequence encoded by an exon between the ERβ and 
SYNE2 genes and the signature 3’ sequence of ERβ5 is the product of a retained 
sequence betweens exons 7 and 8 (Poola et al., 2005a).  
 
Expression of ERβ2 has been detected in endothelial cells within the placenta, 
granulosa cells of the ovary and stromal and epithelial cells in the normal 
endometrium throughout all phases of the cycle of the human female reproductive 
tract (Scobie et al., 2002, Critchley et al., 2002). ERβ3 mRNA expression has only 
been described in the testis (Moore et al., 1998). There are several studies addressing 
the expression and putative role of the ERβ truncated isoforms in the aetiology of 
tumourigenesis and as novel biomarkers in cancer tissues. Shaaban et al. have 
demonstrated the importance of identifying ER localisation with a correlation 
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between ERβ2 cytoplasmic expression and reduced overall survival but conversely 
better outcome for patients with nuclear ERβ2 expression (Shaaban et al., 2008). 
Furthermore, ERβ2 expression is associated with a favourable outcome in 
endometrial cancer where downregulation was associated with endometrioid cancer 
progression (Chakravarty et al., 2007). Increased ERβ5 mRNA transcript levels were 
determined in breast (Park et al., 2006) and endometrial carcinoma when compared 
with normal endometrial specimens (Skrzypczak et al., 2004) and in breast cancer 
cell lines when compared with ERβ levels (Leygue et al., 1999b). 
Chapter 1     Literature Review 16 
 
Figure 1.9 Structure of ERβ isoforms. 
Comparison of the structural domains of ERβ splice variants reveals divergence at 
the carboxy (C)-terminus LBD (A). Molecular modelling reveals disruption at the C-
terminus translates to disruption of helix 12 (green) optimal positioning (ERβ2) and 
complete ablation of helix 12 from ERβ4 and ERβ5 (B). Adapted from Heldring et 
al., 2007 and Leung et al., 2006.   
 
1.7 Mechanisms of oestrogen receptor dependent gene activation 
Four molecular pathways mediated by oestrogen receptors have been identified, three 
of which are dependent upon binding of receptor(s) to oestrogenic ligands (Fig. 
1.10).  These modes of activation can be summarised as 1) direct binding to DNA at 
oestrogen response elements (ERE-dependent), 2) ERE-independent activity 
involving indirect binding to DNA at AP-1 or Sp1 sites, 3) non-genomic activity and 
4) steroid ligand-independent activation resulting from phosphorylation downstream 
of growth factor-dependent cascades (reviewed in Hall et al., 2001, Nilsson et al., 
2001, Heldring et al., 2007). 
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Figure 1.10 Overview of the distinct regulatory pathways of ER actions 
1. Canonical ligand-dependent ER activation enables binding at the ERE. 2. ERE-
independent genomic action makes use of transcription factors such as c-fos and c-
jun and bind at alternative promoter sites (e.g. AP-1 sites). 3. Non-genomic 
membrane-ER signalling via protein-kinase cascades. 4. Ligand-independent 
genomic actions potentiated by growth factor mediated signalling (Adapted from 
Heldring et al., 2007). 
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1.7.1 Ligand-dependent gene activation 
The characteristic activation paradigm of the Type I NRs (including both ER 
subtypes) involves disruption of the association of receptor binding to heat shock 
proteins (hsp56, hsp70 and hsp 90) and corepressors (Onate et al., 1998).  Ligand-
binding induces dissociation from this multiprotein inhibitory complex and a 
conformational change of the receptor such that it can dimerise (McKenna et al., 
1999), and the newly-exposed DBD can bind DNA. ER DNA-binding at the core cis-
acting consensus 13bp ERE sequence 5’-GGTCAnnnTGACC-3’ was first identified 
in the Xenopus vitellogenin A2 gene promoter (Klein-Hitpass et al., 1988). 
Additional non-consensus EREs have also been identified (Berry et al., 1989) and it 
has been reported that the ER-ERE binding affinity can be modulated by flanking 
regulatory factors such as hsp70 (Driscoll et al., 1998). The subsequent interaction 
with coregulatory proteins (through the transactivation function domains AF-1 and 
AF-2) and other transcription factors stabilises the DNA-bound ERs and facilitates 
binding of ribonucleic acid (RNA) polymerase II and initiation of transcription 
(reviewed in Zawel and Reinberg, 1995). More recently however, there is data to 
suggest that the ER interaction with ERE motifs is insufficient for receptor-
chromatin association and the search for additional binding sites by chromosome-
wide mapping has revealed additional sites in close proximity to the ERE consensus 
sequences such as the Forkhead factor sites (Carroll et al., 2005). Chromatin 
immunoprecipitation (CHIP)-microarray mining has revealed that binding of the 
Forkhead factor FoxA1 to these numerous specific sites is involved in directing and 
tethering ERα to the chromatin while ERβ-bound regions tend to cluster at GC-rich 
sites and consequently drive oestrogen-mediated transcription (Carroll and Brown, 
2006). 
1.7.2 ERE-independent gene activation 
The non-classical ERα-dependent activation of genes has been demonstrated through 
ER interaction with the Fos/Jun transcription factors (Jakacka et al., 2001). Insulin-
like growth factor-1 (IGF-1) and collagenase expression is mediated through the ER-
Fos/Jun complex action at activator protein-1 (AP-1)/12-O-tetradecanoyl-phorbol-
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13-acetate-responsive promoter sites in vitro (Philips et al., 1993, Umayahara et al., 
1994, Webb et al., 1995b). Differential ERα- and ERβ-mediated responses to E2 and 
the anti-oestrogen ICI 164, 384 have been demonstrated at the AP-1 site whereby ICI 
164, 384 behaves as an agonist of ERβ (Webb et al., 1995a, Paech et al., 1997). 
ERα-AP-1 activation is mediated by the concerted effects of AF-1 and AF-2 that 
enable coactivator recruitment (Webb et al., 1999) while the action of ERβ at AP-1 
in response to the binding of SERMs has been shown to be AF-independent 
(Kushner et al., 2000). Specific recruitment of histone deacetylases and corepressors 
from AP-1 to the SERM-ERβ complex underpins the AF-independent paradigm such 
that the AP-1 site is rendered free to transcribe incoming activation signals (Jackson 
et al., 1997, Lavinsky et al., 1998). Specificity protein 1 (Sp1) is another example of 
a ubiquitous transcription factor that channels ER-mediated signalling and binds 
DNA at specific consensus sequences 5’-GGCGGG-3’ (GC boxes) in the presence 
and absence of ligand (Porter et al., 1997). Co-operative action of ER and Sp1 has 
been exemplified in the regulation of cathepsin D, RARα and Hsp27 in vitro 
(Krishnan et al., 1995, Rishi et al., 1995, Porter et al., 1996). Differences in E2-
driven gene expression between ERα and ERβ  is understood to partly stem from 
differential DNA binding patterns where ERα has been found to preferentially 
localise at TA-rich sites that include forkhead binding sites (section 1.7.1) while ERβ 
predominantly interacts with the chromatins at GC-rich motifs (Liu et al., 2008). 
1.7.3 Non-genomic gene activation 
An alternative mode of ER-dependent gene activation is non-genomic signalling and 
involves extranuclear ER that induces post-translational modifications and indirect 
activation of gene expression within the nucleus (Watson and Gametchu, 1999, 
Mendelsohn, 2000). Investigations into the non-genomic actions of E2 have 
employed oestrogen-dendrimer conjugates that exist outside of the nuclear 
membrane and revealed a mechanistically distinct mode of ER activation via protein 
kinase signalling that can be abrogated by kinase inhibitors and anti-oestrogen 
compounds (Madak-Erdogan et al., 2008). This study also determined a pool of 
genes that were preferentially expressed via extranuclear non-genomic signalling in 
MCF-7 cells (Madak-Erdogan et al., 2008).  
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Plasma membrane ERα and ERβ comprises 5-10% of total cellular ER (Levin, 2009) 
and it has been reported that the membrane and nuclear forms of ER arise from the 
same gene transcript, share similar affinities for oestradiol (E2) (Razandi et al., 2000) 
but differ in their response to the pure anti-oestrogen ICI 182, 780 (Gu et al., 1999). 
Membrane ER and other E2-binding proteins such as the orphan G protein-coupled 
receptor, GPR30 have been implicated in the rapid E2-dependent signalling to 
downstream kinase cascades (Levin, 2009, Prossnitz et al., 2008, Revankar et al., 
2005). For example, the vascular protective function (vasodilation) of E2 is mediated 
via the activation of eNOS by the interaction of membrane-ER with tyrosine kinases. 
Specifically, E2-bound membrane ER has been shown to bind the p85α subunit of 
the phosphatidylinositol-3-OH kinase at the caveolae (plasma membrane 
microstructures) that in turn leads to eNOS production (Simoncini et al., 2000). 
Further non-genotropic functions of ER activity include maintenance of bone density 
via activation of an Src/Shc/ERK-dependent pathway (Kousteni et al., 2001) and 
anti-apoptotic effects in vitro (Razandi et al., 2000).  
1.7.4 Ligand-independent gene activation 
Extracellular signals can also activate the ERs as a consequence of phosphorylation 
in the absence of oestrogenic ligands (Cenni and Picard, 1999). Seminal studies in 
the 1980’s demonstrating a role of analogues of cyclic adenosine monophosphate 
(cAMP) in replacing progesterone-mediated reproductive activity in ovariectomised 
rats were the first to identify the potential for ligand-independent activation of NRs 
in regulating gene expression (Beyer et al., 1981). Subsequently ERα-dependent 
induction of progesterone receptor expression in response to incubation with insulin-
like growth factor was demonstrated in MCF-7 cells (Katzenellenbogen and Norman, 
1990). Phosphorylation of ERα and ERβ at specific serine and threonine residues 
potentiates transcriptional function in the presence of oestrogenic hormones as well 
as peptide growth factors through mitogen-activated protein signalling cascades in 
vitro (Kato et al., 1995d) (section 1.11.1) and expression of the regulatory subunits 
of cyclin-dependent kinases (CDKs); cyclin D1 (Zwijsen et al., 1998) and cyclin A 
(Trowbridge et al., 1997). The activity of growth factor–mediated signalling 
cascades and cyclin D1 on ERs has been implicated in cancer development and 
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progression and been associated with the development of resistance to endocrine 
therapy during treatment of breast cancers (Picard et al., 1997, Neuman et al., 1997) 
(sections 1.11 to 1.11.3 inclusive). 
1.8 ER dimerisation 
Binding of oestrogenic ligands to the LBD of both ERα and ERβ induces a change in 
receptor conformation (see above) and favours formation of homo or hetero-dimers 
depending upon whether one or more subtype is expressed in the cell (Fig. 1.11). In a 
particular cell context, the formation of hetero-dimers in response to binding of 
oestrogenic ligands in vivo in mice adds to the complexity of ER regulatory and 
signalling patterns (Pettersson et al., 1997). It has been reported that the ERα-ERβ 
conformation is a more favourable arrangement compared with ERβ homo-dimers 
for binding at the ERE (Cowley et al., 1997). In common with homodimers, the 
ERα-ERβ hetero-dimer actively recruits members of the p160 family of coactivators 
(Cowley et al., 1997). Moreover, mutation studies have revealed that only the DBD 
of ERα is a pre-requisite for formation of a ERα-ERβ hetero-dimeric complex (Pace 
et al., 1997) and as such, this is competent when only one receptor within the dimer  
can actively bind ligand (Tremblay G.B. et al., 1999) (section 1.4.2). Studies using 
hetero-dimeric complexes have elucidated that the dominant effects of one partner 
that can determine the efficacy of the activity of the complex, specifically the ERβ-
selective responses of an ERα-ERβ heterodimer to 4-hydroxytamoxifen (4HT) and 
basal levels of E2 (Hall and McDonnell, 1999). Differential activation of reporter 
gene expression by ERα and ERβ homo-dimers also occurs at the AP-1 binding site 
where ERβ opposes signalling in response to E2 and behaves as a transcriptional 
inhibitor in response to incubation with 4HT and the anti-oestrogen ICI 164, 384 
(Paech et al., 1997). 
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Figure 1.11 Schematic overview of ERα/ERβ homo- and hetero-dimerisation 
patterns. 
Taken from Saunders, 1998. 
1.9 ER transcriptional coregulators 
Evidence for additional modulatory factors impacting on the function of NRs 
stemmed from preliminary studies that revealed the phenomenon of ‘squelching’ 
between competing receptors on promoter sequences (Gill and Ptashne, 1988, Meyer 
et al., 1989). ER coregulators play a critical role as mediators of transcriptional 
regulation through direct interaction at the pre-initiation complex and covalent 
modifications at the DNA double-helix. The ER coregulators also serve as points of 
convergence for integrating ligand-dependent and independent signalling pathways 
(Robyr et al., 2000). Coactivators are transactivation factors that function to enhance 
transactivation by acetyltransferase activity and conversely the corepressor 
interaction with ERs reduces transcription through histone deacetyltransferase 
activity (Fig. 1.12) (reviewed in O'Malley et al., 2008).  
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Figure 1.12 Opposing actions of co-regulator activity. 
Coactivators behave as histone acetyltranferases (HATs) that disrupt the 
nucleosomal structure and facilitate ease of access by the transcriptional machinery. 
Corepressors exhibit histone deacetylase (HDAC) activity that controls the loss of 
acetyl groups from individual nucleosomes causing condensation of the chromatin 
and blocking access by the transcriptional activation complex. (Adapted from 
McKenna et al., 1999). 
1.9.1 ER coactivators 
The initial characterisation of the SRC-1/NCoA-1 protein (Onate et al., 1995) led to 
the subsequent unveiling of a complete myriad of structurally and functionally 
related modular factors termed the p160 family of coactivators that bind at the AF-2 
domain of ER LBDs through LxxLL motifs (Heery et al., 1997). This family of 
coactivators also includes SRC-2/human homolog of glucocorticoid receptor-
interacting protein 1, the transcriptional intermediary factor 2 (TIF2) and SRC-
3/amplified in breast cancer-1 (AIB-1) (McDonnell and Norris, 2002). These SRC 
coactivators contain multiple LxxLL motifs that facilitate binding to NRs following 
their conformational changes in response to ligand-binding (Heery et al., 2001). In 
addition, the coactivators are composed of two conserved activation domains (AD1 
and AD2) that are involved in the recruitment of secondary coactivators, an amino-
terminal basic helix-loop-helix/Per-Arnt-Sim (bLHL-PAS) region and a protein 
dimerisation domain (Belandia et al., 2002). 
 
A number of other coactivators that also behave as histone acetylases to remodel the 
chromatin structure and enable better accessibility of the basal transcription 
machinery are targeted to the AF-2 domain of ERs. These include the cointegrator 
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cAMP response element-binding (CREB)-binding protein (CBP)/p300, thyroid 
hormone receptor activating protein (TRAP)/DRIP (Heery et al., 2001) and the 
activating signal co-integrators 1 and 2. CBP/p300 has intrinsic histone 
acetyltransferase activity and acetylation of the specific sequences K266 and K268 of 
the hinge region (D) of ERα enhances receptor DNA binding (Subramanian et al., 
2008). 
 
Recruitment of coactivators to the AF-1 domain of ERα and ERβ by steroid receptor 
RNA activator (SRA) and exclusively to ERβ by the p68 RNA helicase has also been 
described (Lanz et al., 1999, Endoh et al., 1999). Adding to the complexity of the ER 
transcriptional apparatus is a further layer of secondary coactivators that indirectly 
act on the ERs through the aforementioned p160 coactivators which in turn act as 
bridging molecules. These include the arginine-specific protein methyltransferases; 
PRMT1 and coactivator associated arginine methyltransferase 1 that bind at the C-
terminal AD2 of the p160 proteins (Stallcup et al., 2000) and coiled-coil coactivator 
that binds at the bHLHs/PAS domain of the p160 coactivators (Kim et al., 2003). An 
overview of ER coactivators is presented in Table 1.1 below. 
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Table 1.1 ER coactivator listing of coregulators that enhance functional activity. 
(Adapted from Hall and McDonnell, 2005). 
 
 
1.9.2 ER corepressors 
ER corepressors function to blunt ER activity and prevent hyperstimulation of ER 
signalling pathways. Corepressors act by occlusion of coactivator binding and 
histone deacetyltransferase activity (Table 1.2, Fig. 1.12). At unbound ERs, the 
nuclear corepressor (NCoR) and silencing mediator for retinoid and thyroid hormone 
receptors (SMRT) maintain the receptors in an inactive state that is disrupted 
following ligand binding (Chen and Evans, 1995, Horlein et al., 1995). Like the 
LxxLL motif of the AF-2 coactivators, these corepressors contain two corepressors 
NR-interacting (CoRNR) boxes (Hu and Lazar, 1999). These proteins have also been 
shown to function indirectly through secondary cofactors such as mSin3, a histone 
deacetyltransferase linker molecule to mediate their inhibitory effect (Hu and Lazar, 
2000). 
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Table 1.2 ER corepressors that decrease oestrogen stimulatory function. 
(Adapted from Hall and McDonnell, 2005). 
 
1.10 ER Ligands 
The most abundant oestrogen in human serum is 17β-oestradiol (E2) although two 
other oestrogens, oestrone and oestriol are also present and exhibit weaker agonist 
properties. E2 is a small hydrophobic lipophilic molecule structurally composed of 
four rings (A-D) that can bind both ERα and ERβ via the LBD (reviewed in Anstead 
et al., 1997).  E2 binding induces the conformational change and dimerisation of the 
occupied ER to facilitate recruitment of coregulators and binding at the DNA 
promoter sequence (section 1.7.1) (Fig. 1.13). The binding affinity of E2 for ER does 
not discriminate between the full-length receptor subtypes with IC50s of 2.35nM and 
1.98nMs determined for ERα and ERβ respectively (Harris et al., 2002). 
Phytoestrogen is an umbrella term for plant oestrogens encompassing flavanoids, 
coumestans and lignans that occur naturally in the diet and demonstrate preferential 
binding affinity for the ERβ subtype (e.g. genistein) (Miller et al., 2003). 
Epidemiological reports have advocated a role for these exogenous proteins as 
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Figure 1.13 E2 binding enables activation at the ERE. 
The chemical structure of oestradiol is outlined on the left hand side. E2 binding in 
the region of the AF-2 domain stimulates receptor conformational changes, 
dimerisation, recruitment of coregulators and the transcriptional machinery to form 
the pre-initiation complex at the ERE. Taken from Schiff, 2002.   
The primary function of E2 is to mediate cellular differentiation and proliferation. 
Alterations in the regulation of this natural steroid and its metabolites is associated 
with tumourigenesis (reviewed in Yager, 2000). The current treatment modalities to 
combat excess E2 activity target 1) circulatory oestrogen levels directly with 
aromatase inhibitors or 2) the ER signalling path by antagonising ER function 
through endocrine therapy with SERMs and downregulating ER activity with the use 
of ‘pure anti-oestrogens’ (Fig 1.14). 
 
Figure 1.14 Schematic overview of ER agonist, antagonist and SERM activity.  
Taken from Deroo and Korach, 2006. 
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1.10.1 ER Selective agonists 
The differential expression profiles of the ER subtypes are suggestive of differences 
in their biological function at the tissue level. In parallel to the development of 
SERMs, synthetic ERα and ERβ-selective ligands have been developed that exploit 
differences in the two LBDs (~53% homology), in particular the existence of Met-
421 and Leu-384 in ERα that correspond to Ile-373 and Met-336 in ERβ that 
distinguish the receptor subtypes (Katzenellenbogen et al., 2003). 
 
ER-selective agonists include modified oestrogen derivatives; oestradiol-16α-lactone 
and 8β-vinyl oestradiol that selectively bind ERα and ERβ respectively (Hillisch et 
al., 2004). Furthermore, propyl pyrazole triol (PPT™) has a binding affinity for ERα 
that has been determined as 410 fold stronger than for ERβ and in addition this 
compound is reported to act as an agonist when bound to ERα while behaving as an 
antagonist in complex with ERβ (Stauffer et al., 2000). 
 
Diarylpropionitrile (DPN™) is a xenoestrogen that shows a 70 fold higher affinity 
for ERβ than ERα (Meyers et al., 2001) owing to the preferential interaction of the 
nitrile group of DPN™ with the Met-336 residue of ERβ (Sun et al., 2003). 
Genistein is an isoflavanoid that exhibits preferential binding for ERβ (Barkhem et 
al., 1998). Other compounds that have demonstrated ERβ selectivity include WAY-
358 (157 fold ERβ-selective) and the benzoxazole derivative ERβ-041 (≥200 fold 
ERβ-selective) (Manas et al., 2004, Malamas et al., 2004). 
1.10.2 Anti-oestrogens 
ICI 182,780 (ICI/Faslodex™) is a potent anti-oestrogen that is reported to block 
activity of both ERα and ERβ by disrupting nucleocytoplasmic shuttling (Dauvois et 
al., 1993b), receptor dimerisation and by increasing receptor turnover (Parker, 1993) 
(Fig. 1.15A). ICI 182,780 has a greater affinity for the ERs than the ICI 164,384 
compound owing to the fluorine atoms that increase its solubility (Wakeling et al., 
1991). X-ray crystallography studies determined that the bulky alkylamide side chain 
at the 7α position of ICI 182,780 displaces Helix 12 of ERβ and extends beyond the 
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ligand-binding pocket to the coactivator-binding groove (Pike et al., 2001). The 
principle practical application of the pure anti-oestrogen is as a second-line therapy 
against tamoxifen-resistant breast tumours (Howell et al., 1995). 
1.10.3 Selective Oestrogen Receptor Modulators  
A class of structurally distinct therapeutics dubbed the SERMs target oestrogen-
regulated genes and exhibit partial agonist and antagonist behaviour based on 
promoter and tissue context (reviewed in Osborne et al., 2000) (Fig. 1.15B). The 
canonical SERM introduced in 1977 for use in the management of metastatic breast 
cancer patients is 4HT (Osborne, 1998). Based upon the conformation adopted with 
helix 12 (Brzozowski et al., 1997), 4HT is used as an adjuvant therapy to block 
oestrogen activity in the ERα-positive breast tissue but prolonged exposure has been 
linked with low grade endometrial cancers (Fisher et al., 1994). Toremifene is 
another first generation SERM that has positive influence on bone mineral density 
but shares the uterotrophic effects of 4HT and as such is only prescribed as an 
adjuvant therapy in postmenopausal patients with metastatic breast cancer (Holli, 
2002). The consequence of the dual activity of 4HT and toremifene spawned the 
search for alternative SERMs and led to the development of second generation 
SERM compounds such as raloxifene (reviewed in Burger, 2000 and Shang, 2006). 
Like 4HT, raloxifene has antiproliferative activity in the breast but does not exhibit 
agonism in the endometrium and as a result has a reduced chance of inducing 
endometrial cancer (Goldstein et al., 2000).  
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Figure 1.15 Comparison of anti-oestrogen and selective oestrogen receptor 
modulator activity.  
A. ICI 182,780 chemical structure is on the left hand side. ICI 182, 780 binds ERα or 
ERβ with a similar affinity to E2, induces rapid degradation of the receptor and 
facilitates weak ER binding at the ERE. This conformation recruits corepressors and 
inhibits transcriptional activity. B. 4-hydroxy-tamoxifen binding exerts partial 
agonist and antagonist activity that is tissue-context dependent. Taken from Schiff, 
2002. 
1.11 Growth Factors 
Growth factors have an important role in the cell development, differentiation and 
proliferation of their target tissues (Force and Bonventre, 1998). The peptide growth 
factors are defined by a consensus signature composed of six conserved cysteine 
residues bound by intramolecular disulphide bonds.  The growth factor precursor 
ligands are transmembrane proteins that are released as mature growth factors 
through proteolytic activity at the cell surface (Harris et al., 2003). Human EGF is a 
53 amino acid protein product of the gene localised to 4q25-27 (Morton et al., 1986). 
EGF channels its effects through binding of its cognate receptor, the epidermal 
growth factor receptor (EGFR) (reviewed in Harris et al., 2003) that was the first 
receptor tyrosine kinase to be described (Carpenter et al., 1978).  
 
EGFR/HER1 is one of four members of the human epidermal growth factor receptor 
(HER1-4) family of transmembrane glycoproteins (Wells, 1999) originally labelled 
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due to their homology to the erythroblastoma gene – v-erbB. The HER/ErbB family 
of protein tyrosine kinase receptors are responsive to 13 polypeptide ligand factors 
(Prigent and Lemoine, 1992, Citri and Yarden, 2006). Each are comprised of 4 
distinct domains: 1) the extracellular ligand binding domain that is made up of four 
subdomains responsible for change of state during ligand-binding; leucine-rich 1 and 
2 (domains I and III) and cysteine-rich 1 and 2 (domains II and IV),  2) the 
transmembrane domain, 3) a small intracellular tyrosine kinase juxtamembrane 
domain and 4) the C-terminal tail that serves as a docking site for effector signalling 
molecules such as Grb2 (Fig. 1.16). Over the course of the evolution of the HER 
family, accumulated mutations have rendered HER2 and HER3 non-autonomous 
such that HER2 cannot bind ligand (Klapper et al., 1999) and the intracellular kinase 
activity of HER3 is abrogated (Citri and Yarden, 2006). Despite this, both receptors 
actively form heterodimer partnerships and have been implicated in important roles 
in clinical pathologies (e.g. breast cancer) (Osborne et al., 2003, Kirkegaard et al., 
2007). HER1, and the neuregulin-activated HER3 and HER4 (Plowman et al., 1993) 
proteins can form both homo- and heterodimers. Gene mutation experiments 
modifying the function of EGFR have revealed key roles in the brain, kidney and 
skin (Harris et al., 2003). 
1.11.1 GF-mediated Phosphorylation of ER subtypes: The MAPK 
signalling cascade 
As previously described (section 1.7), the functional output of ER does not solely 
stem from a linear ligand-mediated dogma but is attributable to a myriad of both 
divergent and integrated activating signals and pathways. The growth factor family 
of Type I glycosylated transmembrane proteins play a pivotal role in activation of 
ERs through kinase-dependant signalling pathways (reviewed in Levin, 2003). The 
concept of GF-interacting with the multifaceted activation of ER was borne out by 
early mouse studies elucidating an effect of the extracellular ligands on ER-
dependent transcriptional responses (Nelson et al., 1991, Ignar-Trowbridge et al., 
1992). Growth factor-mediated ER transcriptional activity is governed by the 
reversible phosphorylation of specific target serine and threonine residues that can 
occur in the presence or absence of oestrogenic ligands (Lannigan, 2003) and on ERα 
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they are largely concentrated within the 180 amino acid region of the AF-1 domain 
(Bunone et al., 1996b)  
 
Phosphorylation is a reversible process regulated by kinases and phosphatases. 
Activation of the MAPKs of which there are four, namely: extracellular signal-
regulated kinase (ERK), big MAP kinase-1 BMK/ERK5), c-Jun-N-terminal kinase 
(JNK) and p38 kinase is orchestrated by GF mediated stimulation at the extracellular 
domain of cognate membrane-bound receptors (Smith, 1998). The tyrosine signalling 
cascades involve a three-tier system with sequential activation of MAPK kinase 
kinase (MAPK KK/MEKK) that phosphorylates a MAPK kinase (MEK) that in turn 
activates a specific MAPK (reviewed in Pearson et al., 2001). 
 
GF induction (e.g. EGF) of the ERK1/2 MAPK is well described and outlined in Fig. 
1.16 (reviewed in Force and Bonventre, 1998). EGF binding induces EGFR 
dimerisation and intracellular autophosphorylation (Renshaw et al., 1997). Linked by 
the src homology-2 (SH2) domain of GF receptor binding protein 2 (Grb2) at the 
specific phosphorylated tyrosine residues within the cytoplasmic domain of the 
EGFR, this docking site (Grb2) propagates the tyrosine kinase signal. Grb2 recruits 
the guanine nucleotide exchange factor, sons of sevenless (SOS) that in turn can 
activate Ras (Force and Bonventre, 1998). Guanosine-5'-triphosphate (GTP)-bound 
activated Ras activates the Raf family of proteins (Jelinek et al., 1996) that are in 
complex with coregulators such as the molecular chaperone heat shock proteins 
(hsp50 and hsp 90) and the 14-3-3 proteins (Xiao et al., 1995). Activated Raf induces 
the phosphorylation of MEK1 and 2 that in turn phosphorylates the tyrosine and 
threonine residues of ERK1 and 2. Activation of the MAPKs ERK1 and 2 can induce 
p90ribosomal S6 kinases (RSKs) and these in turn have been demonstrated to 
activate the ERα through phosphorylation at specific residues within the AF-1 
domain (Joel et al., 1998b). 
 












































Figure 1.16 Schematic overview of the MAPK (ERK1/2) tyrosine signalling 
cascade and its regulation. 
GF-induced phosphorylation of the ER is the result of a series of stepwise catalytic 
reactions involving MAPKs. The phosphorylated ER end-product fuels the positive 
feedback loop via the regulation of EGF protein. 
 
1.11.2 GF-mediated Phosphorylation of ER subtypes: The target sites 
There are eight target sites of protein kinase-directed phosphorylation on the ERα 
protein that have been identified in vitro at the serine 102 (Ser102)/Ser104 motif, 
Ser106 (Joel et al., 1998c, Thomas et al., 2008, Rogatsky et al., 1999), Ser118 (Joel 
et al., 1995, Bunone et al., 1996b), Ser167 (Arnold et al., 1994, Joel et al., 1998b, 
Martin et al., 2000a, Campbell et al., 2001), Ser236 (Le Goff et al., 1994b, Chen et 
al., 1999) Ser 305 (Rayala et al., 2006, Tharakan et al., 2008) T311 (Lee and Bai, 
2002) and Y537 (Weis et al., 1996, Arnold et al., 1997) (Fig. 1.17). Three phospho-
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target residues at Ser16, Ser106 and Ser 124 have been mapped on the mouse ERβ 
subtype (Cheng and Hart, 2001, Tremblay A. et al., 1999).  
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Figure 1.17 Overview of ERα residues that are targets for phosphorylation and the 
signalling pathways that control them. 
 
Of the four documented target sites within the AF-1 of ERα (Ser104, Ser106, Ser118 
and Ser 167), the phosphorylation of Ser118 is the best characterised. It has been 
deemed imperative in modulating the functional capacity of ERα (Kato et al., 1995b) 
and roles for both direct and indirect EGF- and IGF-mediated signalling (in addition 
to the canonical E2-dependent mechanism) have been linked to this site (Bunone et 
al., 1996b, Murphy et al., 2004). Ser118 is phosphorylated by the complex of TFIIH 
and cyclin-dependent kinase-7 (cdk7) directly (Chen et al., 2000) and also by 
ERK1/2 (p44/p42 MAPK) triggered by EGF activation of the EGFR (Kato et al., 
1995d) (Fig. 1.17). The phosphorylation status of ERα at Ser118 is inherently linked 
to the regulation of receptor activity in a positive and negative manner. Phospho-
Ser118 ERα has been shown to govern the specific recruitment of the coactivator 
splicing factor (SF)-3ap120, a component of the spliceosome (Masuhiro et al., 2005). 
Phospho-Ser118 ERα has also been shown to be negatively regulated by protein 
phosphatase 5 (PP5) activity (Ikeda et al., 2004) and the stromelysin-1 platelet-
derived growth factor (PDGF)-responsive element binding protein (SPBP) 
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corepressor (Gburcik et al., 2005) resulting in the attenuation of the transcriptional 
capacities attributable to EGF-dependant and E2-dependant phosphorylation. 
 
Additional sites identified as phosphorylation targets within the AF-1 (A/B) domain 
of ERα include Ser-102, -104, -106, -167 and -236. The phosphorylation of Ser104 
and/or Ser106 works in concert with phospho-Ser118 as co-operative MAPK binding 
sites (Thomas et al., 2008) and all three sites also carry the signature consensus 
sequence that confers activity by CDKs (Trowbridge et al., 1997, Rogatsky et al., 
1999). Furthermore, there is evidence to suggest susceptibility of serine residues -
102, -104, -106 and -118 to glycogen-synthase 3 kinase (GS3K), itself the product of 
GF or hormonal regulation (Medunjanin et al., 2005). Phosphorylation of Ser167 has 
been demonstrated in response to ligand binding (Arnold et al., 1994) and in 
response to MAPK signalling activity through the serine/threonine protein kinase; 
p90 ribosomal S6 kinase 1 (pp90rsk1) (Joel et al., 1998b) and AKT signalling (Martin 
et al., 2000b, Campbell et al., 2001).  
 
The importance of the AF-2 functional domain in response to ERα phosphorylation 
has been revealed by phospho-target sequences (Ser236, Ser305, threonine311 
(T311) and tyrosine537 (Y537)) detected at this region. In the absence of ligand, the 
AF-2 domain is in a conformation that prevents AF-1 activity. Molecular modelling 
has revealed that ligand binding facilitates exposure of the AF-1 for coregulator 
recruitment and activation via phosphorylation (Tharakan et al., 2008). In studies 
using cancer cell lines, phospho-Ser305 was found to be under the regulation of two 
kinase dependent pathways directed by p21-activated kinase 1 (Wang et al., 2002) 
and protein kinase A (PKA) (Michalides et al., 2004). It was also reported that 
Ser305 imparted an effect with Ser118 on ERα activity in response to 4HT in treated 
HeLa cells (Rayala et al., 2006). This effect may be in part due to the increased 
binding affinity of phospho-Ser305 ERα at target gene promoter sites (Tharakan et 
al., 2008). Located within helix 1 of the LBD, T311 phosphorylation has been 
associated with increased coregulator recruitment and nuclear localisation (Lee and 
Chapter 1     Literature Review 36 
Bai, 2002) while Y537, also in the LBD has been implicated as a modulator of ligand 
and DNA binding functions (Likhite et al., 2006). 
1.11.3  Evidence for an interplay between growth factor and oestrogen 
receptor signalling cascades 
The bidirectional crosstalk between the GF-regulated kinase networks and ER-
dependent signalling pathways are reported to be of clinical significance in patients 
with breast cancer that develop endocrine resistance (reviewed in Smith, 1998). For 
example, Osborne et al. have reported that breast tumour growth is regulated by the 
concerted activity of ER and GF dependent signalling and that the latter is 
responsible for HER2 amplification that may underlie resistance to 4HT (Osborne et 
al., 2005). In addition to MAPK-mediated phosphorylation of the ER protein, ER 
coregulators are substrates for tyrosine kinase cascades (Arpino et al., 2008) and act 
as points of convergence between the two signalling pathways.  In particular, HER-
mediated signalling has been reported to potentiate the activity of the coactivator, 
amplified in breast cancer-1 (AIB1)/SRC-3 (Font de Mora and Brown, 2000, Lopez 
et al., 2001).  Further to this, a number of studies attribute 4HT resistance and poor 
prognosis with the co-expression of AIB1, HER2 and HER3 and the interplay of 
their respective signalling functions (Schiff et al., 2003, Osborne et al., 2003, 
Kirkegaard et al., 2007).  
1.12 Functional analysis of ERs: gene knockout studies 
Mouse ‘knockout’ (KO) models of ER subtypes have been engineered to decipher 
precise roles for the individual ER subtypes in transducing oestrogen-dependent and 
independent signalling pathways (Table 1.3) (reviewed in Couse and Korach, 1999, 
Hewitt and Korach, 2003). These studies have revealed an essential role for ERα and 
ERβ in female fertility. Early-onset infertility in the female α-ERKO mice is believed 
to stem from dysregulation at the pituitary resulting in increased production of 
luteinising hormone (LH) and its cognate receptor (LHR), that in turn results in the 
development of haemorrhagic cysts within the ovary and anovulation (Lubahn et al., 
1993, Schomberg et al., 1999). The uterus of the α-ERKO mice is underdeveloped 
(hypoplastic) and non-responsive to oestradiol (Couse et al., 1995). Studies 
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investigating the uterine response to IGF-1 using α-ERKO mice revealed the 
importance of the presence of ERα in uterine nuclear proliferation, although 
phosphorylation of MAPK was independent of ERα and this result strengthens the 
concept of crosstalk between the IGF receptor (IGFR) and ER signalling pathways 
(Klotz et al., 2002). 
 
β-ERKO female mice exhibited differential sub-fertility patterns with continuous 
matings that included decreased pregnancy rate or reduced number of pups per litter 
compared with wild type animals (Krege et al., 1998, Dupont et al., 2000) that did 
not influence animal behaviour (Ogawa et al., 1999). Like α-ERKO mice, the        
αβ-ERKOs are infertile but are phenotypically distinct from the single gene 
knockouts and had abnormal follicles lacking an oocyte that increased in abundancy 
with age and no corpora lutea (Dupont et al., 2000). The uteri of αβ-deficient mice 
were hypoplastic and resistant to oestrogenic activity (Couse and Korach, 1999). 
 
Examination of non-reproductive function in the KO models has revealed exclusive 
roles for ERα in maintaining bone density and behaviour as a cardioprotectant while 
the β-ERKO female mice had increased bone mineral density and were non-
responsive to crossing with apolipoprotein E, suggesting a receptor-mediated role for 
ERα in these processes (Hewitt and Korach, 2002, Hodgin et al., 2001). 
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Table 1.3 Overview of ER knockout mice model phenotypes.  
(Adapted from Walker and Korach, 2004). 
 
1.13 Oestrogens, oestrogen receptors and human endometrial 
function  
The human endometrium is a dynamic tissue regulated by the sequential exposure to 
oestrogen and progesterone over distinct phases termed the menstrual cycle (Fig. 
1.18) (Simmen and Simmen, 2006). The endometrium consists of functional and 
basal layers. The functional layer responds to the rising concentrations of oestrogen 
during the proliferative phase by thickening and then differentiates in response to a 
surge in progesterone (Jabbour et al., 2006). The follicular phase occurs after the 
functional layer has been shed at menstruation and is characterised by intense mitotic 
activity occurring in the endothelial, epithelial and stromal cellular components 
under the influence of oestrogen (Ferenczy, 1993) and angiogenesis controlled by 
EGF and vascular endothelial growth factor (Nelson et al., 1991, Taylor et al., 2001). 
 
The secretory phase follows the luteinising hormone surge that signals ovulation and 
under the control of progesterone is synonymous with glycogen accumulation in the 
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cytoplasm of the epithelial cells and secretion into the tortuous glandular lumens 
(Ferenczy, 1993). In the absence of fertilisation and the decrease in circulating 
progesterone, the endometrium is shed from the functional layer and regenerated by 




Figure 1.18 Schematic overview of the differentially regulated phases of the 
menstrual cycle. 
Upon shedding of the functionalis layer of the endometrium during menstruation, 
oestrogen influences the thickening of the uterine lining once more during the 
follicular phase of the cycle. After ovulation and in response to progesterone levels 
produced from the corpus luteum, the endometrial columnar epithelium and stroma 
secrete glycogen in preparation for implantation. In the absence of implantation and 
decreasing levels of progesterone the tissue is broken down once more during 
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1.13.1 Oestrogen expression in the human endometrium 
In the human uterus expression of both ER proteins has been immunolocalised using 
staged, full thickness endometrial biopsies (including the functional and basal zones 
of the endometrium and adjacent myometrium). These results have revealed that the 
expression of ERα, ERβ1 and ERβ2 vary in intensity during the normal menstrual 
cycle (Critchley et al., 2001, Critchley et al., 2002, Saunders and Critchley, 2002, 
Henderson et al., 2003). ERα and ERβ are both expressed in endometrial glands and 
stromal fibroblasts. In the functional layer the intensity of immunoexpression of ERα 
is highest at the proliferative phase (oestrogen dominated) but declines during the 
secretory phase (Snijders et al., 1992, Critchley et al., 2001). Like ERα, ERβ was 
expressed in both epithelial and stromal cells during the proliferative phase but 
whereas expression in the glandular epithelial cells declined, expression in the 
stromal fibroblasts and luminal surface epithelium was maintained (Taylor and Al-
Azzawi, 2000, Critchley et al., 2001). Notably expression of both ERα and ERβ 
remains unchanged in the basal compartment (Critchley et al., 2001). 
 
Although the functional significance of the expression of ERβ in the human 
endometrium is still to be determined, it is notable that ERβ is expressed in vascular 
endothelial cells and immune cells including a phenotypically distinct population of 
natural killer cells that are believed to play an essential role in placentation (Critchley 
et al., 2001, Critchley et al., 2002, Lecce et al., 2001, Krikun et al., 2005, Henderson 
et al., 2003).  
1.14 Aims of the thesis 
The overall aim of this thesis was to examine the sub-nuclear kinetics of ERs and 
their transcriptional activity in response to ligands and to delineate differences in the 
response patterns between full-length receptors and splice variants. For this study, 
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The specific aims were: 
• To establish and optimise methods for measuring the intranuclear mobility of 
both full length ERα and ERβ and splice variant isoforms of human ERβ 
(ERβ2 and ERβ5). 
• To determine whether ERβ5 may play a role in oestrogen responsiveness in 
the normal human endometrium. 
• To examine alternative ligand-independent modes of activation of ER with 
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2 General materials and methods 
2.1 Cell Culture  
2.1.1 MDA human caucasian breast adenocarcinoma cells  
The MDA-MB-231 cell line was obtained from the European Collection of Cell 
Cultures (ECACC, Wiltshire, UK, Cat. No.92020424), a health protection agency 
culture collection. These epithelial cells were originally isolated from the pleural 
effusions of a 51 year old Caucasian breast cancer patient (Cailleau et al., 1974). The 
cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Sigma, St. 
Louis, MO, USA, Cat. No.; D5546) that was supplemented with 10% heat-
inactivated foetal calf serum (FCS) (Invitrogen, Paisley, UK, Cat. No. 10082-147), 
1% Non-essential amino acids (Sigma, Cat. No. M7145), 0.5% Fungizone 
(Invitrogen, Cat. No. 15290-018), 1% L-Glutamine (Sigma, Cat. No. G-7513) and 
1% Penicillin-Streptomycin (Sigma, Cat. No.; P-4333). The cells were incubated at 
37°C under conditions of 5% CO2 in air. These cells were transferred to phenol-red 
free DMEM containing 10% charcoal-stripped FCS and supplemented in the same 
way as the DMEM above for 48 hours prior to use in all experimental assays to 
eliminate endogenous growth factor and ligand presence. 
2.1.2 Ishikawa endometrial adenocarcinoma cells 
The Ishikawa cell line was purchased from ECACC (Cat. No.99040201). This well 
differentiated endometrial adenocarcinoma cell line was isolated from a 39-year old 
Asian patient and is positive for ERα (Nishida et al., 1985). These epithelial cells 
were cultured in supplemented DMEM (as outlined above) and kept at 37°C under 
5% CO2 in air.  
2.1.3 hTERT endometrial epithelial cells (hTERT) 
The human TERT (hTERT)-endometrial epithelial cells are positive for endogenous 
ERα expression and were obtained from Dr. Thomas Klonisch, Dept. of Human 
Anatomy and Cell Science, University of Manitoba, Canada. This cell line was 
isolated from the proliferative phase (day 7) of a normal endometrium from a 37 year 
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old nulliparous patient following surgery on uterine myomatosis. Immortalisation of 
these primary cells was conducted by stable transfection of the catalytic human 
telomerase subunit (TERT) and further culturing of the cells (Hombach-Klonisch et 
al., 2005). These cells were kept in Ham’s F-10 media (Lonza Biologics plc, Slough, 
UK, Cat. No.; BE12-618) with 10% charcoal-stripped foetal calf serum, 1% Non-
essential amino acids, 1% insulin, human transferrin and selenous acid (ITS) Premix 
(Becton Dickinson BioSciences, Oxfordshire, UK, Cat. No.; 354351), 1% L-
Glutamine (Sigma, Cat. No. G-7513) and 1% Penicillin-Streptomycin (Sigma, Cat. 
No. P-4333) and maintained at 37°C in 5% CO2. 
2.2 Human Tissue 
2.2.1 Human Endometrial Samples 
Human endometrial biopsies from different stages of the menstrual cycle were 
obtained following hysterectomy, hysteroscopy or laparoscopic sterilisation 
performed at the Royal Infirmary, Edinburgh, UK. Histological staging analysis was 
performed by an expert histologist as previously reported (Critchley et al., 2001) 
(Critchley et al., 2002). Patients provided informed consent consistent with national 
guidelines (Polkinghorne, 1989) and ethical approval was bestowed from the Lothian 
Research Ethics Committee. All recruits from whom endometrial tissue was acquired 
were of reproductive age (30-48 years) and reported regular cycles. 
2.2.2 Tissue processing 
Endometrial tissue samples were fixed in 4% neutral buffered formalin overnight at 
4°C and transferred into 70% ethanol prior to being embedded in paraffin wax 
according to standard methods by the histology team at the MRC Human 
Reproductive Sciences Unit, Edinburgh. Additional endometrial samples required for 
RNA and protein experimentation were immersed in RNA Later (Ambion, 
Warrington, UK) and stored at 4°C. 
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2.3 Ligands  
2.3.1 Oestrogenic Ligands 
2.3.1.1 Natural Oestrogenic Ligand 
The E2 (C18H24O2) was purchased from Sigma (Cat. No. E-8875) and the lyophilised 
product was reconstituted in dimethyl sulfoxide (DMSO). E2 was subsequently 
diluted in PBS giving a variety of serial dilutions (10-3-10-8M) stored at -20°C. 
2.3.1.2 Synthetic Ligands 
The synthetic agonist compounds 2,3-bis(4-Hydroxyphenyl)-propionitrile (DPN™) 
(C15H13NO2) and 4,4',4''-(4-Propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol (PPT™) 
(C24H22N2O3) were purchased from TOCRIS (Ellisville, MO, USA) (Cat. No.’s 1494 
and 1426 respectively). Serial dilutions (10-3-10-8M) of both ligands were prepared 
by reconstitution and dilution in 100% DMSO and stored at -20°C. DPN™ is 
reported to exhibit 70X selective activity for ERβ (Meyers et al., 2001) whilst PPT™ 
has been described as ERα selective (Stauffer et al., 2000). 
2.3.2 Growth Factors 
The EGF was bought from PeproTech EC Ltd., London, UK (Cat. No. AF-100-15), 
reconstituted and diluted to form serial dilutions (10-5-10-8M) in distilled H2O. 
Insulin-like growth factor-I was obtained from Sigma (Product No. I3769), was made 
up from its lyophilised state in sterile phosphate buffered saline (PBS) and 
subsequently diluted to give a range of serial dilutions (10-5-10-8M). All growth 
factors were kept in storage at -20°C. 
2.3.3 Inhibitors 
The pure ER antagonist 7a,17b-[9-[(4,4,5,5,5-Pentafluoropentyl)sulfinyl]nonyl] 
estra-1,3,5(10)-triene-3,17-diol (ICI 182,780) (C32H47F5O3S) was purchased from 
TOCRIS (Cat. No. 1047). A stock solution of 1mM of this compound was prepared 
in 100% ethanol. The proteosome inhibitor MG132 (C26H41N3O5) was bought from 
Sigma (Cat. No. C2211-5MG). A stock solution of 1mg/ml of MG132 was prepared 
using 100% ethanol. The selective inhibitor of p22/44 MAPK kinase 1, PD98059, 
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was purchased from Promega (Cat. No. V1191, Southampton, UK). The dried 
product was resuspended in DMSO to a stock concentration of 20mM. All inhibitors 
were stored at -20°C. 
2.4 Immunohistochemistry 
Immunohistochemical staining (IHC) is a method which enables visualisation of 
specific proteins of interest (antigens) in tissue sections through the binding of 
























Figure 2.1 Schematic overview of immunohistochemistry process.  
Figure includes demonstration of the three blocking steps imposed on all 
experiments: Block 1, methanol peroxide block (section 2.4.3.1); Block 2, serum 
block (section 2.4.3.2); Block 3, avidin-biotin block (section 2.4.3.3). 
2.4.1 IHC of endometrial tissue sections 
IHC was conducted on endometrial tissue in accordance with standard laboratory 
protocols to establish the presence and localisation of the proteins of interest. 
Chapter 2 Materials and Methods  47
2.4.1.1 Tissue processing (sectioning) 
Wax-embedded tissue was pre-chilled on ice to ensure rigidity and enable ease of the 
sectioning process. Sections were cut at 5 microns in thickness using a microtome 
(model RM2135, Leica Microsystems, Wetzlar, Germany) and floated on H20 at 45º 
± 5ºC (model E/65, RA Lamb, Waltham, MA, USA). The sections were picked up on 
glass slides coated with positive charge used to attract the negatively charged 
proteins of the tissue (Cat. No., 406/0179/00; BDH, Lutterworth, UK). All slides 
were placed in an oven (model E28.5, Lamb RA) at 55ºC overnight to ensure 
complete adhesion of tissue section to the slide. 
2.4.1.2 Dewaxing of tissue 
To ensure optimal antibody penetration of the sectioned tissue, complete removal of 
the wax was carried out. The dewaxing process involved plunging slides into two 
consecutive xylene troughs. This was followed by rehydration of tissue in 
diminishing concentrations (100%, 95% and 70%) of alcohol before a final wash in 
tap H20. 
2.4.2 Antigen retrieval 
During the formalin-fixed paraffin embedding (FFPE) process of tissue, changes in 
the orientation of epitopes (antigen recognition sites) of the proteins can arise due to 
formation of cross linkages between Ca++ and other divalent metal cations and 
proteins. These ‘masked’ changes can be disrupted by applying intense heat to the 
tissue and placing in a buffered solution to allow precipitation or chelation of the 
released metal ions (Cattoretti et al., 1993). Antigen retrieval was conducted in a  
pressure cooker for 5 minutes at full pressure preceding a 20 minute standing time 
with slides submerged in either a citrate or an ethylenediamine tetra-acetic acid 
(EDTA) solution (Morgan et al., 1994). EDTA was considered a more suitable buffer 
for particular antibodies tested on endometrial tissue as gave cleaner and stronger 
results.  
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2.4.3 Blocking to promote specific signal amplification 
In a pre-emptive effort to control non-specific antibody binding, a number of 
blocking stages were employed and are detailed below. 
2.4.3.1 Methanol Peroxidase Block 
To prevent endogenous peroxidase responding to chromogens such as horseradish 
peroxidise (HRP), sections were immersed in a solution of 3% H2O2 in methanol and 
placed on a rocker for 30 minutes. After this time, slides were washed in Tris-
Buffered Saline (TBS) solution on a rocker for 5 minutes. 
2.4.3.2 Serum Block 
The use of serum from the species in which the secondary antibody was raised was 
used to prevent non-specific binding of the secondary antibody. For most IHC 
experiments conducted in this project, a secondary antibody raised in goat was used 
and therefore slides were incubated in normal goat serum (NGS; Autogen Bioclear 
UK Ltd., Wiltshire, UK) that was diluted 1:4 in TBS solution mixed with 5% bovine 
serum albumin (BSA; Sigma, Poole, Dorset, UK) for 30 minutes at room temperature 
under humidified conditions. Excess buffer was removed from all sections after this 
blocking stage. 
2.4.3.3 Avidin-Biotin Block 
The use of biotinylated secondary antibodies in the IHC process is dependent on the 
strong affinity of avidin and streptavidin for the vitamin biotin. To prevent avidin-
peroxidase complexes binding directly to the tissue where endogenous biotin is 
expressed, an avidin-biotin blocking stage was performed. Sections were incubated 
with avidin-D (Vector Laboratories, Peterborough, UK) for 15 minutes, underwent 
2x5 minute TBS washes on a rocker, incubated with biotin (Vector Laboratories, 
Peterborough, UK) for 15 minutes before a final 2x5 minute washes in TBS solution.  
2.4.4 Primary Antibodies 
All primary antibodies were prepared by dilution in their appropriate blocking serum. 
Sections were incubated with the primary antibody to the target antigen in a 
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humidified chamber and stored overnight at 4ºC. Table 2.1 outlines the optimised 
conditions used for each antibody. Negative controls were conducted with each 
experiment where the primary antibody was replaced by blocking solution incubation 
alone. 
2.4.5 Secondary Antibodies 
Sections underwent 2x5 minute TBS washes after primary antibody incubations. 
Biotinylated secondary antibodies that had been diluted in their appropriate blocking 
serum were applied to the sections for 30 minutes at room temperature in a 
humidified environment. 
2.4.6 Antigen detection, counterstaining and mounting 
A streptavidin-horseradish peroxidise complex (DAKO, Cambridge, UK) diluted in 
TBS solution was applied to sections for 30 minutes at room temperature in a 
humidified chamber. Following 2x5minute TBS washes, the chromogenic substance 
3, 3’-diaminobenzidine (DAB, K3468; DAKO) was diluted in its substrate and 
applied to the sections and given 2-3 minutes to allow for optimal development. 
Upon sufficient staining, slides were plunged in distilled H2O. Sections were 
counterstained in Harris’ haemotoxylin (cell nuclei turn blue), rehydrated and 
immersed in increasing concentrations of alcohol and finally xylene. The 
immunostained sections were mounted with coverslips using pertex glue (Cell Path, 
Hemel Hempstead, UK). 
2.4.7 Immunofluorescence  
Dual immunofluorescent staining facilitates the detection of co-localised target 
antigens. The principle requisites are that the primary antibodies are derived from 
unique species (although this can be overcome with the use of monovalent secondary 
antibodies with attached FAB fragments) and the dyes used have discernable spectral 
properties. An initial series of titrations were run to determine the most efficient 
dilution concentrations of antibody required to give optimal staining and the 
determined dilutions were employed for all subsequent experiments (Table 2.1). 
Experiments were conducted in the same manner as described for DAB with the use 
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of PBS in place of TBS washes and dilutions. Secondary antibodies used included 
biotinylated or peroxidise forms and these were incubated on sections for 30 minutes 
and 1 hour respectively (Table 2.2).  The biotinylated antibodies were proceeded by 
incubation with streptavidin-conjugated alexa 488 or 546 diluted in PBS (1:200) for 
1 hour. Peroxidase antibody treatment was followed by tyramide-Cy3 chromogen 
diluted (1:50) in tyramide buffer for 10 minutes. Sections were counterstained using 
4', 6-diamidino-2-phenylindole (DAPI) nuclear stain (1:1000) and mounted using 
permafluor (Immunotech, Marseille, France) mounting medium. 
Table 2.1 Summary of primary antibodies used for immunohistochemistry 
Antigen Host Species Dilution  Retrieval Source 
ERα Mouse 1:20 Citrate Vector 1 
ERβ Mouse 1:20 EDTA AbD Serotec2 
ERβ2 Mouse 1:200 EDTA AbD Serotec2 
ERβ5 Mouse 1:40 EDTA In house 
ErbB1  
(HER1) 
Sheep 1:100 Citrate Upstate3 
ErbB2  
(HER2) 
Mouse 1:75 Citrate Abcam4 
ErbB3  
(HER3) 
Mouse 1:75 Citrate Abcam4 
ErbB4  
(HER4) 
Mouse 1:40 Citrate Abcam4 
 
1Vector Laboratories Ltd., Peterborough, UK 
2AbD Serotec, Kidlington, Oxford, UK 
3Upstate Biotechnology Inc., New York, USA 
4Abcam plc, Cambridge, UK 
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Table 2.2 Summary of secondary antibodies used for immunohistochemistry 
Target Host Species Dilution Source 
anti-mouse 
biotinylated 
Goat 1:500 Sigma1 
anti-rabbit 
biotinylated  
Goat 1:500 DAKO2 
anti-sheep 
biotinylated 




Goat 1:500 Abcam3 
anti-mouse Fab 
peroxidase 
Goat 1:200 DAKO2 
Anti-rabbit Alexa 
Fluor 488 








 1:50 Perkin Elmer 
Life Sciences5 
 
1Sigma-Aldrich, St. Louis, MO, USA 
2Dako UK Ltd., Cambridge, UK 
3Abcam plc, Cambridge, UK  
4Molecular Probes Europe BV, Leiden, The Netherlands 
5PerkinElmer Life Sciences, MA, USA 
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2.4.8 Image Analysis 
DAB positive images were captured using a PROVIS microscope (Olympus Optical, 
London, UK) with an attached Canon DS126131 camera. Dual fluorescent images 
were viewed using a LSM 510 Meta-Confocal (Carl Zeiss, Hertfordshire, UK). 
2.5 Ribonucleic Acid (RNA) Analysis 
2.5.1 RNA extraction from cell lines and human tissue 
Total RNA was extracted using the RNAeasy® Mini extraction kit (Qiagen, Crawley, 
UK) and was carried out in accordance with the manufacturer’s protocol. Cell 
samples were harvested following trypsinisation and collected in Buffer RLT (a 
potent denaturing buffer that inactivates RNase activity) supplemented with β-
mercaptoethanol (10µl/ml). Cells were homogenised using a QIAshredder® spin 
column. Sample preparation from frozen endometrial tissue was conducted using a 
Qiagen Tissue Lyser. Defrosted tissue was weighed out (approximately 30mg) and 
homogenised in a solution of 600µl Buffer RNeasy® lysis buffer (RLT) (Qiagen, 
Crawley, UK) to which β-mercaptoethanol (10µl/ml) was added using a handheld 
tissue lyser (Z35,997-1, Sigma). A 1:1 volume of ethanol was added to the 
homogenates (cell and tissue) to provide optimal binding conditions. This solution 
was transferred to a RNeasy® spin column placed in a 2ml collection tube and briefly 
centrifuged (15 seconds) at 10,000 rpm. RNA binds to the silica membrane of the 
RNeasy® spin column and all contaminants were discarded in the flow-through 
following successive washing and subsequent spinning steps with Buffer RPE 
(Qiagen, Crawley, UK). Extracted RNA from all samples (cell and tissue) was 
subjected to on-column DNase digestion treatment involving a DNase I incubation 
mix of DNase I stock solution and Buffer RNeasy® DNase digestion (RDD, Qiagen, 
Crawley, UK) to prevent any genomic DNA contamination. Pure, concentrated RNA 
was eluted in a final volume of 50µl RNase-free H2O. 
2.5.2 RNA Quantification (Nanodrop®) 
Extracted RNA was eluted in 50µl RNase-free H20 and quantified using the 
Nanodrop® ND-1000 Spectrophotometer (Nanodrop Technologies, Wilmington, DE, 
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USA). Prepared RNA sample concentration was adjusted to 100ng/µl using RNase-
free water to enable further accurate analysis between corrected samples and stored 
at -80°C. 
2.5.3 Qualitative Polymerase Chain Reaction (PCR) 
2.5.3.1 Reverse transcription of RNA using oligo dTs 
 
Oligo dTs are specific to the poly-A tail of mRNAs and exclusively amplify mRNA. 
Oligo dTs (Applied Biosystems, Warrington, UK, Cat. No. N808-0128) were 
annealed to the RNA by incubation of 1µg RNA with 2.5µM oligo dTs (Applied 
Biosystems) made up to a final 12µl with RNase free H2O and heating to 70°C for 5 
minutes. The Bioscript Reverse Transcriptase (RT) reaction mastermix (Bioline, 
Germany) was then added and incubated with individual samples at 40°C for 60 
minutes followed by 72°C for 10 minutes to produce cDNA. 
Final Concentration 
RNase Inhibitor    0.5U/µl 
5X Reaction Buffer            1X 
dNTPs        200µM 
Bioscript RT      2.5U/µl 
The reaction mix for each individual reaction was made up to 9µl using RNase-free 
H2O. 
 
The subsequent PCR reaction was performed using GoTaq® (Promega) in 10µl under 
the following conditions; 
95°C for 10 minutes 
95°C for 1 minute 
55-58°C for 1 minute 
72°C for 10 minutes 
for 30-35 cycles and a final 72°C for 10 minutes.  
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The housekeeping gene glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) was 
used as a positive control for these reactions and is routinely used because it is 
constitutively and stably expressed to high levels in a wide range of cell and tissue 
types. 
2.5.4 Quantitative-Real Time-PCR (Taqman® Method) 
Figure 2.2 outlines an overview of the steps involved in a Taqman® quantitative real 
time PCR (qRT-PCR). This in vitro method for enzymatic amplification of defined 
RNA sequences can be subdivided into two main steps; a) the preparation of samples 
by reverse transcription of the RNA to complementary DNA (cDNA) sequences and 
subsequent mixing with the specific primer/probe mix from the Universal Probe 
Library™, and b) running the PCR process on the ABI 7900 instrumentation to 
sensitively acquire a measure of the transcription levels of specific genes of interest. 
 
RNA cDNA
A. Reverse Transcription & 
Sample Preparation
B. Real time Taqman®
PCR Reaction
+ UPL™ Primer/probe Mix
ABI Prism 7900 





Fluorescence α Amt. of DNA
 
Figure 2.2 Overview of qRT-PCR experimental setup. 
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2.5.4.1 Reverse transcription of RNA using random hexamers 
The use of random hexamers enables total RNA to be amplified including that of the 
18S ribosomal RNA used for analysis as an internal control measure. The preparation 
of cDNA was carried out using a final concentration of 400ng of the total RNA 
extract (RNA Extraction; section 2.5.1) per 20µl reaction mix. A mastermix was 
prepared using reagents from the Applied Biosystems Taqman Reverse Transcription 
Kit at the following final concentrations; PCR buffer I (1x), MgCl2 (5mM), dNTPs 
(1mM), RNase inhibitor (1µg/µl), Multiscribe reverse transcriptase (2.5µg/µl), 
random hexamers (2.5µM) and 5µl of H2O per 20µl reaction mix. Individual 
reactions were mixed together in sterile PCR tubes and placed in a Biometra PCR 
machine set according to the following conditions; 
25°C for 20 minutes 
42°C for 60 minutes   
95°C for 5 minutes.       
              
2.5.4.2 Preparation of Taqman® reaction mix using the universal    
probe library™ 
The Universal Probe Library™ (UPL) (Roche, West Sussex, UK) is comprised of 
short (8-9 nucleotides in length) hydrolysis probes that are labelled with fluorescein 
(FAM) at the 5’ end and a dark quencher dye at their 3’end. These short probes are 
based on locked nucleic acids (LNAs) as they have a ‘locked’ ribose ring where the 
2’-O atom is connected to the 4’-C atom via a methylene bridge and have the ability 
to bind to their target sequences despite their short length. The resultant specificity of 
these short LNA-probes facilitates distinction between transcripts of various splice 
variants (e.g. ERβ isoforms) by using a probe that can only bind to one transcript or 
the other (Table 2.3). 
 
Primers were designed by using the Roche online ‘probe finder’ assay design method 
at https://www.roche-appliedscience.com/sis/rtpcr/upl/. 
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Table 2.3 Primer and Probe Sequences (UPL) used in qRT-PCR 






















2.5.4.3 Quantitative real time Taqman® PCR 
Quantitative Real Time Taqman® PCR is an automated, high throughput variation of 
conventional PCR. The Taqman® method employs the use of fluorogenic probes 
from the UPL (section 2.5.4.2) to enable quantification of DNA content based on a 
measure of fluorescence detection after each PCR cycle. Fluorescence emission 
occurs upon cleavage of the probe resulting from the activity of the Taq polymerase 
during each PCR cycle. Each reaction was prepared using the qPCR Supermix with 
Premixed ROX kit (11795-01K; Invitrogen), conducted in triplicate, plated in a 96-
well MicroAmp Fast Optical reaction plate (Applied Biosystems) and run on the fast 
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Reagent   Final Concentration  Vol. /15µl reaction (µl) 
 
2X Express Supermix  1X    7.5 
Forward Primer 20µM 200nM    0.15 
Reverse Primer 20µM  200nM    0.15 
Probe 10µM   100nM    0.15 
18S     (10nM primer, 40nM probe) 0.1125 
H20        5.4375 
cDNA        1.5  
2.5.4.4 Analysis of computational output 
An absolute quantification is processed and presented as an amplification plot on the 
ABI7900 sequence detection system. Levels of fluorescence are determined at each 
PCR cycle and are directly proportional to the amount of DNA product present at 
that point in the reaction. The FAM threshold cycle (Ct) value is the point on the 
exponential curve at which the level of fluorescence reached is considered 
statistically greater than background levels. The Ct value equates to the amount of 
PCR product formed and a change of one-fold Ct value represents a two-fold in the 
initial cDNA concentration.  
 
Analysis was performed using the comparative Ct method where the fold change 
expressed is relative to a reference sample (e.g. untreated endogenous sample). First, 
the reporter signal was measured against that of an internal 18S ribosomal  RNA 
control to correct for fluctuations between samples; ∆Ct = FAM Ct – 18S VIC Ct. 
The average of the ∆Ct triplicates was determined. ∆∆Ct = ∆Ct sample – ∆Ct 
reference sample. The fold change in gene expression is calculated as 2-∆∆Ct where 
the reference control was given a 2-∆∆Ct of 1 and is based on the mathematical 
equation that describes the exponential amplification of a PCR: Xn = X0 x (1+Ex)
n 
(Xn = number of target molecules at cycle n of the reaction, X0 = number of target 
molecules, Ex = efficiency of target amplification, n is the number of cycles) (Livak 
and Schmittgen, 2001). 
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2.5.4.5 Primer/probe Validation 
To validate use of the primer/probe mix, log ng cDNA values are plotted against the 
average of the ∆Ct values. Serial dilutions of the prepared cDNA (neat, 1:10, 1:100, 
and 1:1000) were analysed and the resultant straight graph depicts efficiency of the 
primer/probe mix over a range of cDNA concentrations (Figure 2.3).  
 
ERα Primer Validation I

































Figure 2.3 Validation of primer/probe mix used in Taqman® reactions. 
A comparison of the efficiency of the primer/probe (e.g. ERα) to the 18S 
primer/probe is important to establish the efficacy of the sample primers relative to 
the endogenous 18S control (Figure 2.4). 
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Figure 2.4 Validation of gene of interest primer/probe usage relative to 18S 
primer/probe control mix. 
 
2.6 Protein Extraction and Quantification 
2.6.1 Total protein extraction from cell lines and human tissue 
During the process of protein extraction, all materials were kept on ice to prevent 
protein degradation. Total protein was extracted directly by disruption of PBS-
washed cells using 1X RIPA buffer (section 2.10). For endometrial protein 
extraction, approximately 30mg of tissue was placed in 1ml of complete 1X RIPA 
buffer and homogenised with a rotostator homogeniser set at 20Hz for 2 minutes. 
The homogenates (both cell and tissue) were spun at 2,500 rpm for 10 minutes at 4°C 
and resulting supernatants (total protein content) were transferred to pre-chilled tubes 
for storage at -80°C. In some cases where the RIPA extraction method was too harsh 
to preserve phosphorylation status, NP-40 lysis buffer was used. The 0.1% SDS 
detergent content of this recipe promotes disruption of non-covalent bonds and 
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2.6.2 Nuclear protein extraction from cell lines 
Nuclear protein isolation was conducted using reagents from the Active Motif 
Nuclear Extraction Kit (Cat. No. 40010, Active Motif Inc., Carlsbad, California, 
USA) and in accordance with manufacturer’s instructions. This assay involved the 
preparation of a PBS/phosphatase inhibitor solution in H2O and using this mix to 
wash the cells. This step precludes further protein modifications such as 
dephosphorylation and proteolysis from occurring. In this solution cells were 
centrifuged at 4°C for 5 minutes at 500rpm; the supernatant was discarded and the 
residual pellet was resuspended in a 1X hypotonic buffer solution (used to swell the 
cytoplasmic membrane) and detergent (which enables leakage of the cytoplasmic 
proteins into the supernatant). Following a brief 30 second spin at 4°C, this solution 
was separated into the cytoplasmic supernatant fraction and the pelleted nuclear 
fraction. Pellets were resuspended in lysis buffer AM1 (Active Motif Inc., Carlsbad, 
California, USA) (causing lysis of nuclear pellets) to which 10mM of the reducing 
agent dithiothreitol (DTT) and protease inhibitor cocktail were added. Following 
incubation for 30 minutes in slushy ice on a rocking plate the suspensions were 
vortexed briefly followed by a final centrifugation of 10 minutes at 14,000g at 4°C. 
The resultant nuclear supernatants were transferred to pre-chilled tubes for storage at 
-80°C. 
2.6.3 Protein Quantification (Lowry method) 
The quantification of protein samples was carried out in a 96-well flat bottomed plate 
using the Biorad DC Protein Assay Kit (Hemel Hempstead, Herts, UK) that is based 
on the Lowry method of protein quantification. The underlying principle of this 
method is a reaction between copper and the protein sample in an alkaline medium 
followed by a reduction of folin reagent by this copper treated protein sample. This 
reduction reaction yields a reduced species that gives rise to the characteristic blue 
colour observed. Detected protein values were compared to a standard curve formed 
by the use of a series of controls prepared with a known concentration of bovine 
serum albumin (BSA) (0.125-1.5 mg/ml) diluted in the same lysis buffer as that used 
for the collection of the protein extract being quantified. In accordance with the 
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guidelines provided by the manufacturer, 5µl of each sample being tested were used. 
To each sample 25µl of reagent mix ‘A/S’ was added (25µl of reagent S/ml reagent 
A) and followed by 200µl of reagent B. Thereafter the sample/reagent mixtures were 
left to incubate in the dark for 15 minutes at room temperature before being read on a 
plate reader (Labsystems Miltiskan Ex, VWR) at 690nm. Final concentrations of 
sample proteins were derived by comparison with the standard curve generated from 
the BSA standard series. 
2.7 Western Blotting 
Western blotting was conducted using NuPAGE® (Invitrogen, Paisley, UK) 
reagents, gels and buffers. 
2.7.1 Sample preparation 
Protein samples (~25µg) were prepared by suspending in 4X NuPAGE LDS Sample 
Buffer and 10X NuPAGE Reducing Agent and heating the final solutions at 70°C for 
10 minutes. Following the denaturation process, samples were loaded on precast 4-
12% Bis-Tris NuPAGE polyacrylamide gels alongside 10µl of 1X SeeBlue Plus2® 
Prestained marker dye (Invitrogen). 
2.7.2 NuPage® Polyacrylamide Gel Electrophoresis 
Loaded gels plunged in an electrophoresis tank filled with 1X NuPAGE® MOPS 
SDS Running Buffer (supplemented with NuPAGE® antioxidant) (Invitrogen) were 
run at 200V for approximately 50 minutes or until the bromophenol blue dye got to 
the bottom of the gel. 
2.7.3 Protein transfer  
Following protein separation, the gels were set up for transfer on to polvinylidene 
fluoride (PVDF) membranes (Millipore, Bedforf, UK). Each gel and its matching 
membrane (pre-soaked in methanol) were carefully placed in a cassette sandwiched 
between Whatmann paper and porous fibre pads (pre-soaked in transfer buffer to 
prevent dehydration of the gel during cassette assembly) in a transfer unit with 1X 
NuPAGE® Transfer Buffer (Invitrogen) with the gel at the negative electrode side for 
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4 hours at 40V. This assembly facilitates the movement of separated (negatively 
charged) proteins of the gel from the cathode towards the membrane at the anode. 
After transfer, membranes were blocked in a solution of 40% Odyssey Blocking 
Buffer (LI-COR™), 40% PBS, 20% pure goat serum for 1 hour at room temperature 
to prevent non-specific binding before 2x5 minute washes in PBS 0.1% Tween-20 
(Sigma). Blocked membranes were incubated in the appropriate dilution of primary 
antibody (Table 2.4) at 4°C overnight. As a loading control measure, a β-tubulin 
antibody was included. 
2.7.4 Antibodies (and peptides) 
Following overnight incubation with the primary antibody to the protein of interest, 
the membrane was washed in PBS 0.1% Tween-20 (Sigma) for 4x5 minute washes 
to ensure the removal of residual primary antibody. Fluorescently labelled secondary 
antibodies (Table 2.5) that had been diluted 1:10,000 in Odyssey Blocking Buffer 
(LI-COR™) were applied to membrane for 1 hour at room temperature followed by       
4x5min washes in PBS 0.1% Tween-20. The membrane was then transferred to a 
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Table 2.4 Primary antibodies used for Western blotting 
Antigen Host Species  Dilution  Source 
ERα Mouse 1:200 Vector1 
ERβ (H-150) Rabbit 1:200 Santa Cruz2 
ERβ2 Mouse 1:200 Serotec3 
ERβ5 Mouse 1:100 In-house4  
ErbB1 (HER1) Rabbit 1:200 Santa Cruz2 
ErbB2 (HER2) Mouse 1:40 Abcam5 
ErbB3 (HER3) Mouse 1:1000 Abcam5  
ErbB4 (HER4) Rabbit 1:4000 Abcam5 
IGF-IRα (N-20) Rabbit 1:200 Santa Cruz2 
IGF-IRβ (C-20) Rabbit 1:200 Santa Cruz2 
β-tubulin Mouse 1:600 Sigma6 
β-tubulin Rabbit 1:600 Santa Cruz2 
 
1Vector Laboratories Ltd., Peterborough, UK 
2Santa Cruz Biotechnology, CA, USA 
3AbD Serotec, Kidlington, Oxford, UK 
4In collaboration with Prof. N. Groome, Oxford Brookes University, Oxford, UK 
5Abcam plc, Cambridge, UK 
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Table 2.5 Secondary antibodies used for Western blotting  
Target Dilution  Excitation Wavelength (nm)/ 




1:10000 800(green) Rockland1 
Goat anti 
mouse 
1:10000 680 (red) Molecular 
Probes2 
 
1Rockland Immunochemicals Inc., PA, USA 
2 Molecular Probes Europe BV, Leiden, The Netherlands 
2.7.5 Protein expression assessment (LI-COR™ Instruments) 
Protein determination was visualised using the LI-COR™ fluorescence detection 
system that enables simultaneous detection of two proteins distinguishable by use of 
different coloured fluorescent markers of the secondary antibodies. The use of direct 
infrared detection on membranes equate to the high sensitivity of this assay. 
Correction for sample variation in the amounts of proteins recognised by the primary 
antibody can be determined by quantitating the fluorescence levels (by drawing a 
rectangular marker around the band in question) of each protein under investigation 
and expressing it relative to the amount of protein detected using the control antibody 
(β-tubulin) for that same sample. 
2.8 Fluorescent Recovery After Photobleaching (FRAP) 
2.8.1 Background 
FRAP is an in vivo microscopy technique that enables the study of intra-cellular 
protein dynamics and functionality. Originally described with associated 
mathematical quantitations in the mid-1970s (Poo and Cone, 1973, Axelrod et al., 
1976), FRAP is a useful and robust method to infer information regarding patterns of 
mobility of biological proteins. The          mid-1990s saw a resurgence in popularity 
of the use of FRAP owing to the advances in confocal laser scanning microscopes 
coupled with the advent of green fluorescent protein (GFP)-derived fluorophores 
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(Cole et al., 1996, Lippincott-Schwartz and Smith, 1997). The experiments in this 
study used yellow fluorescent protein (YFP)-appended ER proteins (section 2.8.4). 
The process itself exploits the phenomenon of photobleaching of fluorescent 
molecules of a defined region (strip) of the nucleus and monitoring recovery as a 
function of time as this region becomes repopulated with unbleached fluorescent 
molecules from outside of the bleached region (Fig. 2.5). 
 
 
Figure 2.5 Overview of the concept of a FRAP experiment. 
A cell is selected based on relatively uniform distribution of fluorescence (A), a 
region within the cell is selected for bleaching (termed Region of Interest I, B), the 
process of photobleaching abolishes fluorescence within this zone (C) and the 
redistribution of fluorescence back into the zone is recorded over time (D). 
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2.8.2 Live Cell Maintenance 
Cells were cultured on 35mm glass bottom microwell dishes (Plastik® Cultureware, 
MatTek Corp., Ashland, MA, USA) at a density of 1 x 105cells/ml. For live cell 
image acquisition, infected/transfected cells were maintained in a 2.5% HEPES 
(Sigma, Cat. No. H-0887)/PBS solution (50µl/2ml) and in a heated chamber at 37°C. 
2.8.3 Transient Transfection (Controls)  
After plating for twenty-four hours, cells were transfected with the CY24 Plasmid 
(YFP tag) as a positive control (gratefully received from Dr. Rory Duncan, 
University of Edinburgh) using the JetPEI (Autogen Bioclear, Nottingham, UK, Cat. 
No.; 205-10) transfection reagent. The CY24 plasmid contained a cDNA construct 
encoding YFP (27kDa donor fluorophore) and CFP (27kDa acceptor fluorophore) 
separated by a flexible 25 amino acid linker. CY24 plasmid DNA (2µg/confocal 
dish) was added to 200µl 150mM NaCl and this mixture in turn was added to a 
solution made up of a 2:1 ratio of µg of plasmid DNA to JetPEI in 200µl 150mM 
NaCl. Following 30 minute incubation at room temperature, this mixture was added 
to the cells following removal of the existing media and the wells were topped up 
with DMEM only (no additions). Transfection efficiency was determined by 
monitoring the fluorescence levels emitted from cells by observation under a Plan-
Apochromat 20X on an Axiovert 200M inverted microscope (Zeiss, Germany) 
twenty-four hours later. 
2.8.4 Cell Infection  
The cells were infected with adenoviral constructs expressing the ER of interest 
tagged with the 27kDa YFP at the N terminus of the protein (Table 2.6). YFP was 
selected for use on the basis of being a readily bleachable fluorophore that is 
insensitive to oxygen scavengers and other radical quenchers due to protection of the 
chromophore element of the molecule by a bulk solvent.  The constructs were 
produced by insertion of full length cDNA clones to the ER of interest between the 
Eco RI and Bam HI restriction sites of a YFP shuttle vector (pEYFP-C1, Clontech, 
Mountain View, CA, USA). The shuttle vector was then co-transfected with the 
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adenoviral genome (pBHG1ox∆E1, 3Cre, Microbix, Ontario, Canada) for 
recombination in HEK293 cells and the resultant plaques were purified for the viral 
particles. These viral particles were then amplified in the HEK293 cell line and 
concentrated with the use of a commercial kit system (Vivascience, Littleton, MA, 
USA) by the Biomolecular Core Facility within the MRC Human Reproductive 
Sciences Unit, Edinburgh. 
 
Table 2.6 Concentrations of Adenoviral Constructs used 
Adenoviral Construct Plaque forming unit no./ml 
ERα-YFP 2.49 x 1011 
ERβ-YFP 7.08 x 1010 
ERβ2-YFP 2 x 1010        
ERβ5-YFP  8.9 x 1010        
 
2.8.5  The Process  
In setting up a FRAP experiment, three Regions of Interest (ROI) are selected, each 
with the same dimensions (width and height) within the field of view. ROI I and ROI 
II were defined strips within the nucleus and ROI III is a region outside of the actual 
cell being investigated. ROI I was the region to be bleached while ROI II served as 
the reference region within the same nucleus. The use of strip-FRAP permitted 
change in the orientation of the strips and therefore allowed us to identify anisotropic 
diffusion patterns within the nucleus. ROI I was subjected to focused photobleaching 
whereby irreversible quenching of the fluorophores occur. Photobleaching involves 
the use of focused rapid pulses (iterations) of a high intensity laser to extinguish 
fluorescence and arises due to the covalent modifications involved in converting the 
molecule from an excited singlet to an excited triplet state and the photon-induced 
damage to the excited molecule.  The photobleaching period was kept to a minimum 
as diffusion of molecules was still taking place during this time and the exchange of 
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bleached molecules outside of the ROI I would have an impact on the fluorescence 
levels outside of the ROI I. Fluorescence recovery back into the ROI I was measured 
as a function of time and occurs as quickly as possible after the bleach period to 
capture the most accurate data for the recovery curves (Fig. 2.5). This recovery was 
assessed under conditions of minimal laser power. The fluorescence intensity values 
are the output of the experiments and were used to quantify the parameters of activity 
and mobility (http://www.embl.de/eamnet/downloads/courses/FRAP2004/lsm510_ 
inlivecellimaging.pdf). 
2.8.6 Instrumentation Setup 
FRAP was conducted using a Zeiss LSM 510 confocal inverted light scanning 
microscope equipped with acousto-optical tunable filters (AOTFs). AOTFs function 
to enable rapid switching between high and low intensity powers during and after the 
photobleaching process (Meyvis et al., 1999). Images were captured in a 256 X x 
100 Y frame through 63X objective lens before and after ligand treatment at 3 sec 
intervals for (~30sec) time periods after bleaching. Bleaching was carried out on a 
single z-section of the chosen cell (ROI I) with excitation of the Argon 12 laser (488 
and 514nm) and emission via the 530-600 band pass yellow filter. The pinhole was 
kept open to the maximum and the number of iterations kept at 100.  
          
2.8.7 Quantitative Interpretation 
Raw data in the form of total of averaged pixel values acquired was the output from 
the Zeiss LSM 510 microscope. These values were transferred to Microsoft Excel 
software and the data was corrected for and normalised as outlined below. 
 
Data from ROI I and ROI II were first corrected for background noise levels of 
fluorescence by subtraction of the fluorescence intensity values of ROI III.  The 
corrected ROI I value was expressed as a percentage figure of corrected ROI II to 
normalise against decay in overall fluorescence levels throughout the nucleus due to 
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acquisition bleaching. Acquisition bleaching could arise from the exchange of 

















        (2.1) 
where 
 
fl ROI I  =  fluorescence intensity value of  ROI I 
fl ROI II = fluorescence intensity value of ROI II 
fl ROI III = fluorescence intensity value of ROI III 
fl Norm, 1 = fluorescence intensity following normalisation step 1 
 
The percentages of recovery were deducted by expressing the normalised 
percentages over the average of percentage values for scans taken prior to the 
bleaching process (Eq. 2.2). This reveals the fraction of molecules actually bleached 
and the recovery percentages over time arising from the flux of fluorescent 





















fl Norm, 1  = fluorescence intensity following normalisation step 1 
prebleachAvg.  = average of two prebleach intensity values 
fl Norm, bleached pop.= fluorescence intensity value of bleached molecule                                         
following normalisation 
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Finally, the data was normalised by setting the time of the first scan taken post 
bleach at 0 (Eq. 2.3) and subtracting the original value at this timepoint from all 
subsequent scan times. 
 





T0 = time at which first postbleach value is plotted, sec 
fl Norm. postbleach 1 = normalised fluorescence intensity value of first scan 
postbleach 
 
This first percentage recovery value at T0 was also set to 0 and all successive 
percentage values were normalised to this first value (Fig. 2.6, red dotted line) (van 
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Figure 2.6 FRAP normalisation methodology. 
 
Statistical evaluation of the normalised data values was conducted using GraphPad 
Prism version 5.02 for Windows (GraphPad Software, SanDiego California, USA, 
www.graphpad.com). In this context, a one-phase association non-linear regression 
analysis was applied (Eq. 2.4). 
 
Y=Y0 + (Plateau-Y0)*(1-exp(-K*x)) 
(2.4) 
where 
Y0 = Y value when X (time) is zero, sec 
Plateau (YMAX) = Y value at infinite times; the asymptote of the ROI I 
fluorescence recovery curve, % recovery 
K = rate constant, sec-1 
Half-time = ln(2)/K, time taken for curve to reach 50% of plateau 
fluorescence intensity level, sec 
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Goodness of fit was determined by a R2≥0.9 and any set of values which did not 
achieve this value were designated outliers and dismissed from further analysis at 
this stage. The non-linear regression output values of YMAX, K and  half-time were 
assessed for normality using the D’agostino-Pearson normality test (the less sensitive 
Shapiro-Wilk and Kolmogorov-Smirnov normality tests were also performed at this 
stage to reaffirm normality of the values). Assuming Gaussian distribution following 
tests for normality, an unpaired t-test was performed between untreated and treated 
datasets to discern statistical power.  
2.9 Luciferase Gene Reporter Assay 
2.9.1 Bright-Glo™ Luciferase Assay System (Promega) 
Reporter Assays were performed using the Bright-Glo™ Luciferase System Protocol 
(Promega). Cells were seeded at ~1 x 105 cells/ml in charcoal-stripped foetal calf 
serum DMEM on 24-well plates 24 hours prior to infection. Cells were infected at a 
multiplicity of infection (MOI) of 50 for each of the adenoviral constructs ERα-YFP, 
ERβ-YFP, ERβ2-YFP and ERβ5-YFP independently or at a MOI of 25 when co-
infecting the cells. The 3x ERE-tk-luciferase required to enable quantification of ER 
action at the ERE is an adenoviral vector containing three copies of the vitellogenin 
consensus ERE fused to the firefly luciferase cDNA clone and was a gift provided by 
Prof. DP McDonnell (Nagel et al., 2001) (Duke University Medical Centre, North 
Carolina, USA). Infection with the 3x Ad-ERE-tk-luciferase was kept at a constant 
MOI of 50. After infection, cells were incubated for 4 hours in 200µl phenol-free 
DMEM to enable uptake of the constructs. Thereafter, wells were topped up to 500µl 
media. After 24 hours, cells were treated with DMSO alone or ligands diluted in 
DMSO for a further 24 hours. Cells were washed in cold-PBS, lysed in Glo lysis 
buffer (Promega) and harvested. Luciferase activity was assessed as per the Bright-
Glo™ Luciferase Assay System (Promega) protocol. This system works on the 
premise of the luciferase enzyme catalysing a reaction that involves the mono-
oxygenation of firefly luciferin to oxyluciferin that generates a luminescent signal. 
Luminescence was measured using the FLUOstar OPTIMA luminometer (BMG 
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Labtech, Offenburg, Germany). The relative light unit values were normalised to 
total protein values of the samples from the same experiment (section 2.6.3). 
2.10 Commonly used Buffer Solutions 
Phosphate Buffered Saline (PBS) (1X Stock) 
 
NaCl    8.00g 
KCl    0.20g 
Na2HPO4   2.29g 
KH2PO2   0.20g 
Stock solution was made up to 1L with distilled water. 
 
Tris Buffered Saline (TBS) (10X Stock) 
 
Tris (Sigma)   60.5g 
NaCl    87.6g 
HCl    300ml 
pH was adjusted to 7.4. 
Stock solution was made up to 10L, 1X solution was prepared for use by diluting 
with distilled water. 
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RIPA Protein Extraction Lysis Buffer 
Final Concentration 
HEPES-NaOH (pH7.5)      15mM 
EDTA         10mM 
Sodium orthovanadate          1mM 
NaCl        0.15mM 
Triton X-100           1.0% 
Sodium deoxycholate          1.0% 
Sodium dodecyl sulphate (SDS)                0.1% 
Protease inhibitor cocktail (Roche)            10X 
 
NP-40 Protein Extraction Lysis Buffer 
Final Concentration 
NaCl      150mM 
Tris Cl (pH 7.4)        50mM 
EDTA          10mM 
EGTA          10mM 
NP-40 (Igepal)                   0.6% 
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ERα and ERβ are the products of different genes that appear to promote different 
functions (reviewed in Griekspoor et al., 2007). X-ray crystallography studies have 
resolved the protein structures of the ligand binding domains of both proteins 
(Brzozowski et al., 1997). Sequence comparisons have revealed almost 100% 
conservation in the DNA-binding domains, ~53% sequence homology in the LBD and 
limited homology at the N-terminus (Cowley and Parker, 1999). Ligands that exhibit 
selective binding to ERα and ERβ have been developed (reviewed in 
Katzenellenbogen et al., 2000). Gene targeting experiments in mice have revealed a 
role for ERβ in having an influence on the function of ERα through reversing and 
inhibiting its effects (Damdimopoulos et al., 2008). Expression of ERβ has been 
negatively associated with tumour grade and changes in the mRNA expression of 
cognate splice variants (i.e. ERβ2) have been related to tumourigenesis in breast 
cancer tissue (Leygue et al., 1999a).  
 
The canonical mode of ER activation is through ligand binding. Differential responses 
to ligand arise from the binding of ligand to receptor with associated changes in 
conformation and binding to cofactors and other transcription factors. The differences 
in the sequences of the ER N termini and the LBD are likely to underpin the 
differential responses observed between ligand treatments. It is believed that the AF-1 
region plays a significant role in eliciting the differential responses to ligand observed 
between receptor subtypes (Pettersson and Gustafsson, 2001a, Picard et al., 2008). 
The impact of the pure anti-oestrogen ICI 182,780 (Fulvestrant™) on receptor 
function arises from its capacity to physically disrupt the active conformation adopted 
between Helix 12 and the LBD during agonist binding which in turn prevents binding 
of coactivators such as SRC-1 that are required to necessitate functional responses 
(Pike et al., 2001, Stenoien et al., 2001a). 
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FRAP is a technique that is commonly employed to address the influence of 
compounds on intracellular mobility that has been made possible by advances in 
fluorescence labelling of proteins and the technology associated with advanced 
confocal microscopy (van Royen et al., 2009). This method reveals the changes in 
mobility owing to changes in the nuclear distribution and allows one to probe the 
importance of associations with the nuclear architecture (Misteli, 2001). A number of 
studies have reported details of FRAP studies investigating ERα intranuclear dynamics 
in transfected cell lines (Stenoien et al., 2001b, Reid et al., 2003, Sharp et al., 2006). 
However, there is limited data relating to the intranuclear kinetics of ERβ with only 
recently published reports on mouse ERβ mobility (Picard et al., 2008) and a single 
report using human constructs (Damdimopoulos et al., 2008).  
 
The discovery of ERβ in the rat (Kuiper et al., 1996) and human (Mosselman et al., 
1996) and the identification of ERβ splice variants isoforms of the human gene 
(Moore et al., 1998, Ogawa et al., 1998b) has increased the range of possible 
combinations for heterodimeric partnerships. Previous studies have demonstrated 
preferential binding of ERβ to ERα in a heterodimeric state (Cowley et al., 1997) and 
the ability of the truncated ERβ2 isoform to form heterodimers with ERα (Leygue et 
al., 1999a, Leung et al., 2006). The formation of heterodimers between full length ER 
subtypes as well as the splice variants may facilitate cross talk between different 
signalling pathways and as such, may expand the regulatory potential of ERs.  
 
3.1.1 Aims of this chapter 
The primary objective of the studies in this chapter was to analyse the subnuclear 
dynamics of ERα, ERβ and ERβ2. In order to achieve this objective, studies were 
undertaken to establish and optimise the FRAP methodology for studies on YFP-
tagged ERs. The impact of ligands on subnuclear distribution and mobility of 
receptors (homodimers) was examined in addition to the effect of co-expression of 
receptors (formation of heterodimers) on receptor dynamics. Furthermore, an 
assessment of correlations between receptor dynamics and transcriptional activity 
using a 3X-ERE-tk-luciferase reporter gene was addressed. 
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3.2 Materials and Methods 
3.2.1 Cells 
MDA, Ishikawa and hTERT cells were used for this study and maintained as 
described in section 2.1. 
3.2.2 Taqman® qRT-PCR 
RNA was extracted from lysed cells using a Qiashredder™ spin column for cell 
homogenisation (section 2.5.1) and quantified using the Nanodrop® ND 1000 
(Labtech International, East Crawley, UK). Complimentary DNA (cDNA) was 
prepared using random hexamers (section 2.5.4.1) and was used for the Taqman 
reaction protocol outlined in section 2.5.4.3. Taqman analysis was conducted in 
triplicate and run on the ABI Prism 7900 using the Roche Universal Probe Library™ 
for ERα, ERβ and ERβ2. Data output from the detection system was quantified in 
accordance with the 2-∆∆Ct algorithm (section 2.5.4.4). Results are expressed as means 
and standard errors and statistical analysis was conducted using a Student’s t-test.  
3.2.3 Adenoviral Infection 
MDA cells were seeded at a density of 1 x 105 cells/ml on a 24 well plate and infected 
with the adenoviral constructs of ERα, ERβ, and ERβ2 that all included an N-terminal 
‘tag’ consisting of a YFP independently or in combination (Chapter 2, section 2.8.4). 
Adenoviral uptake is through the Coxsakie-Adenovirus Receptor (CAR) on the cell 
surface and enables greater efficiency of uptake of receptor constructs than 
comparable methods employing transient transfection. The adenoviral constructs were 
infected over a wide range of MOI values (10, 25, 50 and 100). MOI values reflect the 
number of adenoviral particles infected per cell and are derived by calculation with 
using the titre of the virus involved. Adenoviral titre is determined by the number of 
plaques formed in response to viral inoculation into the growth media of cells and is 
expressed as plaque forming units/ml (pfu/ml). To define the amount of virus to use in 
a given assay, the total number of viral particles required (i.e. MOI value x no. of cells 
present) is divided by the viral titre. Infected cells were imaged using a Plan-
Apochromat 20X on an Axiovert 200M inverted microscope (Zeiss).  
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3.2.4 Western Immunoblotting 
Western blotting was performed on total protein extracts from MDA cells that had 
been infected with viral particles containing YFP-tagged or untagged cDNA 
constructs of ERα, ERβ and ERβ2. The infected cells were lysed with high-salt RIPA 
buffer (section 2.6.1) and quantified in accordance with the Biorad DC Protein Assay 
(section 2.6.3). The protein extracts were separated on polyacrylamide gels by 
electrophoresis (section 2.7.2) and electro-transferred to PVDF membranes (section 
2.7.3). Membranes were incubated with antibodies specific for ERα or ERβ (specific 
to the N-terminal domain that is common to all ERβ splice variants) for verification of 
infected protein size. After incubation with appropriate secondary antibody (Table 2.4) 
they were scanned using the LI-COR™ infrared detection system (2.7.5).  
3.2.5 Cell Treatments 
To establish the impact of different ligands on ER receptor activity, cells were 
incubated with E2 or the selective agonists PPT™ and DPN™ all at final 
concentrations of 10-8M or the ER antagonist ICI 182,780. Control treatments using a 
DMSO vehicle at 10-8M were run in parallel. Ligands were added 1 hour prior to live-
cell FRAP analyses and 24 hours in advance of cell harvesting for luciferase assays 
(see section 3.2.7 below). 
3.2.6 Fluorescence Recovery After Photobleaching  
FRAP analysis was carried out on a LSM 510 confocal inverted light scanning 
microscope (section 2.8.6). In brief, live cells were maintained in PBS buffered with 
10mM HEPES in an enclosed chamber heated to 37°C (section 2.8.2). Cells 
expressing YFP were selected for bleaching on the basis of uniform distribution of 
levels of fluorescence. Three ROIs of equal dimension were chosen (section 2.8.5). 
Two prebleach images were captured at 3 second intervals followed by 
photobleaching resulting from a series of focused pulsed iterations using the Argon 12 
laser (488 and 514nm) at maximal power. Eight subsequent images were taken to 
establish recovery patterns using an attenuated laser (514nm set between 1-5% power) 
(section 2.8.6). Data collation and quantitation was conducted and subject to 
correction, normalisation and statistical evaluation as outlined in section 2.8.7. 
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3.2.7 Luciferase Gene Reporter Assay 
Ligand activation was assessed using a luciferase reporter assay carried out as 
described in section 2.9.1. Luciferase activity expressed as ‘relative light units’ 
detected on the FLUOstar OPTIMA luminometer (BMG Labtech) was normalised 
against total protein content from samples of the same experiment and conditions 
using data obtained with the Biorad DC Protein Assay (section 2.6.3). 
 
3.3 Results 
3.3.1 Characterisation of Cell lines 
3.3.1.1 Expression of mRNAs in cell lines 
Expression of ERα, ERβ and ERβ2 mRNA was measured by Taqman™ qRT-PCR for 
each of the three cell lines (MDA, Ishikawa and hTERT) and compared to a human 
RNA control (Fig. 3.1). Expression of ER mRNAs was barely detectable in MDA 
cells and this line was used for FRAP in order to optimise the imaging techniques for 
the study of the impacts of treatments on ERs in a background of low basal 
endogenous receptor. In line with published results (Nishida et al., 1985), the Ishikawa 
cell line was ERα positive but expressed low ERβ and no ERβ2 mRNAs. hTERT cells 
were ERα+ve/ERβ+ve/ERβ2+ve (Fig. 3.1). After optimising the conditions required 
for optimal imaging and FRAP assays, the Ishikawa cells were employed to study the 
role of ligands in an endometrial adenocarcinoma background and subsequently the 
hTERT studies were conducted to decipher the role of ligand-dependent ER activity in 
untransformed endometrial epithelial cells. 
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Figure 3.1 Comparison of mRNA expression of endogenous ERα, ERβ and ERβ2 in 
Ishikawa and hTERT cell lines relative to the MDA cell line. 
Ishikawa and hTERT cells are ERα-positive and hTERT cells are ERβ and ERβ2 
positive; the MDA cell line lacked endogenous ER expression. 
 
3.3.1.2 Multiplicity of Infection determination; single infections 
The effect of adenoviral-mediated ER expression on cell viability was examined. 
Titration assays were carried out in the MDA cells to define the optimum number of 
adenoviral particles required, i.e. MOI value, to infect a given number of cells (1 x 
105). Cells were infected with increasing amounts (MOI) of virus expressing ERα, 
ERβ and ERβ2 for 24 hours with the resultant images presented in Fig. 3.2. The 
merged phase contrast and fluorescent images presented highlight the ratio of relative 
infectivity levels to the actual number of cells present. All YFP-tagged ERs were 
detected in the nuclear compartment of the cells consistent with the pattern of 
expression of endogenous ERs. The optimal level of infectivity was determined as a 
compromise between fluorescence expression and cell viability. At MOIs of 10, 25 
and 50 the ratio of infected cells to the overall cell population was low. At an MOI of 
100, infectivity was deemed significant with ~55-60% of cells expressing fluorescent 
ER and was selected as the optimal MOI to be used for all constructs in future 
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Figure 3.2 Observational evaluation of MDA cells infected with yellow fluorescent 
labelled adenoviral ER constructs.  
Cells were infected over a range of MOI values (namely 10, 25, 50 and 100) with 
either of the constructs ERα, ERβ or ERβ2 to establish optimum viral levels required 
for infection and localisation at the nucleus. A final MOI value of 100 was chosen for 
infection of cells with a single ER construct.   Images presented are merged 
representations of phase contrast and fluorescent cells to establish infection rates 
relative to the actual number of cells present. Images were captured at 20X using a 
Zeiss Axiovert 200M microscope.  
 
3.3.1.3 Optimal MOI determination; multiple infection 
The morphological appearance of MDA cells infected simultaneously with two 
fluorescent-labelled ER constructs is depicted in Fig. 3.3. At low MOI values of 10 
and 25 for each construct, there were insufficient levels of fluorescence to warrant 
further experimentation. An MOI of 50 for each of the fluorescent constructs was 
selected thereby giving a final total MOI of 100 per 1 x 105 cells. An MOI of 100 for 
each infected construct yielded cytotoxic effects on cells where a significant reduction 
in cell viability was associated with floating and rounded up cells. 
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Figure 3.3 Observational evaluation of MDA cells infected with two YFP-tagged ER 
constructs.   
Cells were infected over a range of MOI values (namely 10, 25, 50 and 100) to 
establish optimum viral levels required for infection and localisation at the nucleus. A 
final MOI value of 50 for each construct was considered optimum for infection of 
cells. Images presented are merged representations of phase contrast and fluorescent 
cells taken at 20X using a Zeiss Axiovert 200M microscope. 
 
3.3.1.4 Expression of mRNAs in cells infected with viral constructs 
Further to the observation that infection of the ER constructs was optimal at an MOI 
of 100 (section 3.3.1.2), ER mRNA expression in cells infected with MOI values of 50 
and 100 was evaluated by qRT-PCR.  The data presented have been normalised in 
accordance with the comparative CT method outlined in Section 2.5.4.4.  Compared 
with endogenous ERα levels in MDA cells, infected cells with a MOI of 50 and 100 
ERα-YFP showed ~10,000 and 30,000 fold increase in mRNA concentrations 
respectively (Fig 3.4; A). The expression of ERβ and ERβ2 mRNA was also 
significantly increased following infection with ERβ-YFP (~7000 and ~28000 fold 
induction respectively) and ERβ2-YFP (~15000 and ~35000 fold induction 
respectively) at MOI values of 50 and 100 (Fig 3.4; B and C). Table 3.1 illustrates the 
raw threshold cycle (Ct) values acquired from the Taqman™ run.  The high Ct values 
determined from endogenous ERα, ERβ and ERβ2 samples reaffirm the low basal 
expression of ERs in the MDA cell line. 
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Endogenous ERα mRNA expression was readily detectable in Ishikawa cells by 
quantitative Taqman™ PCR. Compared with endogenous ERα levels in Ishikawa 
cells, infected cells at  MOI  values of 50 and 100 ERα-YFP demonstrated a negligible 
effect on mRNA levels (~1.5 and 3 fold increase respectively)  (Fig 3.5; A).  The 
expression of ERβ and ERβ2 mRNA was significantly increased following infection 
with ERβ-YFP (~15000 and ~85000 fold induction respectively) and ERβ2-YFP 
(~70000 and ~100000 fold induction respectively) at MOIs of 50 and 100 (Fig 3.5; B 
and C). Table 3.1 illustrates the raw threshold cycle (Ct) values acquired from the 
Taqman™ run.  A relatively low Ct value of 24.5 was obtained for endogenous ERα 
levels in Ishikawa cells and infection of more ERα-YFP into these cells did not 
significantly impact on the doubling rates of the original cDNA content (Table 3.1). 
Significant changes to Ct values were determined with infection of ERβ and ERβ2 
with respect to their cognate endogenous high Ct values. This data establishes the 
Ishikawa cells as an ERα positive cell line with comparably low ERβ basal levels of 
expression. 
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Figure 3.4 ER mRNA expression in MDA cells.  
Cells were infected with constructs of ERα (A), ERβ (B) and ERβ2 (C) at multiplicity of 
infection values of 50 and 100 respectively via adenoviral delivery. Messenger RNA 
levels are presented relative to endogenous oestrogen receptor expression levels in 
MDA cells and are representative of N=3±SEM. 
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Figure 3.5 ER mRNA expression in Ishikawa cells.  
Cells were infected with constructs of ERα (A), ERβ (B) and ERβ2 (C) at multiplicity of 
infection values of 50 and 100 respectively via adenoviral delivery. Messenger RNA 
levels are presented relative to endogenous oestrogen receptor expression levels in 
Ishikawa cells and are representative of N=3±SEM. 
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Figure 3.6 ER mRNA expression in hTERT cells.  
Cells were infected with constructs of ERα (A), ERβ (B) and ERβ2 (C) at multiplicity of 
infection values of 50 and 100 respectively via adenoviral delivery. Messenger RNA 
levels are presented relative to endogenous oestrogen receptor expression levels in 
hTERT cells and are representative of N=3±SEM. 
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ERα mRNA expression was readily detectable in hTERT cells by quantitative 
Taqman™ PCR. Compared with endogenous ERα levels in hTERT cells, infected 
cells at MOI values of 50 and 100 ERα-YFP exhibited a minor effect on mRNA levels 
(~10 and 20 fold increase respectively) (Fig 3.6; A).  The expression of ERβ and ERβ2 
mRNA was significantly increased following infection with ERβ-YFP (~60000 and 
~125000 fold induction respectively) and ERβ2-YFP (~30000 and ~60000 fold 
induction respectively) at MOI values of 50 and 100 (Fig 3.6; B and C). The raw 
threshold cycle (Ct) values acquired from the Taqman™ run revealed early detection 
of endogenous ERα in comparison to endogenous ERβ and ERβ2. Significant changes 
to these Ct values were produced following infection of the YFP-tagged ERs at MOI 
values of 50 and 100. 
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Table 3.1 Average threshold cycle (Ct) values determined by the ABI 7900 sequence 
detection system (Applied Biosystems). 
Specific primer and probe sequences from the Universal Probe Library™ to ERα, 
ERβ and ERβ2 were used to compare the doubling rates of DNA in samples infected 
with MOIs of 50 and 100 of individual ERs in comparison to the endogenous amount 
of ER present in MDA, Ishikawa and hTERT cell lines (prior to normalisation with the 
18S ribosomal RNA control). 
 
 ERα ERβ ERβ2 
MDA    
Endogenous 37.0 37.0 35.0 
MOI 50 24.0 23.0 21.0 
MOI 100 22.0 21.0 20.0 
Ishikawa     
Endogenous 24.5 35.0 34.0 
MOI 50 24.0 23.0 19.0 
MOI 100 23.0 21.0 18.0 
hTERT    
Endogenous 22.0 33.0 33.0 
MOI 50 19.0 18.0 19.0 
MOI 100 18.5 17.0 18.0 
3.3.1.5  Protein expression 
MDA cells did not contain detectable amounts of ERα or ERβ proteins (Control Lane 
1: Fig. 3.7 and 3.8) as was predicted from the low basal levels of mRNA as 
determined by qRT-PCR (Fig. 3.1). On this basis, this cell line was selected and 
utilised for further experimentation to assess the impact of natural and synthetic 
compounds on individual ERs both independently and in combination. To validate the 
use of the ER constructs, total protein was extracted from cells that had been 
transfected with a control plasmid encoding a YFP protein linked to a cyan fluorescent 
protein (CFP) (Lane 2) and cells that had been infected with both the tagged and 
untagged constructs (MOI of 50 each) of either the ERα (Lane 3), ERβ1 (Lane 4) or 
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ERβ2 (Lane 5). Western blot analysis confirmed ERα untagged protein (red band) at 
~66kDa and the addition of a YFP tag (27kDa) generating a product size of ~93kDa 
(Fig.3.7). The antibody specific to the YFP detected the YFP/CFP plasmid (Lane 2) at 
~54kDa and the YFP label of the cells infected with tagged ERβ1 and ERβ2 (green 
bands) (Lanes 4 and 5).  
 
 
              1        2           3       4          5 
Figure 3.7 Western blot analysis of ERα and YFP-labelled protein expression in 
MDA cells.  
Protein extracted from: Lane 1, Uninfected cells (C); Lane 2, cells transfected with a 
control plasmid expressing YFP and CFP separated by a 25 amino acid linker 
sequence (total size ~55kDa); Lane 3, cells co-infected with untagged and YFP-tagged 
ERα constructs; Lane 4, cells infected with untagged and YFP-tagged ERβ constructs; 
Lane 5, cells infected with untagged and YFP-tagged ERβ2 constructs. Membrane was 
incubated with anti-ERα (red) and anti-YFP (green). 
 
The same samples were used to generate a membrane that was probed with an anti-
ERβ antibody that was specific to the N-terminus of the receptor (Fig. 3.8). This 
antibody should detect all ERβ splice variants (which only differ at the C terminal 
domain). No ERβ was detected in the control lane, but both untagged (green) and 
YFP-labelled ERβ (red) were detected at the correct sizes in lanes 4 and 5. A very 
weak YFP band was detected in the ERα-YFP infected sample but it is thought that 
this sample did not run properly and may have been contaminated with salt. 
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         1          2     3        4          5 
Figure 3.8 Western analysis of ERβ protein expression in MDA cells.  
Protein extracted from: Lane 1, Uninfected cells (C); Lane 2, cells transfected with a 
control plasmid expressing YFP and CFP separated by a 25 amino acid linker 
sequence (total size ~55kDa); Lane 3, cells co-infected with untagged and YFP-tagged 
ERα constructs; Lane 4, cells infected with untagged and YFP-tagged ERβ constructs; 
Lane 5, cells infected with untagged and YFP-tagged ERβ2 constructs. Membrane was 
incubated with a generic anti-ERβ (green) antibody directed against the N-terminus of 
ERβ and anti-YFP (red).  
 
 
3.3.2 Intranuclear dynamics of ER homodimers 
The spatiotemporal response of ER subtypes to ligand activation was examined. For 
each treatment, an observational assessment of ER sub-nuclear distribution was made. 
Secondly, the temporal effect of treatments on intranuclear mobility was further 
investigated using FRAP quantitation methods. 
 
3.3.2.1 Agonist Response 
A panel of ligands was used to investigate the influence of natural (E2) and synthetic 
(PPT™ and DPN™) agonist compounds on the intranuclear dynamics of ERα, ERβ 
and ERβ2 in different cell contexts. Following infection with an individual ER 
subtype, experiments were conducted using a DMSO vehicle control. The results 
obtained after agonist stimulation were compared to this vehicle control response
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3.3.2.1.1 MDA cells 
ERα 
Infection of ERα-YFP into MDA cells yielded homogenous nuclear distribution of 
fluorescence (Fig 3.9). The application of a DMSO vehicle control for 1 hour had no 
impact on this observation. Treatment of cells with E2 for 1 hour induced the 
redistribution of the receptor with the accumulation of ‘speckles’ throughout the 
nucleoplasm giving a punctate appearance to the nucleus. This punctate appearance 
was observed albeit to a lesser extent with 1 hour PPT™ and DPN™ incubations (Fig 
3.9).  
 
Under conditions of FRAP, the region enclosed within the red box represents the area 
to undergo photobleaching (ROI I). Fig 3.9 depicts a snapshot of the images captured 
following photobleaching of cells incubated with DMSO (control), E2, PPT™ or 
DPN™. Re-equilibrium of ERα-YFP after DMSO treatment was achieved at 18 
seconds following bleaching (left hand panel). There was no significant apparent 
recovery of fluorescent molecules into the red zone (ROI I) following E2 incubation 
up to and including 18 seconds after photobleaching. It was noted that there is some 
recovery of fluorescent ERα-YFP molecules back into the ROI I of nuclei treated with 
PPT™ and DPN™.  
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Figure 3.9 Qualitative FRAP assessment. 
Live MDA cells were infected with ERα-YFP and subjected to treatment with either a 




M or DPN™ 10
-8
M for 60 minutes. The 
fluorescent molecules of a designated region (red box) were annihilated during the 
bleaching process and recovery back into this zone was monitored up to 18 seconds. 




A number of parameters were quantified to substantiate the observational findings 
from the ligand treatments on ERα in MDA cells.  Measurements were normalised and 
corrected for background fluorescence as well as varying fluorescent levels between 
nuclei. In cells incubated with DMSO (control), total recovery into the bleached ROI I 
was averaged at ~60% of the initial fluorescence in this zone after 25 seconds (Fig. 
3.10; A, B, C: black line). All ligand treatments were compared against this result. In 
all cells recovery into the bleached zone was maximal at ~25 seconds. This value is 
designated as the YMAX value (i.e. the point following a number of successive equal 
values where the response has reached a plateau level in all subsequent result 
sections). Fig 3.10A shows data obtained with ERα which confirmed the impact of E2 
on ERα mobility within the nuclear domain with an obvious and significant effect on 
the percentage of recovery into ROI I. The YMAX was used as a parameter for direct 
comparison between vehicle-treated and ligand-treated ERs. In the DMSO treated 
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control cells the percentage recovery for ERα was ~60%. Notably, treatment of ERα 
with the agonists PPT™ and DPN™ also resulted in a significant impact on the 
recovery rates of ERα molecules back into the bleached zone (Fig. 3.10B and C 
respectively) although the changes in YMAX were less pronounced that that with E2 
treatment. 
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Figure 3.10 Quantitative analysis of intra-nuclear kinetics of ERα-infected MDA 
cells.  
Graphical depiction of impact of ligand treatment on the recovery rates of ERα 
fluorophores over time back into the bleached zone. This recovery is denoted by the 
point at which the YMAX is achieved and a plateau is reached on the graph. Recovery 
rates of ERα-infected MDA cells are presented in response to E2 (A), PPT™ (B) and 
DPN™ (C) stimulation at a concentration of 10
-8
M. *** (P<0.001), ** (P<0.01) and 
*(P<0.05) denotes significance in variation of ligand treatments compared with the 
vehicle control (black column) as derived from the Student’s t-test (N≥8). 
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ERβ 
The distribution of ERβ-YFP in the nuclei of MDA cells was not uniform and the 
ERβ-YFP appeared to localise to certain regions within the nuclear architecture in its 
endogenous unliganded state. The DMSO vehicle control had no impact on this 
distribution (Fig 3.11 left hand panel). Treatment with E2 augmented the accumulation 
of speckles throughout the nucleoplasm giving a punctate appearance to the nucleus 
and limited recovery into ROI I was observed. This punctate appearance and reduced 
mobility (recovery) was also observed after incubation with DPN™. The distribution 
of ERβ-YFP following PPT™ treatment mirrored the pattern of the control nuclei and 
rapid recovery after bleaching resembled that in the DMSO cells (Fig 3.11). In DMSO 
treated cells the YMAX recovery of ERβ after ~25 seconds was ~40%. The impact of 
E2 on ERβ-YFP recovery within the nucleus was readily apparent on the YMAX curves 
(Fig. 3.12A) with E2 treatment having a significant effect on slowing the recovery rate 
of fluorescing molecules back into ROI I. The treatment of cells expressing ERβ with 
the synthetic compound PPT™ had no impact on ERβ-YFP dynamics with regard to 
YMAX (Fig 3.12B). Treatment with DPN™ had a significant impact on YMAX in line 
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Figure 3.11 Qualitative FRAP assessment of ERβ infected MDA cells.  




M or DPN™ 
10
-8
M for 60 minutes.  
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Figure 3.12 Quantitative analysis of intra-nuclear kinetics of ERβ-infected MDA 
cells.  
Graphical depiction of impact of ligand treatment on the recovery rates of ERβ 
fluorophores over time back into the bleached zone. This recovery is denoted by the 
point at which the YMAX is achieved and a plateau is reached on the graph. Recovery 
rates of ERβ-infected MDA cells are presented in response to E2 (A), PPT™ (B) and 
DPN™ (C) stimulation at a concentration of 10-8M. *** (P<0.001) and ** (P<0.01) 
denotes significance in variation of ligand treatments compared with the vehicle 
control as derived from the Student’s t-test (N≥8). 
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ERβ2 
Uniform nuclear distribution of fluorescence was observed following infection of 
MDA cells with YFP-labelled ERβ2 adenoviral constructs. This appearance was 
retained following all treatments including DMSO, E2, PPT™ and DPN™. 
Regardless of the presence or absence of ligand, a rapid (~6 second) recovery to the 
primary state of fluorescence was also observed following each treatment upon 
bleaching (Fig. 3.13). In the control (DMSO-treated) cells maximum recovery was 
~40%. There were no significant ligand-mediated influences by any treatment (E2, 
PPT™ and DPN™) when YMAX was calculated (Fig. 3.14A-C). 
 
 
Figure 3.13 Qualitative FRAP assessment of ERβ2 infected MDA cells.  




M or DPN™ 
10
-8
M for 60 minutes.  
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Figure 3.14 Quantitative analysis of intra-nuclear kinetics of ERβ2-infected MDA 
cells.  
Graphical depiction of impact of ligand treatment on the recovery rates of ERβ2 
fluorophores over time back into the bleached zone. This recovery is denoted by the 
point at which the YMAX is achieved and a plateau is reached on the graph. Recovery 
rates of ERβ2-infected MDA cells are presented in response to E2 (A), PPT™ (B) 
and DPN™ (C) stimulation at a concentration of 10
-8
M. Ligand treatments were 
compared with the vehicle control as derived from the Student’s t-test (N≥8).
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3.3.2.1.2 Ishikawa cells 
Ishikawa cells express endogenous ERα (section 3.3.1.1). When cells were 
transfected with the CY24 plasmid comprising the YFP tag linked to the CFP tag,  
maximal recovery following photobleaching was instantaneous (YMAX levels reached 
at first scan post-bleach) (Fig. 3.15A) and treatment with E2 had no marked effect on 
this response model (Fig. 3.15B). This confirms that the YFP protein did not interact 
with endogenous ERα and therefore any changes in mobility of YFP-tagged ERs is 
due to the ER itself and not the tag. 
 
 
Figure 3.15 Control FRAP experiments in Ishikawa cells.  
Cells were transfected with the CY24 plasmid consisting of a YFP tag conjugated to 
a CFP tag by a 25 amino acid sequence linker. Transfected cells were treated with a 





Infection of ERα-YFP into Ishikawa cells generated a homogenous nuclear 
dissemination of fluorescence, addition of the DMSO vehicle control for 1 hour had 
no impact on subnuclear distribution patterns. Treatment with E2 for 1 hour induced 
relocation of receptor resulting in a punctate appearance of fluorescence in the 
nucleus and low levels of recovery back into the bleached zone. This distinctive 
reorganisation of receptor distribution was also seen after 1 hour incubation with 
PPT™ incubation but not with DPN™ (Fig 3.16). 
 
In DMSO treated cells, the percentage recovery was ~60%. Fig 3.17 shows analysis 
of cells such as those shown in Fig. 3.16. Incubation with E2 (Fig. 3.17A) and PPT™ 
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(Fig. 3.17B) on ERα had a significant impact on YMAX values whereas the impact of 
DPN™ was minimal (Fig. 3.17C).  
 
 
Figure 3.16 Qualitative FRAP assessment of ERα infected Ishikawa cells. 




M or DPN™ 
10
-8
M for 60 minutes. 
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Figure 3.17 Quantitative analysis of intra-nuclear kinetics of ERα-infected 
Ishikawa cells.  
Graphical depiction of impact of ligand treatment on the recovery rates of ERα 
fluorophores over time back into the bleached zone. This recovery is denoted by the 
point at which the YMAX is achieved and a plateau is reached on the graph. Recovery 
rates of ERα-infected Ishikawa cells are presented in response to E2 (A), PPT™ (B) 
and DPN™ (C) stimulation at a concentration of 10
-8
M. *** (P<0.001) and ** 
(P<0.01) denotes significance in variation of ligand treatments compared with the 
vehicle control as derived from the Student’s t-test (N≥8). 
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ERβ 
Distribution of ERβ-YFP in the nuclei of Ishikawa cells was not as uniform as that 
observed following infection with ERα-YFP in the same cell line. ERβ-YFP 
appeared to be localised to certain regions within the nuclear architecture and the 
application of a DMSO vehicle control for 1 hour had no impact on this distribution. 
Incubation with E2 resulted in a more pronounced accumulation of ‘speckles’ 
throughout the nucleoplasm. Poor levels of recovery following bleaching of E2-
treated ERβ-YFP molecules were also noted consistent with reduced mobility. This 
punctate appearance and reduced mobility was also observed after incubation with 
DPN™. Treatment with PPT™ did not alter the mobility of ERβ (Fig 3.18).  
 
 
Figure 3.18 Qualitative FRAP assessment of ERβ infected Ishikawa cells. 
Cells were treated with a DMSO vehicle control, E2 10-8M, PPT™ 10-8M or 
DPN™ 10-8M for 60 minutes. 
 
The impact of E2 on ERβ-YFP recovery within the nucleus was also studied over a 
longer time course (~80 seconds) but little change in the YMAX levels was recorded 
after 25 seconds and they remained significantly reduced compared with control cells 
(Fig. 3.19A). E2 treatment had a significant effect in slowing the recovery rate of 
fluorescing molecules back into the bleached zone. Incubation of cells expressing 
ERβ with PPT™ had no impact on ERβ-YFP dynamics with regard to YMAX 
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analysis. Treatment with DPN™ had a striking and significant impact on percentage 
recovery which remained less than ~10% after 30 seconds (Fig. 3.19C). 
 
 
Figure 3.19 Quantitative analysis of intra-nuclear kinetics of ERβ-infected 
Ishikawa cells.  
Impact of ligand treatment on the recovery rates of ERβ fluorophores over time into 
the bleached zone. Recovery is denoted by the point at which the YMAX is achieved 
and a plateau is reached on the graph. Recovery rates of ERβ-infected Ishikawa cells 
are in response to E2 (A), PPT™ (B) and DPN™ (C) at a concentration of 10
-8
M. 
*** (P<0.001) denotes significance in variation of ligand treatments compared with 
the vehicle control as derived from the Student’s t-test (N≥8). 
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ERβ2 
Uniform nuclear distribution of fluorescence was achieved following infection of 
Ishikawa cells with YFP-labelled ERβ2 adenoviral constructs (Fig. 3.20). This 
appearance was retained following all treatments including DMSO, E2, PPT™ and 
DPN™. Rapid recovery in fluorescence (~6 seconds) was observed after 
photobleaching with each of the treatments (Fig. 3.20). No significant influences by 
either treatment E2, PPT™ or DPN™ were found from analysis of the statistical 




Figure 3.20 Qualitative FRAP assessment of ERβ2 infected Ishikawa cells.  




M or DPN™ 
10
-8
M for 60 minutes.  
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Figure 3.21 Quantitative analysis of intra-nuclear kinetics of ERβ2-infected 
Ishikawa cells.  
Graphical depiction of impact of ligand treatment on the recovery rates of ERβ2 
fluorophores over time back into the bleached zone. This recovery is denoted by the 
point at which the YMAX is achieved and a plateau is reached on the graph. Recovery 
rates of ERβ2-infected Ishikawa cells are presented in response to E2 (A), PPT™ (B) 
and DPN™ (C) stimulation at a concentration of 10
-8
M. Significance in variation of 
ligand treatments compared with the vehicle control was assessed by the Student’s t-
test (N≥8).  
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3.3.2.1.3 hTERT cells 
hTERT cells transfected with the CY24 plasmid comprising the YFP tag linked to 
the CFP tag only were studied following treatment with and without E2. Following 
photobleaching, maximal recovery was almost instantaneous (YMAX levels reached at 
first scan post-bleach) (Fig. 3.22A) and treatment with E2 did not effect this response 
(Fig. 3.22B) suggesting that the fluorescent proteins on their own did not associate 
with DNA, ligand or ERs. 
 
 
Figure 3.22 Control FRAP experiments in hTERT cells.  
Cells were transfected with the CY24 plasmid consisting of a YFP tag conjugated to 
a CFP tag by a 25 amino acid sequence linker. Transfected cells were treated with a 





The infection of ERα-YFP for into hTERT cells resulted in uniform levels of 
fluorescence throughout the nucleus when cells were examined after 24 hours. 
Treatment with the DMSO vehicle control for 1 hour did not have any impact on 
nuclear distribution of ERα-YFP. However incubation with E2 for 1 hour resulted in 
redistribution of receptor that adopted a punctate appearance in the nucleus 
associated with very low levels of recovery back into the bleached zone. This 
distinctive appearance was also seen after 1 hour incubation with PPT™ but not 
following DPN™ treatment (Fig. 3.23). 
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Figure 3.23 Qualitative FRAP assessment of ERα infected into hTERT  cells. 
Cells were treated with a DMSO vehicle control, E2 10-8M, PPT™ 10-8M or 
DPN™ 10-8M for 60 minutes.  
 
Fig 3.24A illustrates the significant impact of E2 on ERα-YFP mobility within the 
nuclear domain. E2 treatment has a significant effect in slowing the percentage of 
recovery into ROI I resulting in a reduction of YMAX from ~60% to less than ~40% 
after 25 seconds. Treatment of ERα-YFP molecules with the agonist PPT™ resulted 
in an effect on recovery rates of fluorescent ERα molecules with a significant 
reduction in YMAX (Fig. 3.10B). DPN™ had no impact on ERα-YFP molecules in the 
hTERT cell environment (Fig. 3.10C). 
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Figure 3.24 Quantitative analysis of intra-nuclear kinetics of ERα-infected hTERT 
cells.  
Graphical depiction of impact of ligand treatment on the recovery rates of ERα 
fluorophores over time back into the bleached zone. This recovery is denoted by the 
point at which the YMAX is achieved and a plateau is reached on the graph. Recovery 
rates of ERα-infected hTERT cells are presented in response to E2 (A), PPT™ (B) 
and DPN™ (C) stimulation at a concentration of 10
-8
M. ** (P<0.01) denotes 
significance in variation of ligand treatments compared with the vehicle control as 
derived from the Student’s t-test (N≥8).  
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ERβ 
Expression of ERβ-YFP in the hTERT cell line is not as uniform as that observed 
following infection of ERα-YFP in the same cells. The application of a DMSO 
vehicle control for 1 hour had no impact on ERβ-YFP distribution but incubation 
with E2 resulted in redistribution of ERβ and a pronounced accumulation of 
‘speckles’ throughout the nucleoplasm (Fig 3.25). Reduced rates of recovery 
following bleaching of E2-treated ERβ-YFP molecules were also noted. YMAX 
reduced to ~30% compared with ~40% in control untreated cells (Fig 3.26). This 
punctate appearance and reduced YMAX was also observed with a 1 hour DPN™ 
incubation. Uniform distribution of ERβ-YFP induced fluorescence was observed in 
nuclei following PPT™ treatment (1 hour) both before and after bleaching (Fig 3.25) 




Figure 3.25 Qualitative FRAP assessment of ERβ infected hTERT cells. 
Cells were treated with a DMSO vehicle control, E2 10-8M, PPT™ 10-8M or 
DPN™ 10-8M for 60 minutes.  
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Figure 3.26 Quantitative analysis of intra-nuclear kinetics of ERβ-infected hTERT 
cells.  
Graphical depiction of impact of ligand treatment on the recovery rates of ERβ 
fluorophores over time back into the bleached zone. This recovery is denoted by the 
point at which the YMAX is achieved and a plateau is reached on the graph. Recovery 
rates of ERβ-infected hTERT cells are presented in response to E2 (A), PPT™ (B) 
and DPN™ (C) stimulation at a concentration of 10
-8
M. ** (P<0.01) denotes 
significance in variation of ligand treatments compared with the vehicle control as 
derived from the Student’s t-test (N≥8).  
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ERβ2 
Homogenous nuclear distribution of fluorescence was achieved following infection 
of hTERT cells with YFP-labelled ERβ2 adenoviral constructs. This appearance was 
retained following all treatments including DMSO, E2, PPT™ and DPN™. A rapid 
(~6 second) recovery to the primary state of fluorescence was also observed 
following each treatment upon bleaching (Fig. 3.27). A slight but significant effect 
on YMAX was observed on ERβ2-YFP molecules following E2 stimulation with 
reduction by ~5% compared with controls (Fig. 3.28A). Treatment with PPT™ or 
DPN™ had no impact on YMAX (Fig. 3.28B and C). 
 
 
Figure 3.27 Qualitative FRAP assessment of ERβ2 infected hTERT cells. 
 Cells were treated with a DMSO vehicle control, E2 10-8M, PPT™ 10-8M or 
DPN™ 10-8M for 60 minutes.  
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Figure 3.28 Quantitative analysis of intra-nuclear kinetics of ERβ2-infected 
hTERT cells.  
Depiction of impact of ligand treatment on the recovery rates of ERβ2-YFP over time 
back into the bleached zone. This recovery is denoted by the point at which the YMAX 
is achieved and a plateau is reached on the graph. Recovery rates of ERβ2-infected 
hTERT cells are presented in response to E2 (A), PPT™ (B) and DPN™ (C) 
stimulation at a concentration of 10
-8
M. Significance in variation of ligand 
treatments compared with the vehicle control was assessed by the Student’s t-test 
(N≥8).  
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3.3.2.2 Impact of anti-oestrogen on receptor dynamics 
Following the study of E2 and the selective ER agonists on the intranuclear dynamics 
of ERs, the impact of the pure anti-oestrogen ICI 182.780 (Fulvestrant™) was 
examined. Analysis of treatment outcome was conducted after incubation of cells for 
1 hour with ICI 182,780. 
3.3.2.2.1 Ishikawa cells 
The impact of ICI 182,780 was identical in both the cell lines tested (Ishikawa and 
hTERT cells) and only the data from the Ishikawa cell line is presented here. 
ERα 
The interaction of the ICI 182,780 molecule with ERα-YFP in the Ishikawa nuclei 
resulted in a punctate appearance similar to that observed following E2 treatment. In 
comparison to the weak recovery of E2 treated ER molecules back into the bleached 
zone, no recovery was observed in the cells treated with ICI 182,780 for 1 hour 
followed by E2 for 1 hour (Fig 3.29). 
 
 
Figure 3.29 Qualitative FRAP assessment of ERα infected Ishikawa cells. 
Cells were treated with a DMSO vehicle control, E2 10
-8
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The percentage of recovery observed in ICI 182,780/E2-treated cells was extremely 
low (<10%) (Fig. 3.30) and did not climb above this value over extended time 
periods (data not shown). 
 
Figure 3.30 Quantitative analysis of intra-nuclear kinetics of ERα-infected 
Ishikawa cells.  
Graphical depiction of impact of ligand treatment on the recovery rates of ERα 
fluorophores over time back into the bleached zone. This recovery is denoted by the 
point at which the YMAX is achieved and a plateau is reached on the graph. Recovery 
rates of ERα-infected Ishikawa cells are presented in response to E2 (red) and ICI 
182,780 with E2 (grey) stimulation at a concentration of 10
-8
M. *** (P<0.001) 
*(P<0.05) denotes significance in variation of ligand treatments compared with the 
vehicle control as derived from the Student’s t-test (N≥8).  
 
ERβ 
Incubation of ERβ-infected Ishikawa cells with ICI 182,780 resulted in receptor 
redistribution and the development of a punctate appearance in the nucleoplasm not 
dissimilar to that displayed by E2-treated cells (Fig. 3.31). The incubation of ICI 
182,780 for 1 hour followed by E2 for 1 hour with ERβ-YFP molecules in Ishikawa 
nuclei resulted in a significant impact on the YMAX (Fig. 3.32). 
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Figure 3.31 Qualitative FRAP assessment of ERβ infected Ishikawa cells.  
Cells were treated with a DMSO vehicle control, E2 10
-8





Figure 3.32 Quantitative analysis of intra-nuclear kinetics of ERβ-infected 
Ishikawa cells. 
Impact of ligand treatment on the recovery rates of ERβ fluorophores over time back 
into the bleached zone. This recovery is denoted by the point at which the YMAX is 
achieved and a plateau is reached on the graph. Recovery rates of ERβ-infected 
Ishikawa cells are presented in response to E2 (red) and ICI 182,780 followed by E2 
(grey) at a concentration of 10-8M. *** (P<0.001) denotes significance of 
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treatments compared with the vehicle control as derived from the Student’s t-test 
(N≥8).  
ERβ2 
In comparison to the null effect of E2 stimulation on ERβ2-YFP dynamics within the 
Ishikawa nucleus, the treatment with ICI 182,780 did have a significant effect a 
phenotypic appearance of the receptor with the appearance of strong fluorescent foci 
clearly visible after treatment (Fig. 3.33). While the effect of ICI 182,780 treatment 
with E2 did not yield significant results on the dynamic mobility when this was 
assessed quantitatively (Fig. 3.34), a trend similar to that observed with the full 




Figure 3.33 Qualitative FRAP assessment of ERβ2 infected Ishikawa cells.  
Cells were treated with a DMSO vehicle control, E2 10
-8
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Figure 3.34 Quantitative analysis of intra-nuclear kinetics of ERβ2-infected 
Ishikawa cells.  
Graphical depiction of impact of ligand treatment on the recovery rates of ERβ2 
fluorophores over time back into the bleached zone. This recovery is denoted by the 
point at which the YMAX is achieved and a plateau is reached on the graph. Recovery 
rates of ERβ2-infected Ishikawa cells are presented in response to E2 (red) and ICI 
182,780 in combination with E2 (grey) stimulation at a concentration of 10
-8
M. 
Significance in variation of ligand treatments was compared with the vehicle control 
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3.3.3 Intranuclear dynamics of ER heterodimers 
After examination of the ER responses to a panel of ligands as individual entities, the 
impact of ligand treatment on cells that were co-expressed with two ER subtypes was 
investigated. This study was conducted in MDA cells to prevent interference from 
background levels of ER expression. Fluorescence resonance energy transfer (FRET) 
studies performed within the lab derived results suggestive of effective dimerisation 
arising from co-expression of the combinations of ER subtypes presented below. 
3.3.3.1 Agonist Response 
The impact of E2 and the synthetic compounds PPT™ and DPN™ on intranuclear 
mobility was retested following co-expression of two ER subtypes in the MDA cell 
line. 
ERα and ERβ-YFP 
Unlabelled ERα and ERβ-YFP were co-infected into MDA cells so as to assess the 
impact of ERα on ERβ-YFP intra-nuclear mobility when they had the potential to 
form heterodimers. Incubation with E2 resulted in a pronounced impact on the dual 
infected nuclei with reduced recovery observed into the bleached region. In 
comparison, rapid recovery of fluorescence levels was observed in the bleached 
region in PPT™ treated cells but repopulation of the bleached zone was reduced in 
DPN™ treated cells (Fig. 3.35). 
 
In line with the observational study, quantitative analysis confirmed that E2 
treatment had a significant impact on ERβ-YFP mobility and YMAX in MDA cells co-
infected with ERα (Fig. 3.36A). Surprisingly incubation of cells with PPT™ 
generated a recovery curve matching that of the DMSO vehicle control (Fig. 3.36B). 
In contrast incubation with DPN™ for 1 hour had a significant impact with striking 
reduction in the value of YMAX (Fig. 3.36C). 
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Figure 3.35 Qualitative FRAP assessment of dual infected MDA cells.  
Cells were infected with unlabelled ERα and ERβ-YFP to assess the effect of ligand 
on heterodimers. Heterodimeric status is assumed based on relative proximity 
calculations verified by FRET studies conducted in the lab (data not presented). 





M or DPN™ 10
-8
M for 60 minutes. The fluorescent molecules of a 
designated region (red box) were annihilated during the bleaching process and 
recovery back into this zone was monitored over time. This time period was chosen 
on the basis of full recovery observed in the control nuclei.  
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Figure 3.36 Quantitative analysis of intra-nuclear kinetics of dual infected MDA 
cells.  
Graphical depiction of impact of ligand treatment on the recovery rates of ERβ-YFP 
over time in a background of untagged ERα constructs back into the bleached zone. 
This recovery is denoted by the point at which the YMAX is achieved and a plateau is 
reached on the graph. Recovery rates of ERβ-YFP infected MDA cells are presented 
in response to E2 (A), PPT™ (B) and DPN™ (C) stimulation at a concentration of 
10
-8
M. *** (P<0.001), and *(P<0.05) denotes significance in variation of ligand 
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ERα and ERβ2-YFP 
E2 treatment of MDA cells co-expressing unlabelled ERα and ERβ2-YFP resulted in 
reduced mobility of ERβ2-YFP compared with that seen in cells exposed to DMSO 
(control). Exposure of cells to PPT™ and DPN™ did not have an obvious impact on 
mobility (Fig. 3.37). Quantitative analysis of cells incubated with ERβ2-YFP and 
ERα confirmed that treatment with E2 resulted in a significant decrease in the 
percentage recovery of fluorescent molecules (YMAX) in comparison with those cells 
treated with DMSO alone (Fig. 3.38A). Treatment of cells with PPT™ or DPN™ 
had no significant impact on the dynamics of ERβ2-YFP compared to DMSO 
controls (Fig. 3.37B, C). 
 
 
Figure 3.37 Qualitative FRAP assessment of dual infected MDA cells.  
MDA cells were infected with ERβ2-YFP and unlabelled ERα to assess the effect of 
ligand on heterodimers. Heterodimeric status is assumed based on relative proximity 
calculations verified by FRET studies conducted in the lab (data not presented). 





M or DPN™ 10
-8
M for 60 minutes. The fluorescent molecules of a 
designated region (red box) were annihilated during the bleaching process and 
recovery back into this zone was monitored over time. This time period was chosen 
on the basis of full recovery observed in the control nuclei. 
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Figure 3.38 Quantitative analysis of intra-nuclear kinetics of dual infected MDA 
cells.  
Graphical depiction of impact of ligand treatment on the recovery rates of ERβ2 
fluorophores over time in a background of untagged ERα constructs back into the 
bleached zone. This recovery is denoted by the point at which the YMAX is achieved 
and a plateau is reached on the graph. Recovery rates of ERβ2-YFP infected MDA 
cells are presented in response to E2 (A), PPT™ (B) and DPN™ (C) stimulation at a 
concentration of 10-8M. ** (P<0.01) denotes significance in variation of ligand 
treatments compared with the vehicle control as derived from the Student’s t-test 
(N≥8).
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ERβ (+/-YFP) and ERβ2 (+/-YFP) 
MDA cells were co-infected with a combination of ERβ and ERβ2 and for each co-
infection one subtype was fluorescently labelled with a YFP tag while the other 
subtype was untagged. When the mobility of ERβ2-YFP was assessed following 
treatment of cells for 1 hour with E2 the recovery of fluorescence following 
photobleaching was identical to that of the DMSO vehicle control. In the study with 
the alternative combination (ERβ-YFP and ERβ2 untagged), the ERβ-YFP molecule 
remained largely mobile in the presence of PPT™ but incubation with DPN™ 
resulted in an apparent reduction in mobility (Fig. 3.39). Statistical analysis of the 
impact of E2 treatment on co-infected ERβ2-YFP and ERβ MDA cells demonstrated 
no effect of E2 on ERβ2-YFP (Fig. 3.40A). In cells co-expressing ERβ-YFP and 
ERβ2, PPT™ treatment did not alter the mobility pattern of ERβ-YFP (Fig.3.40 B) 
while DPN™ induced a significant reduction in the mobility of ERβ-YFP molecules 
under the same experimental conditions (Fig. 3.40 C). 
 
 
Figure 3.39 Qualitative FRAP assessment of dual infected MDA cells.  
MDA cells were infected with ERβ (-YFP) and ERβ2 (-YFP) to assess the effect of 
ligands on heterodimers. Cells infected with ERβ2-YFP and ERβ were subjected to 
treatment with either a DMSO vehicle control or E2 10
-8
M. MDA cells infected with 
ERβ-YFP and ERβ2 were incubated with PPT™ 10
-8
M or DPN™ 10
-8
M. 
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Figure 3.40 Quantitative analysis of intra-nuclear kinetics of dual infected MDA 
cells.  
Impact of E2 treatment on the recovery rates of ERβ2-YFP over time in a 
background of untagged ERβ constructs back into the bleached zone (A). Recovery is 
denoted by the point at which the YMAX is achieved and a plateau is reached. 
Recovery rates of ERβ-YFP and untagged ERβ2 co-infected MDA cells are presented 
in response to PPT™ (B) and DPN™ (C) stimulation at a concentration of 10
-8
M. 
*(P<0.05) denotes significance in variation of ligand treatments compared with the 
vehicle control as derived from the Student’s t-test (N≥8). 
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3.3.4 Analysis of reporter gene activation in response to ER activity 
As an extension of the investigations into the impact of natural and synthetic ER 
agonists on receptor mobility, their impact on transcriptional efficiency of the same 
ER subtypes in various combinations was examined after a 24 hour treatment period. 
This study involved an examination of the amount of luciferase activity generated as 
a result of activation of a 3X-ERE-tk-luc construct co-infected with the ER subtypes 
in MDA cells. Parallel control studies run using MDA cells that were not infected 
with ER constructs and infected with or without the 3X-ERE-tk-luc construct did not 
respond to E2 stimulation (data not presented). 
 
3.3.4.1 Homodimeric Response 
As expected incubation of E2 of cells infected with ERα alone resulted in a 
significant increase in the amount of luciferase activity that equated to ~17X greater 
activity than that recorded in DMSO-treated cells. A similar, significant, increase 
was induced by PPT™ treatment while incubation with DPN™ did not result in an 
increase in luciferase (Fig. 3.41A). The figure inset shows the results of the same 
experiment conducted with ERα-YFP infected cells and shows that tagged receptor 
had identical activity to that of ERα-YFP at the ERE (Fig. 3.41A). 
 
Incubation of ERβ infected MDA cells also resulted in a significant increase in 
luciferase activity (~12 fold) although this was slightly less than that in the ERα-
infected cells. Incubation with PPT™ had no impact on luciferase levels compared 
with control but incubation with DPN™ had a significant effect on the transcriptional 
activation of ERβ that emulated the response to E2 (Fig. 3.41B). The same panel of 
ligand treatments were ineffective in generating a transcriptional response and 
increase in luciferase activity in cells that had been infected with ERβ2 (Fig. 3.41C). 
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Figure 3.41 Impact of natural and synthetic agonists with ERs on luciferase 
reporter activity in MDA cells.  
Cells were infected with ERα-YFP (A), ERβ-YFP (B) or ERβ2-YFP (C) and each 
with the 3xERE-Luc reporter. The YFP tag on the constructs had no discernable 
effect on the assay results. The results of cells infected with an untagged ERα (inset) 
were use to assess this. Treatment was with a DMSO vehicle control (black column), 
E2 10
-8
M (red column), PPT™ 10
-8
M (blue column) or DPN™ 10
-8
M (green 
column) for 24hours prior to luciferase production reading. Fold difference is 
expressed relative to the vehicle-treated cell, each bar represents N=3±SEM, is 
comparison of PPT™ and DPN™ treatments to the response observed with E2 
treatment. *** (P<0.001) denotes significance in variation of ligand treatments 
compared with the vehicle control as derived from the Student’s t-test (N≥8). 
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3.3.4.2 Heterodimeric Response 
Further to the FRAP study of ligand impact on the intranuclear dynamics of cells 
expressing two ER subtypes, a series of luciferase assays were performed using cells 
that had been co-infected with two untagged ERs. 
 
In cells infected with ERα and ERβ in equal ratios, following treatment with either 
E2 or DPN™ an approximate 12 fold increase in luciferase activity was noted when 
compared to cells treated with the DMSO vehicle control. Interestingly, no increase 
in luciferase activity occurred in response to PPT™ treatment (Fig. 3.42A). 
 
MDA cells co-expressing equal levels of ERα and ERβ2 appeared to respond equally 
well to both E2 and PPT™ (~15X increase in luciferase activity observed) with no 
significant discrepancy between the luciferase activity in the two treatments. In 
contrast, there was no increase in luciferase activity following incubation with 
DPN™ (Fig. 3.42B). Fig. 3.42C illustrates the luciferase responses recorded 
following co-infection of MDA cells with ERβ and ERβ2. While lower fold 
differences (~7 fold) were determined in comparison to the other co-infection 
experimental studies, significant increases in luciferase activity of approximately 
equal measure were observed following E2 and DPN™ treatment. There was no 
significant response as a result of PPT™ treatment. 
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Figure 3.42 Impact of natural and synthetic agonists with two ERs on luciferase 
reporter activity in MDA cells.  
Cells were infected with combinations of ERα and ERβ (A), ERα and ERβ2 (B) ERβ 
and ERβ2 (C) and each with the 3x ERE-Luc reporter. Treatment was with a DMSO 
vehicle control (black column), E2 10
-8
M (red column), PPT™ 10
-8
M (blue column) 
or DPN™ 10
-8
M (green column) for 24hours prior to luciferase production reading. 
Fold difference is expressed relative to the vehicle-treated cell, each bar represents 
N=3±SEM, a is comparison of PPT™ and DPN™ treatments to the response 
observed with E2 treatment. *** (P<0.001) denotes significance in variation of 
ligand treatments compared with the vehicle control as derived from the Student’s t-
test (N≥8). 
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3.4 Discussion 
The studies described in this chapter have compared and contrasted the impact of 
ligand on the intranuclear mobility of ERα, ERβ and ERβ2 and their ability to 
activate an ERE-dependent reporter gene. Previous studies in our own laboratory 
using transient transfections enjoyed mixed success when we attempted to examine 
dynamic properties, therefore in the current studies it was decided to infect the cells 
using an adenoviral delivery system. This method avoids issues such as auto-
squelching due to overexpression of the protein of interest which may mask true 
behaviour and results. After trial experiments, an optimal final MOI value of 100 per 
1 x 105 cells was deemed appropriate as it resulted in relatively uniform fluorescent 
distribution in ~60-70% of the cell population. 
 
Immunohistochemical studies have revealed cell-specific patterns of expression of 
ERs in reproductive tissue but these do not provide information regarding the 
dynamic nature of the ER response to different ligands (Saunders et al., 2001, 
Saunders et al., 2002, Saunders and Critchley, 2002, Critchley et al., 2002, Saunders 
et al., 2003, Collins et al., 2009). A thorough interrogation of the impact of ligand 
binding on the function of ERs requires investigation of real-time activities to 
address the numerous interactions that take place between the ER and a contingent of 
cofactors and other transcription factors prior to binding at the DNA helix. FRAP 
analysis facilitates the spatio- and temporal probing of responses to ligand 
stimulation through the marriage of time-lapse microscopy combined with 
photobleaching (Axelrod et al., 1976). The photobleaching process is irreversible 
resulting from the transition of the excited molecule from a singlet to an excited 
triplet state. Nuclear dimming and incomplete recovery curves are a direct result of 
photobleaching of the ROI I whereby the fluorescence of this sub-population (ROI I) 
of fluorophores has been irreversibly destroyed or immobilised at the site of 
bleaching (Houtsmuller and Vermeulen, 2001). In the current study all data output 
was normalised to take account of any overall dimming as outlined in section 2.8.7.  
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3.4.1 Differential ER subtype nuclear distribution and expression 
patterns  
The MDA breast adenocarcinoma cell was selected to conduct initial FRAP 
experiments on the basis of low levels of basal endogenous ER expression. This 
milieu afforded the analysis of YFP-tagged ER proteins individually and without the 
influence of endogenous ER. Strip-FRAP was used for all cell contexts and 
treatments. Interchanging strip orientation was used to assess for anisotropic effects 
of ligand treatment. There were no discrepancies in the results acquired between 
horizontal and vertical strips which confirms the stochastic model of unliganded ER 
in the nucleus as described by Reid et al. (Reid et al., 2003). 
 
Infection of the MDA cell line with ERα-YFP recapitulated the endogenous 
expression of nuclear ER with homogenous fluorescent expression throughout the 
nucleus. In contrast, infection of the MDA cells with ERβ-YFP did not result in 
uniform distribution of fluorescence within the nucleus and ‘regions/pockets’ of 
more intense fluorescence were observed. This expression pattern concurs with 
recent observations of the distribution of ERβ in transfected MCF-7 cells 
(Damdimopoulos et al., 2008). Following infection of cells with the ERβ2 splice 
variant, the intranuclear pattern was consistently even and uniform. To date, there 
have only been limited studies published that have examined the effect of ligand 
incubation on mouse ERβ (Picard et al., 2008) and human ERβ (Damdimopoulos et 
al., 2008) in transfected HEK293 and MCF-7 cells respectively with no reported 
studies conducted on the subnuclear mobility of ERβ splice variants. 
 
3.4.2 Changes in intranuclear dynamics are cell context dependent 
In order to give a comprehensive insight into the behaviour of ERα, ERβ and ERβ 
variants in different cell environments, parallel studies were conducted using two 
different cell lines of endometrial origin (Table 3.2) in addition to the MDA cells 
(section 3.4.1). These Ishikawa cells and hTERT cells were used to examine the 
impact of the cellular environment of an adenocarcinoma endometrial cell line 
compared with that of an epithelial cell line derived from cells recovered from a 
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healthy endometrium. In contrast to the MDA breast cancer cells both of these cell 
lines express endogenous ERα and basal levels of ERβ and ERβ2 (Fig. 3.1). 
 
Regardless of the cell line used, ERα-YFP responded in a similar fashion to 
incubation with E2 10-8M. The response was characterised by a striking reduction in 
receptor recovery into the bleached zone during FRAP and was associated with rapid 
adoption of a ‘punctate’ appearance. This redistribution of receptor in response to E2 
treatment may be reflective of the association of ERα homodimers with specific 
nuclear components (Press et al., 1989) such as lysine/arginine rich motifs in nuclear 
lysosomes (Ylikomi et al., 1992, Dauvois et al., 1993). 
 
Reduced mobility (i.e. decreased YMAX) also occurred in response to the ERα 
selective agonist PPT™ and this was more significant in Ishikawa and hTERT cells 
in comparison to MDA cells. It is tempting to speculate that this may be due to a 
more complete repertoire of cofactors and the other transcription factors required for 
formation of the preinitiation complex being present in the endometrial cells. DPN™ 
is reported to have 70-fold higher affinity for ERβ than ERα (Meyers et al., 2001). 
Therefore it was surprising that incubation of MDA cells with DPN™ had a 
significant impact on mobility of ERα-YFP molecules. This effect was not observed 
when using Ishikawa and hTERT cell lines, where no significant impact on the YMAX 
levels of ERα was detected.  
 
The ERβ response to E2 also displayed a trend towards a decrease in the mobility 
and stochastic dynamics of this receptor, albeit to slightly less significance in the 
hTERT cell line. Like ERα, cell nuclei expressing ERβ-YFP also adopted a speckled 
punctate appearance after exposure to E2. Incubation of ERβ-YFP with PPT™ had 
no impact on receptor mobility in all three cell lines. PPT™ has previously been 
described as ERα-selective arising from a selective interaction between the C(4)-
propyl group and pyrazole core of the compound with a confined region of the ERα 
that is smaller than in ERβ (Stauffer et al., 2000) and the data in the current study are 
consistent with this. Exposure to DPN™ resulted in a decrease in mobility of ERβ-
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YFP in all three cell lines, with the most striking impact observed in the Ishikawa 
cell line. While a dominant effect of DPN™ on ERβ activity by the selective binding 
affinity and relative potency in comparison to ERα (70X and 170X greater 
respectively) dictated by its nitrile functionality has been described (Meyers et al., 
2001), DPN™ is not entirely ERβ selective as determined from the results of the 
ERα-YFP study in MDA cells. It is believed that the current study is the first to 
examine the impact of synthetic ligands on the intranuclear dynamics of human ERβ. 
 
ERβ2 is a splice variant isoform of human ERβ, also known as ERβcx (Ogawa et al., 
1998c) that lacks amino acids encoded by the gene for exon 8. Molecular modelling 
of the protein suggests that it lacks an intact binding pocket (Leung et al., 2006). In 
agreement with this, incubation of ERβ2 with a panel of natural and synthetic 
agonists had minimal impact on ERβ2 mobility in all the cell lines. A weak but 
significant response to E2 was detected in the hTERT cells, suggestive of 
heterodimeric associations with endogenous ERs within the hTERT nucleoplasm. A 
summary of the FRAP findings and differences across cell lines is presented in Table 
3.2. 
 
3.4.3 Incubation with anti-oestrogenic ligand influences ER sub-
nuclear mobility 
ICI 182,780 (Fulvestrant™) is a commercially available pure anti-oestrogenic drug 
used in the treatment of tamoxifen-resistant advanced breast cancers (Howell et al., 
2002). ICI 182,780 is reported to act by inducing increased turnover of receptors 
(Dauvois et al., 1993b). In the current study the impact of ICI 182,780 on the 
mobility of all three ER subtypes within the Ishikawa nucleus was examined. 
Following 1 hour incubation with ICI 182,780 reduced levels of fluorescence were 
observed in comparison with DMSO treated control cells. The reduction in 
fluorescence intensity and the formation of well defined speckled accumulations 
within the nuclei may reflect ER turnover due to processing via the ubiquitin 
proteosomal pathway (UPP) (Reid et al., 2003). Comparison of ERα and ERβ 
mobility revealed a more pronounced impact on ERα than ERβ. Although ICI 
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182,780 treatment caused a significant decrease in ERβ mobility, ERβ molecules 
were still dynamic while the impact on ERα resulted in complete immobilisation. 
This effect is in line with a recent report using transfected MCF-7 and HEK293 cells 
(Damdimopoulos et al., 2008). In our study the ERα response was not rescued 
following a 1 hour additional incubation with E2 (data not presented), suggesting a 
dominant effect of ICI 182,780 over oestrogenic compounds. There are two plausible 
explanations for this observation; firstly that since only one ligand can bind at any 
one time to a receptor, ICI 182,780 may be imparting a dominant effect and altering 
the Helix 12/LBD region such that E2 is unable to physically interact with the 
receptor after ICI 182,780 binding or secondly the impact of ICI 182,780 binding 
may alter ER to the extent that it ablates the functional capacity of the receptor and 
no E2-mediated effects can occur.  
 
In addition to differential responses between subtypes, cell specific differences in the 
response of ERβ2 to ICI 182,780 treatment was demonstrated with a clear reduction 
in mobility observed in the hTERT cells (data not shown) and no impact on mobility 
in the Ishikawa cells. It is possible that this is merely the effect of formation of 
heterodimers within these cells as it is known that only one partner of a heterodimer 
is required to be bound to ligand to initiate a response (Tremblay G.B. et al., 1999). 
Conversely, it has also been reported that ICI 182,780 causes disruption of the 
dimerisation process of ERs thus facilitating turnover (Dauvois et al., 1993). The ICI 
182,780-induced change in ERβ2-YFP mobility observed in the hTERT cells is 
surprising as it has been documented that this splice variant lacks an intact ligand 
binding pocket (Leung et al., 2006). The conformation adopted from binding of the 
7α-alkylamide bulky side chain of the ICI 182,780 anti-oestrogenic compound 
appears to transcend the inability of agonist ligands to mediate an effect at ERβ2. 
Previous studies have resolved the conformation formed by the interaction of ICI 
182,780 with ERα by X-ray crystallography analyses and have described an 
interaction that is distinct from that observed following agonist binding where ICI 
182,780 disrupts association between Helix 12 and the rest of the ligand binding 
domain (Pike et al., 2001). The results observed with ERβ2 could negate the 
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controversial observation that Helix 12 is essential for ICI 182,780 efficacy as 
described by Stenoien et al. (Stenoien et al., 2001b) that was questioned in a recent 
study using juxtaposed C termini of ERα and ERβ mutants to address the same issue 
(Damdimopoulos et al., 2008). However, in the latter study ERβ wild type did not 
respond to ICI 182,780 so further investigations using methods such as FRET or 
immuno-precipitation are required. 
 
It has also been suggested that a result of ICI 182,780 binding is impairment of 
nucleocytoplasmic shuttling (Dauvois et al., 1993b). This is in agreement with the 
results observed in the current study where no change in ERβ2-YFP distribution is 
seen following a 1 hour treatment with E2 compared with the weak fluorescent 
distribution observed in the cell nuclei following ICI 182, 780 treatment (data not 
shown), suggesting impaired nucleocytoplasmic shuttling. 
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Table 3.2 Comparison of intranuclear mobility responses to ligand treatment in 
MDA, Ishikawa and hTERT lines 
Treatment Construct  Cell Line  
  MDA Ishikawa hTERT 
 ERα M M M 
DMSO ERβ M M M 
 ERβ2 M M M 
     
 ERα D D D 
E2  ERβ D D D 
 ERβ2 M M D 
     
 ERα - I - 
ICI (+/-E2) ERβ - D - 
 ERβ2 - M - 
     
 ERα D D D 
PPT™ ERβ M M M 
 ERβ2 M M M 
     
 ERα D M M 
DPN™ ERβ D D D 
 ERβ2 M M M 
The changes in the mobility of each protein were scored as: 
Mobile (M, rapid recovery into ROI within ~25 seconds) 
Dynamic (D, with reduced percentage recovery compared with control cells) 
Immobile (I, percentage recovery does not increase post-bleach)  
 
3.4.4 Impact of co-infecting two ER subtypes on intra-nuclear 
dynamics 
The formation of heterodimers between different ER subtypes can alter the nature of 
the gene expression pathways that can be targeted within different cell types. FRET 
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studies conducted within the lab have revealed high percentage FRET efficiency 
after ligand treatment following co-infection of differentially labelled ERs (i.e. with 
YFP and CFP tags respectively) (unpublished data). Further to these observations 
suggesting close proximity (i.e. within 10 Angstroms) between the combinations of 
ERα and ERβ, ERα and ERβ2, and ERβ and ERβ2, FRAP experiments were 
conducted to elucidate the heterodimeric response to the same panel of agonists (E2, 
PPT™ and DPN™) used for testing of individual ERs (putative homodimers). These 
experiments were conducted in the MDA cell line so as to study the heterodimeric 
responses independently of background endogenous receptor levels. Cells were 
infected with equal ratios of one unlabelled receptor construct and one YFP-labelled 
receptor construct whose mobility was tracked and heterodimerisation was assumed 
based on the results of the concurrent FRET investigations (Karen Tuzi, 
unpublished). 
 
FRAP experiments using MDA cells that were co-infected with unlabelled ERα and 
ERβ-YFP and treated with E2 demonstrated a significant decrease in mobility of the 
tagged receptor that matched the level of significance acquired following infection 
with either ERα or ERβ alone. It is possible that this result reflects the action of an 
ERβ-YFP homodimer response but co-infection of the similar ERα and ERβ-YFP 
constructs followed by E2 stimulation gave rise to relatively high FRET efficiency 
values (Karen Tuzi, unpublished data) consistent with formation of heterodimers. 
Treatment with PPT™ did not have a significant impact on the final YMAX level 
reached compared to the DMSO vehicle control. This insignificant impact mirrors 
the result acquired following infection of ERβ alone and may only reflect the ERβ 
homodimeric response. This result could also be interpreted as a heterodimeric 
response whereby the ERβ partner of the dimer infers a dominant negative role on 
the ERα. The response of co-infected MDA cells (ERβ-YFP and ERα) to DPN™ 
was a significant decrease in mobility albeit not to the extent acquired with either of 
the homodimers for ERα or ERβ. The result indicates that DPN™ has a stronger 
effect on a homodimeric partnership over a heterodimeric state. 
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MDA cells co-infected with unlabelled ERα and ERβ2-YFP in equal ratio and 
incubated with ligand were also examined. In this set of experiments the YFP of the 
adenoviral ERβ2 construct was monitored and heterodimerisation between ERα and 
ERβ2 was assumed. Notably, the response of the co-infected cells to E2 treatment 
favours this supposition as a significant decrease in the mobility of ERβ2-YFP was 
observed following 1 hour incubations with E2. This result was markedly different 
from the response of MDA cells infected with ERβ2-YFP alone and mirrored the 
findings (albeit to slightly less extent) of the ERα homodimer. This result suggests a 
role for ERβ2 in a heterodimeric partnership whereby it does not drastically impair 
the functional output of ERα and as such substantiates the fact that only one pair of a 
dimer is required to be ligand-bound to elicit a significant effect (Leung et al., 2006). 
No impact of PPT™ or DPN™ treatments on cells co-infected with ERα and ERβ2-
YFP was observed. This result may reflect a role for ERβ2 as a dominant negative 
inhibitor of ERα with DPN™ treatment. It may also however be indicative of a 
ERβ2-YFP homodimeric response although our FRET studies suggest association of 
ERα and ERβ2 in response to PPT™ (Karen Tuzi, unpublished).  
 
Treatment of MDA cells co-infected with ERβ and ERβ2-YFP with E2 resulted in an 
insignificant impact on the mobility of ERβ2-YFP. FRET efficiency curves have 
demonstrated close proximity values of these two ERs following E2 stimulation. The 
results of the FRAP study suggest a dominant inhibitory role for ERβ2 whereby the 
ERβ response to E2 is completely abrogated or it may depict the results of ERβ2 
homodimeric responses only. FRAP analyses of cells co-infected with ERβ-YFP and 
ERβ2 demonstrated an insignificant response of ERβ-YFP to PPT™. This 
observation echoed the responses of both ERβ and ERβ2 responses to the compound 
when infected individually and is consistent with PPT™ acting as a selective agonist 
for ERα. In contrast, there was a significant DPN™-mediated impact on mobility 
determined in cells co-infected with ERβ-YFP and ERβ2, and although not to the 
extent of that determined upon infection with ERβ alone, it was greater that that 
following infection with ERβ2 alone. This result implies an attenuated ERβ response 
to DPN™ in the presence of the splice variant ERβ2 in this cellular context.  
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3.4.5 The ability of natural and synthetic ligands to transactivate ER 
subtypes alone and in combination at an Oestrogen Response 
Element  
As an extension of the FRAP study on the intranuclear dynamics of ER subtypes, the 
same panel of natural and synthetic agonists were used to assess the transcriptional 
activity of the ligand-activated receptors using a 3xERE promoter sequence fused to 
the luciferase gene. The aim of this study was to establish if any correlation exists 
between the mobility patterns and the functional integrity of the ER subtypes under 
investigation and it was conducted using MDA cells.  
 
There was no significant difference between the luciferase output in response to E2 
and PPT™ in MDA cells infected with ERα-YFP. Both compounds induced a 
significant ~15X increase in the luciferase activity in comparison to a DMSO control 
vehicle. There was no significant activity induced at the ERE by ERα following 
DPN™ incubation. To validate the FRAP experiments using YFP labelled ER 
subtypes, concomitant luciferase assays were conducted using unlabelled ERs. There 
were no discrepancies found between assay outputs using untagged versus YFP 
tagged receptors. A significant impact on the mobility of ERα-YFP was established 
in response to each of the three agonists in the FRAP studies of MDA cells. This 
effect on mobility is mirrored by the transcriptional activity of ERα in response to E2 
and PPT™ but not with DPN™ treatment.  
 
While E2 and DPN™ treatments yielded a similar effect by increasing the luciferase 
activity driven from the ERE in ERβ-YFP infected MDA cells, there was no effect 
observed following PPT™ treatment, confirming that PPT™ functions as a potent 
agonist for ERα but not for ERβ. The increase in E2-mediated ERβ activity was 
noted as being lower than that of the E2-mediated ERα response and this attenuated 
transcriptional activity of ERβ has been previously described (Tremblay et al., 1997, 
Pettersson et al., 1997). Cells infected with ERβ2-YFP alone and subjected to E2, 
PPT™ and DPN™ treatments did not generate any activity at the ERE. The results 
of the luciferase activity response assays to homodimers confirms the selective 
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nature of PPT™ and DPN™ and their ability to potentiate transcription at an ERE 
after binding to ERα and ERβ respectively. While the tracking of ER mobility within 
the nucleoplasm tends to be indicative of a final transcriptional output, the two 
measures are not inherently linked and contradictory results have been found (e.g. 
ERα + DPN™). 
 
The formation of heterodimers between different ER subtypes could putatively 
expand the regulatory potential of the receptors. The activity of heterodimers was 
explored with a series of experiments involving co-infection of two receptors in 
equal ratio in the MDA cell line. FRET studies conducted within the lab have 
highlighted close proximal formations between each of the combinations tested in 
response to E2, PPT™ and DPN™ treatments (Karen Tuzi, unpublished data). 
Previous studies have identified that the heterodimer is the preferential state of ERβ 
when in the presence of ERα (Cowley et al., 1997). The ~12X increase in luciferase 
activity in response to E2 following co-infection with ERα and ERβ reflects an 
altered response to that of either receptor infected individually. The combination of 
ERα and ERβ gives rise to a slight increase over the response observed with the ERβ 
homodimer while at the same time the impact of ERβ in a conformation with ERα 
serves to weaken the transcriptional activity of ERα in comparison to its 
homodimeric state. Equal decreases on the intranuclear dynamics of each of the three 
combinations was derived from the FRAP study. This highlights a caveat in FRAP 
interpretation whereby the results cannot be presented in isolation as they do not 
necessarily represent a complete picture on the nature of activity of the protein being 
studied. 
 
PPT™ had no impact on the transcriptional output of the luciferase assay system in 
cells co-expressing ERα and ERβ. The lack of activity observed following PPT™ 
treatment in the presence of ERβ homodimers was not rescued in the partnership 
with ERα suggesting that ERβ imposed a dominant negative influence on ERα in this 
context. In FRAP experiments, an impact on mobility was only observed in ERα 
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infected cells in response to PPT™. Taken together, these results highlight the 
selective nature of PPT™ for ERα. 
 
DPN™ was primarily ERβ selective according to the results of the luciferase assays 
in accordance with expectations based on previously published papers (Meyers et al., 
2001, Sierens et al., 2004). The increase in luciferase activity was slightly greater in 
the heterodimeric formation between ERβ and ERα than with ERβ alone and this 
may underlie the apparent favoured state of ERβ to be in a heterodimeric association 
over a homodimeric pairing. There is a negligible effect on transcriptional output in 
response to DPN™ in ERα infected cells. The 12X increase in luciferase activity in 
the heterodimeric conformation substantiates the perception that only one partner of 
a dimer is required to be bound to ligand to facilitate active transcription (Tremblay 
G.B. et al., 1999).   
 
The formation of ERα–ERβ2 heterodimers is assumed based on the differential 
responses to luciferase activity generated in comparison to the independent 
homodimer formations. For example, E2 elicited a ~15X increase in activity of the 
luciferase gene in MDA cells co-infected with ERα and ERβ2 in equal measure. This 
response conveys an attenuated ERα impact in comparison to the ERα homodimer 
that may be an influence caused by ERβ2. These results mirror the effect observed 
with the FRAP analyses whereby the level of significance on the decrease in mobility 
was lower in the heterodimer in comparison to the ERα homodimer. There were no 
changes brought about in intranuclear dynamics or transcriptional activity following 
incubation of any of the agonists tested on ERβ2. Furthermore, the response of ERα 
to PPT™ was maintained in the presence of ERβ2 in the luciferase assay. While a 
significant decrease on the mobility of ERα was found in response to PPT™ in the 
FRAP study, co-expression of unlabelled ERα with ERβ2-YFP and incubation with 
PPT™ had no impact on mobility of the latter. Cumulatively, the results of the co-
infection studies may signify that heterodimerisation does not occur between ERα 
and ERβ2 in response to PPT™. The weak luciferase emission acquired following 
DPN™ incubation in ERα infected MDA cells was not replicated following co-
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infection with ERβ2. These results are in line with those of the FRAP experiments 
whereby DPN™ treatment yielded a significant effect in slowing down the mobility 
of ERα-YFP infected cells. A decrease, albeit to a lesser degree of significance was 
found following co-infection of ERα with ERβ2-YFP. Taken together, these results 
demonstrate active heterodimeric association between ERα and ERβ2 in response to 
DPN™ because of 1) the difference on the impact on mobility observed when 
tracking ERβ2 alone (no effect on mobility) and when co-infected with unlabelled 
ERα and 2) the differential transcriptional output response noted between ERα in 
isolation and when co-infected with ERβ2. As ERβ2 is not thought to bind DPN™ 
this suggests the ligand has induced a change in the conformation of ERα favouring 
binding to ERβ2. 
 
Incubation of E2 with ERβ-ERβ2 resulted in transcriptional activity that was less 
than that of the ERβ alone. This finding indicates that heterodimeric associations 
between ERβ and ERβ2 many occur although no significant effect was observed in 
relation to intranuclear dynamics. In concurrence with the FRAP study PPT™ had no 
effect on the transcriptional activity of ERβ or ERβ2 alone or in combination at the 
ERE but an attenuating effect of ERβ2 on the mobility and transcriptional response 
of ERβ was observed in response to DPN™. These results are suggestive of a 
function for ERβ2 in antagonising the response to ligand-bound ERβ. 
 
3.5 Conclusions 
The results of this study have identified differential responses of ER subtypes to 
natural and synthetic compounds that behave as agonists and antagonists of the ER. 
Characteristic ER subtype responses have also been found to be dependent on 
cellular context. These assessments are based upon investigation of the mobility 
patterns observed within the nucleus and the functional capacity as defined by 
activation of a cognate response element. It was found that the dynamic patterns 
largely translated with the final transcriptional output and that these separate 
functions may be linked. The impact of ligands on receptor heterodimers was also 
examined and revealed further complexity and variation in responses. 
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Evidence presented in this chapter indicated a putative role for the truncated splice 
variant ERβ2 as a partner in an active heterodimer. A number of clinical studies 
(Peng et al., 2003, Davies et al., 2004, Shaaban et al., 2008) have suggested the use 
of truncated ER isoforms as potential diagnostic markers. The next chapter of this 
thesis therefore focuses on the intranuclear response of the particular splice variant 
ERβ5 to ligand. Unlike ERβ2, ERβ5 is completely devoid of the LBD and the 
following study investigates the role of the ERβ5 isoform in the endometrium in 
mediating a cellular response.  






Role of ERβ5 in the human endometrium 
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4 Role of ERβ5 in the human endometrium 
4.1 Introduction 
ERα has long been employed as the gold standard prognostic tool when assigning 
breast cancer cases for endocrine therapy (Pertschuk and Axiotis, 1999). Despite this, 
it has been shown that up to 40% of ERα-positive breast neoplasms are non-
responsive to anti-oestrogen therapy (Locker, 1998). Investigations into expression 
of ERs in various reproductive pathologies have revealed the co-expression of ERα 
and ERβ mRNA and protein (reviewed in Saunders and Critchley, 2002). Specific 
examination of the expression patterns of the truncated human ERβ splice variants 
has detected their expression in several cell lines including the MDA-MB435 breast 
cancer line (Moore et al., 1998), COS-1 cells (Inoue et al., 2000) and Ishikawa cells 
(Scobie et al., 2002). 
 
The two human receptor isoforms, ERβ2 and ERβ5, diverge from ERβ at amino acid 
469 (Moore et al., 1998). ERβ2 has a distinct C-terminal domain in place of the 
amino acids encoded by exon 8 in the wild type, full-length human ERβ protein 
comprising of a unique 26 amino acid sequence encoded by a different exon (Zhao et 
al., 2008). ERβ5 completely lacks a ligand-binding domain and the C-terminus is 
defined by the intron code found between exons seven and eight in full length human 
ERβ (Peng et al., 2003; Poola et al., 2005a).  
 
Several clinical studies examining the role of human ERβ splice variants as putative 
diagnostic candidates have alluded to the importance of investigating expression of 
the different isoforms (Peng et al., 2003). A study of neoplastic breast tissue 
demonstrated higher expression of ERβ2 and ERβ5 mRNAs compared with ERβ1 
mRNA levels and with normal breast tissue levels (Leygue et al., 1999b). Davies et 
al. reported significant association of ERβ2 and ERβ5 expression with relapse free 
survival in a study of post-menopausal breast cancer patients undergoing adjuvant 
therapy, with a particular correlation between ERβ2 and overall survival (OS) 
(Davies et al., 2004). Another study reported that expression of nuclear ERβ2 was 
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associated with better OS and disease free survival but conversely cytoplasmic ERβ2 
was related to poor prognosis. This study also demonstrated that nuclear ERβ5 
expression was associated with improved survival (Shaaban et al., 2008). 
 
Cowley et al. reported that co-expression of ERα and ERβ in a 1:1 or 1:2 ratio 
resulted in preferential heterodimerisation between the two subtypes (Cowley et al., 
1997). Heterodimerisation between ERα and each of the splice variant isoforms has 
also been demonstrated as well as heterodimer formation between the ERβ isoforms 
themselves (Leung et al., 2006). Preferential binding of ERβ2 with ERα rather than 
ERβ has been reported (Ogawa et al., 1998c) and Hall and McDonnell described an 
AF-1 mediated repressor function of ERβ at subsaturating hormone levels that can 
compete at the ERE to block ERα function in cells where the receptors are co-
expressed (Hall and McDonnell, 1999). 
 
As ERβ2 and ERβ5 are reported to have an attenuated DNA-binding capacity and an 
inability to recruit coactivators, they may not initiate transcription in a ligand-
dependent manner (Ogawa et al., 1998b, Moore et al., 1998, Peng et al., 2003). 
Irrespective of this, studies have demonstrated the ability of ERα variants; ERα∆E3 
and ERα∆E5 (Bollig and Miksicek, 2000) and the ERβ splice variants; ERβ2 and 
ERβ5 (Peng et al., 2003) to repress ERE-mediated transcription of ERα. Conversely, 
a role for ERα in the regulation of ERβ was demonstrated through the inhibition of 
E2-independent transactivation of ERβ5 in vitro (Poola et al., 2005a). Cumulatively, 
the studies to date suggest that co-expression of ERβ splice variants with ERα can 
alter ERα-dependent gene expression. These observations may indicate differential 
modulation of E2-dependent and independent action based on ER expression status 
and may be of pharmacological relevance in designing novel treatments based on 
different ratios of receptors. 
4.1.1 Aims of the chapter 
In the previous chapter, the intranuclear dynamics of full length ERs and the 
truncated splice variant ERβ2 in response to ligand stimulation were examined. 
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ERβ2 demonstrated a putative role as a partner in an active heterodimeric state with 
ERα. A role for ERβ splice variants as diagnostic tools has been postulated and 
therefore, the intranuclear response and functionality of ERβ5 upon ligand 
stimulation is examined in this chapter. 
 
The overall aim of this chapter was to determine whether the ERβ splice variant 
ERβ5 might have an impact on oestrogen responsiveness in the normal human 
endometrium. Expression of ERβ5 was examined using immunohistochemistry. The 
regulation of ERβ5 through the examination of the intranuclear dynamics of ERβ5 in 
response to known ER effector compounds both as a single entity (homodimers) and 
in combination with ERα or ERβ (heterodimers) was studied. The impact of ERβ5 on 
ERE-promoter element was examined in the presence and absence of the full length 
ERα subtype. 
4.2 Materials and Methods 
4.2.1 Taqman® qRT-PCR  
RNA was extracted from lysed cells using a Qiashredder™ spin column for cell 
homogenisation (section 2.5.1) and quantified using the Nanodrop® ND 1000 
(Labtech International, East Crawley, UK). Complementary DNA was prepared 
using random hexamers (section 2.5.4.1) and was used for the Taqman reaction 
protocol outlined in section 2.5.4.3. Taqman analysis of mRNA using the Roche 
Universal Probe Library™ was conducted in triplicate for ERα, ERβ and ERβ5. Data 
output from the detection system was quantified in accordance with the 2-∆∆Ct 
algorithm (section 2.5.4.4). Results are expressed as means and standard errors and 
statistical analysis was conducted using a Student’s t-test.  
4.2.2 Collection of endometrial tissue 
As detailed in Chapter 2, section 2.2.1, human endometrial tissue was acquired from 
different phases of the menstrual cycle following hysterectomy, hysteroscopy or 
laparoscopic sterilisation performed at the Royal Infirmary, Edinburgh, UK. All 
patients gave written informed consent following discussion with research nurses. 
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Histological staging was performed by an expert histologist as previously reported 
(Critchley et al., 2001, Critchley et al., 2002).  
4.2.3 Immunohistochemistry 
Immunohistochemistry was performed using thin sections of paraffin embedded 
endometrial tissue to identify the expression patterns of the proteins of interest as 
outlined in section 2.4.1 
4.2.3.1 Non Fluorescent Immunohistochemistry  
In brief, tissue was processed and sections mounted on glass slides as described in 
section 2.4.1.1. The sections were then dewaxed, rehydrated (2.4.1.2) and subjected 
to antigen retrieval by means of pressure cooking in citrate buffer (2.4.2). Three 
blocking steps were employed to prevent endogenous peroxidase activity, non-
specific binding of the secondary antibody and the formation of avidin-peroxidase 
complexes binding directly to the tissue where endogenous biotin is expressed as 
outlined in 2.4.3.1, 2.4.3.2 and 2.4.3.3 respectively. A mouse ERβ5 monoclonal 
antibody (Wong et al., 2005, Collins et al., 2009) was incubated with the tissue 
overnight at 4°C (Table 2.1). Bound antibody was detected with a goat anti-mouse 
biotinylated secondary antibody (Table 2.2) used and the signal was localised using 
the chromogenic substance DAB (K3468; DAKO) diluted in its substrate. The 
corresponding negative control sections were incubated with blocking serum only to 
enable confirmation of antibody specificity. 
4.2.3.2 Immunofluorescence 
Dual fluorescent immunohistochemistry was employed in order to co-localise two 
ERs simultaneously (2.4.7).  The primary and secondary antibodies used are listed in 
Table 4.1. 
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Table 4.1 Summary of primary and secondary antibodies and the fluorescent labels 













ERβ5 1:40 GAM 
(Fab)-b 
Alexa 488 ERα 1:20 GAM-p Tyr cy 3 
ERβ5 1:40 GAM 
(Fab)-b 
Alexa 488 ERβ 1:20 GAM-p Tyr cy 3 
ERβ5 1:40 GAM 
(Fab)-b 
Alexa 488 ERβ2 1:200 GAM-p Tyr cy 3 
Key: 
GAM (Fab)-b: Goat anti-mouse Fab fragment biotinylated 
Alexa 488: Alexafluor 488 (green) 
GAM-p: Goat anti-mouse peroxidase 
Tyr cy 3: Tyramide Cy3 (red) 
4.2.4 Western Immunoblotting 
Western blotting was performed on nuclear protein extracts (section 2.6.2) from 
Ishikawa cells that had been infected with adenoviral constructs expressing untagged 
ERβ5. The infected cells were lysed and separated into cytoplasmic and nuclear 
fractions and quantified in accordance with the Biorad DC Protein Assay (section 
2.6.3). The nuclear protein extracts were separated on acrylamide gels (section 
2.7.2), electro-transferred to PVDF membrane (section 2.7.3) and scanned for 
detection using the LI-COR™ infrared detection system (2.7.5). Membranes were 
incubated with the anti-ERβ5 monoclonal antibody for verification of protein size. 
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Table 4.2 Primary antibodies used for Western blotting 
Antigen Host Species  Dilution  Source 
ERβ5 Mouse 1:100 In-house1  
β-tubulin Rabbit 1:600 Santa Cruz2 
1 In collaboration with Prof. N. Groome, Oxford Brookes University, Oxford, UK 
2Santa Cruz Biotechnology, CA, USA 
4.2.5 Cell treatments 
To establish the impact of ligands on functional activity of ERβ5, cells were 
incubated with either E2 or one of the selective agonists PPT™ and DPN™ at a final 
concentration of 10-8M. The impact of antagonist treatment was investigated by 
incubating cells with ICI 182,780 at a final concentration of 10-8M. Control 
treatments using the DMSO vehicle at 10-8M were conducted and used to analyse the 
overriding effects of agonist and antagonist treatment. Ligand treatment was 
conducted 1 hour prior to live-cell FRAP analyses and 24 hours in advance of cell 
harvesting for luciferase assays. 
4.2.6 FRAP 
FRAP was conducted on a LSM 510 confocal inverted light scanning microscope 
(section 2.8.6). In brief, live cells were maintained in PBS buffered with 10mM 
HEPES in an enclosed chamber heated to 37°C (section 2.8.2). Cells expressing YFP 
were selected for bleaching on the basis of uniform distribution of levels of 
fluorescence. Three ROIs were of equal dimension were chosen (section 2.8.5). Two 
prebleach images were captured at 3 second intervals followed by photobleaching 
owing to a series of focused pulsed iterations using the Argon 12 laser (488 and 
514nm) laser at maximal power. Eight subsequent images were taken to establish 
recovery patterns using an attenuated laser (514nm set between 1-5% power) (section 
2.8.6). Data collation and quantitation was conducted and subject to correction, 
normalisation and statistical evaluation as outlined (section 2.8.7). 
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4.2.7 Luciferase Gene Reporter Assay 
Luciferase reporter assay were carried out as previously described (section 2.9.1). 
Luciferase output was measured as relative light units using the FLUOstar OPTIMA 
luminometer (BMG Labtech) and normalised against total protein content from 
samples of the same experiment and conditions using the Biorad DC Protein Assay 
(section 2.6.3). 
4.3 Results 
4.3.1 ERβ5 expression pattern in the endometrium 
4.3.1.1 ER mRNA expression across the menstrual cycle 
Analysis of expression of mRNA encoding different ER subtypes during the 
proliferative and secretory phases of the menstrual cycle using quantitative RT-PCR 
revealed very high levels of ERα mRNA in the proliferative endometrium that 
tapered off with progression into the secretory stages of the cycle (Fig. 4.1 A). In 
agreement with previous publications (Critchley et al., 2002), the endogenous 
mRNA concentrations of ERβ and its splice variants ERβ2 and ERβ5 were much 
lower than the levels of expression detected for ERα. However, there were changes 
in the levels of expression observed where the pattern of ERβ expression opposed 
that of ERα with increasing levels determined with progression of the menstrual 
cycle (Fig. 4.1 B). This pattern of expression was mimicked by ERβ5 (Fig. 4.1 D). 
Although ERβ2 mRNA was greatest during the early secretory stage of the cycle, 
this observation may be sample dependent and is representative only of an N=3 (Fig. 
4.1.C). 
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Figure 4.1 Expression of mRNAs encoding ER subtypes ERα and ERβ and the 
splice variants ERβ2 and ERβ5 in normal endometrium during the proliferative 
and secretory (luteal) phases of the menstrual cycle. 
Decreasing levels of ERα mRNA were detected with progression of the cycle (A) and 
sustained low basal levels of ERβ (B), ERβ2 (C) and ERβ5 (D) were found. The fold 
differences expressed are relative to the levels of expression determined from a 
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4.3.1.2 Immunolocalisation of Endometrial ERβ5 in endometrium 
across the cycle 
On endometrial tissue sections, the specificity of the antibodies used against ERβ, 
ERβ2 and ERβ5 was validated (Fig. 4.2 upper panels). Nuclear staining with the 
monoclonal antibodies against ERβ, ERβ2 and ERβ5 was abolished by preabsorbing 
with the concomitant recombinant antigen protein (Fig. 4.2 lower panels). 
 
 
Figure 4.2 Validation of anti-ERβ antibodies used for histological evaluation of 
human endometrial tissue.  
Immunodetection of ERβ, ERβ2 and ERβ5 in the endometrium (upper panel) were 
compared with images acquired of controls preabsorbed in the associated antigen 
peptide (lower panel), using the same tissue sample. 
 
Using the specific monoclonal antibody ERβ5 was immunolocalised to cell nuclei 
throughout the endometrium at all phases of the menstrual cycle investigated 
(proliferative, early-, mid- and late-secretory) (Fig. 4.3). Intense ERβ5 
immunoexpression was detected in the cell nuclei of stromal cells and epithelial cells 
lining the glands (Fig. 4.4) as well as endothelial cells lining the vasculature at all 
stages of the cycle (Fig. 4.3 and 4.4 arrows). 
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Figure 4.3 ERβ5 immunoexpression in the endometrium.  
Immunodetection of ERβ5 in the functionalis of human endometrium during the 
proliferative (A), early secretory (B), mid-secretory (C) and late secretory (D) 
phases of the menstrual cycle. ERβ5 was detected in nuclei of the glandular 
epithelial (g) and stromal (s) cells at all phases of the cycle. ERβ5 staining was 
detected in the vascular muscle of the spiral arteries (a) and the vascular 
endothelium (arrows) in the mid- and late secretory phases. Insets are negative 
controls. Magnification X20; scale bar, 100µm.  
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Figure 4.4 High power view of ERβ5 expression in human endometrium.  
Immunolocalisation of ERβ5 in the nuclei of glandular epithelial (g), stromal (s) and 
vascular epithelial (arrows) during the proliferative (A), early secretory (B), mid-
secretory (C) and late secretory (D) phases of the menstrual cycle. In panel D the 
vascular compartment is outlined and arrows are pointing to immunopositive 
endothelial cells. Magnification X40; scale bar, 100µm. 
 
4.3.1.3 Co-localisation of ERβ5 and ERα in endometrial tissue 
Using double fluorescent immunohistochemistry ERβ5 immunopositive nuclei 
(green) were found to co-localise with ERα positive nuclei (red) in the proliferative 
and early-mid secretory phases of the cycle in the endometrium (Fig. 4.5 merged 
panel; yellow nuclei). The weak immunopositive staining detected by the anti-ERα 
antibody at the later stages of the secretory stage was overwhelmed by intense ERβ5 
staining in cell nuclei of the stromal and epithelial compartments so that most nuclei 
appeared green (Fig. 4.5). 




Figure 4.5 Co-expression of ERβ5 (green) and ERα (red) in normal endometrial 
tissue from stages across the menstrual cycle. 
The merged image depicts co-localisation of the two ERs (yellow) in both the stromal 
(s) and epithelial cells of the glandular (g) compartments in the proliferative and 
early secretory phases. ERβ5 expression predominates in the merged image of the 
late secretory phase endometrium. Scale bar, 20µm. 
 
4.3.1.4 Co-localisation of ERβ5 and ERβ 
Dual immunofluorescent staining for ERβ5 (green) and ERβ (red) revealed co-
expression of the proteins in nuclei of stromal and epithelial cell types throughout the 
menstrual cycle. Weaker ERβ protein immunoexpression at the late secretory phase 
resulted in dominant intense ERβ5 staining in the endothelial cells lining the blood 
vessels (arrows) and the epithelial nuclei of the glandular regions (Fig. 4.6). 
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Figure 4.6 Co-expression of ERβ1 (red) and ERβ5 (green) in normal endometrial 
tissue from stages across the menstrual cycle.  
The merged image depicts co-localisation of the two ERs (yellow) in both the stromal 
(s) and epithelial cells of the glandular (g) compartments in the proliferative and 
early secretory phases. ERβ5 expression is dominant in both the epithelial cells of 
the glands (g) and the endothelial cells surrounding the blood vessels (arrows) in the 
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4.3.1.5 Co-localisation of ERβ5 and ERβ2 
Immunofluorescent co-staining for ERβ5 (green) and ERβ2 (red) was detected across 




Figure 4.7 Co-expression of ERβ2 (red) and ERβ5 (green) in normal endometrial 
tissue from stages across the menstrual cycle. 
The merged image depicts co-localisation of the two ERs (yellow) in both the stromal 
(s) and epithelial cells of the glandular (g) compartments across the proliferative 
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4.3.2 Western analysis of ERβ5 in Ishikawa cells 
The expression of endogenous ERβ5 in Ishikawa cells was examined using nuclear 
protein extracts from untreated Ishikawa cells and compared with nuclear protein 
from Ishikawa cells that had been infected with untagged ERβ5 (MOI 50) using 
Western immunoblotting. ERβ5 protein of the expected molecular weight of 53kDa 
was detected in all Ishikawa cells (Fig. 4.8). 
 
 
Figure 4.8 Determination of ERβ5 protein levels in the Ishikawa cell line.  
This is a representative Western blot following nuclear protein extraction and 
probing for ERβ5 endogenous protein expression in the Ishikawa cells (Lane 1, 
Control, C) and in Ishikawa cells infected with an ERβ5 adenoviral construct (Lane 
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4.3.3 Intranuclear dynamics of ERβ5 protein 
4.3.3.1 ERβ5 response to incubation with agonists in Ishikawa cells 
Infection of Ishikawa cells with ERβ5-YFP resulted in uniform nuclear distribution 
of fluorescence. The application of a DMSO vehicle control for 1 hour did not affect 
this state. There were no changes in morphological appearance of the nuclei in 
response to any treatments (E2, PPT™, DPN™; Fig 4.9). 
 
 
Figure 4.9 Qualitative FRAP assessment of ERβ5 infected Ishikawa cells. 




M or DPN 10
-
8
M for 60 minutes. 
 
In agreement with the observational analysis of ERβ5-YFP infected Ishikawa cells, 
there were no significant ligand-mediated influences by any treatment (E2, PPT™ 
and DPN™) revealed by analysis of the percentage recovery values (Fig. 4.10). For 
PPT™ and DPN™ treatments, the recovery patterns mimicked that of the DMSO 
vehicle control response. E2 incubation induced a trend towards reduced percentage 
recovery compared with the DMSO-treated control cells (Fig. 4.10A). 
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Figure 4.10 Quantitative analysis of intra-nuclear kinetics of ERβ5-infected 
Ishikawa cells.  
Graphical depiction of impact of ligand treatment on the recovery rates of ERβ5-
YFP fluorophores over time back into the bleached zone. This recovery is denoted by 
the point at which the YMAX is achieved and a plateau is reached on the graph. 
Recovery rates of ERβ5-YFP infected Ishikawa cells are presented in response to E2 
(A), PPT (B) and DPN (C) stimulation at a concentration of 10
-8
M. Significance of 
results was examined using the Student’s t-test (N≥8).  
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4.3.3.2 ERβ5 Response to agonists in hTERT cells 
The results acquired from the intranuclear dynamics investigation of ERβ5-YFP in 
the hTERT cell line mirrored those of the Ishikawa analysis (section 4.3.5.1). The 
homogenous distribution of ERβ5-YFP dispersed throughout the nucleus remained 
unchanged following incubation with either the DMSO vehicle control or any of the 
treatments E2, PPT™ and DPN™ for 1 hour (Fig. 4.11). Longer treatment times 
with E2 (up to 3 hours) were also tested with no effect on the YFP distribution 
pattern (data not presented). The rapid recovery of the bleached zone (red box) is 
observed within 6 seconds of photobleaching following each of the treatments. 
 
 
Figure 4.11 Qualitative FRAP assessment of ERβ5 infected hTERT cells.  
Cells were treated with a DMSO vehicle control, E2 10-8M, PPT 10-8M or DPN 10-
8M for 60 minutes.  
 
Analysis of the statistical parameters of FRAP compound the observational data 
where no change in recovery response (YMAX) following incubation with PPT™ or 
DPN™ is discernable in comparison to the values obtained from the DMSO vehicle 
control treatment (Fig. 4.12B and C). However, a slight trend towards a decrease in 
mobility of ERβ5-YFP infected cells treated with E2 was observed (Fig. 4.12A). 
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Figure 4.12 Quantitative analysis of intra-nuclear kinetics of ERβ5-infected 
hTERT cells.  
Graphical depiction of impact of ligand treatment on the recovery rates of ERβ5 
fluorophores over time back into the bleached zone. This recovery is denoted by the 
point at which the YMAX is achieved and a plateau is reached on the graph. Recovery 
rates of ERβ5-infected hTERT cells are presented in response to E2 (A), PPT (B) and 
DPN (C) stimulation at a concentration of 10
-8
M. Recovery rates of ERα-infected 
Ishikawa cells are presented in response to E2 (A), PPT (B) and DPN (C) 
stimulation at a concentration of 10
-8
M. Significance of results was examined using 
the Student’s t-test (N≥8).  
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4.3.3.3 ERβ5 Response to antagonist in Ishikawa cells 
Treatment of Ishikawa cells expressing ERβ5-YFP with ICI 182,780 resulted in 
redistributed fluorescence in the nucleus and a punctate appearance similar to that 
brought about (ICI 182,780 induced) in ERα-YFP infected Ishikawa cells (section 
3.3.2.2.1). After photobleaching, levels of fluorescence in the bleached zone did not 




Figure 4.13 Qualitative FRAP assessment of ERβ5 infected Ishikawa cells. 
Cells were treated with a DMSO vehicle control, E2 10
-8




ICI 182,780 treatment yielded a significant decrease in the mobility of ERβ5-YFP in 
Ishikawa cells that decreased YMAX from ~65% to ~25% (Fig. 4.14).  
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Figure 4.14 Quantitative analysis of intra-nuclear kinetics of ERβ5-infected 
Ishikawa cells.  
Graphical depiction of impact of ligand treatment on the recovery rates of ERβ5 
fluorophores over time back into the bleached zone. This recovery is denoted by the 
point at which the YMAX is achieved and a plateau is reached on the graph. Recovery 
rates of ERβ5-infected Ishikawa cells are presented in response to E2 (red) and ICI 
182,780 (grey) stimulation at a concentration of 10
-8
M. Significance of results was 
examined using the Student’s t-test (N≥8).  
 
4.3.3.4 ERβ5 Response to antagonist in hTERT cells 
The spatiotemporal effect of ICI 182,780 incubation on nuclear mobility of ERβ5-
YFP infected into hTERT cells paralleled the results acquired following the same 
experimental setup in Ishikawa adenocarcinoma cells (section 4.3.3.3). A clear 
change in the nuclear patterning distribution of ERβ5 was seen alongside very poor 
recovery rates post-bleaching of the ROI I and this effect was sustained at up to 72 
seconds post-bleach (red box) (Fig.4.15). The interaction of ICI 182,780 with ERβ5-
YFP molecules in hTERT nuclei resulted in a striking and significant impact on the 
YMAX of the ERβ5 subtype (Fig. 4.16). 
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Figure 4.15 Qualitative FRAP assessment of ERβ5 infected hTERT cells.  
Cells were treated with a DMSO vehicle control, E2 10-8M and ICI 182,780 10-8M. 
Note the ICI response was sustained at longer time periods examined i.e. 72 seconds 
post-bleach. 
 
Figure 4.16 Quantitative analysis of intra-nuclear kinetics of ERβ5-infected 
hTERT cells.  
Graphical depiction of impact of ligand treatment on the recovery rates of ERβ5 
fluorophores over time back into the bleached zone. This recovery is denoted by the 
point at which the YMAX is achieved and a plateau is reached on the graph. Recovery 
rates of ERβ5-infected hTERT cells are presented in response to E2 (red) and ICI 
182,780 (grey) stimulation at a concentration of 10
-8
M. Significance of results was 
examined using the Student’s t-test (N≥8).  
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4.3.4 Intranuclear dynamics of ERβ5 in combination with ERα 
4.3.4.1 E2-mediated response on ERβ5-YFP and ERα in Ishikawa cells 
Ishikawa cells express endogenous ERα (Fig. 4.10) but results obtained following 
infection of cells with ERβ5-YFP did not reveal a significant impact on receptor 
mobility although there was a trend towards reduced mobility with E2. Therefore 
ERα expression in the cells was increased by infection of untagged receptor and the 
impact of E2 treatment on ERβ5-YFP was re-examined. Although no obvious impact 
of the E2 treatment on redistribution of the receptor was discernable from the 
phenotypic analysis of the cell nuclei following bleaching (Fig. 4.17). 
 
 
Figure 4.17 Qualitative FRAP assessment of ERβ5-YFP and ERα infected 
Ishikawa cells. 
Cells infected with ERβ5-YFP and untagged ERα were treated with a DMSO vehicle 
control and E2 10
-8
M for 60 minutes. 
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Statistical analysis of E2 treated Ishikawa cells co-infected with ERβ5-YFP and ERα 
revealed a significant impact of the treatment on the percentage recovery of the 
ERβ5-YFP molecule back into the bleached region upon photobleaching with 
reduced YMAX (Fig. 4.18). 
 
 
Figure 4.18 Quantitative analysis of intra-nuclear kinetics of ERβ5-YFP and 
untagged ERα infected Ishikawa cells.  
Graphical depiction of impact of ligand treatment on the recovery rates of ERβ5 
fluorophores over time back into the bleached zone. This recovery is denoted by the 
point at which the YMAX is achieved and a plateau is reached on the graph. Recovery 
rates of ERβ5-YFP are presented in response to E2 stimulation at a concentration of 
10
-8
M. Significance of results was determined using the Student’s t-test (N≥8).  
 
4.3.4.2 E2-mediated response of ERβ5-YFP and ERα in hTERT cells 
An identical experiment to that described in section 4.3.4.1 was carried out in 
hTERT cells. As in Ishikawa cells, there was no obvious impact of E2 incubation on 
ERβ5-YFP on the confocal microscope (Fig. 4.19). However, statistical analysis of 
E2-stimulated co-infected hTERT cells revealed a significant impact on the mobility 
of the ERβ5-YFP with a dramatic reduction in YMAX (Fig. 4.20). 
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Figure 4.19  Qualitative FRAP assessment of ERβ5-YFP and ERα infected 
hTERT cells. 
Cells were treated with a DMSO vehicle control, E2 10
-8




Figure 4.20 Quantitative analysis of intra-nuclear kinetics of ERβ5-YFP and 
untagged ERα infected hTERT cells.  
Graphical depiction of impact of ligand treatment on the recovery rates of ERβ5 
fluorophores over time back into the bleached zone. This recovery is denoted by the 
point at which the YMAX is achieved and a plateau is reached on the graph. Recovery 
rates of ERβ5-YFP are presented in response to E2 (red) stimulation at a 
concentration of 10
-8
M. Significance of results was examined using the Student’s t-
test (N≥8).  
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4.3.5 Analysis of reporter gene activation in response to ER activity 
4.3.5.1 Comparison of YFP labelled versus unlabelled ERβ5 
constructs 
In order to validate the use of YFP-labelled ERβ5 in the FRAP studies, experiments 
were set up in MDA cells that lack endogenous ER expression to compare the 
functional activity of YFP-tagged versus untagged ER constructs in response to the 
primary natural oestrogen, E2. No significant difference in luciferase reporter output 
between tagged and untagged constructs was detected consistent with the studies 
using tagged and untagged ERα and ERβ (Chapter 3) (Fig. 4.21).  
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Figure 4.21 Comparison of tagged versus untagged constructs in MDA cells.  
Luciferase reporter assays were conducted comparing untagged ERβ5 and ERβ5-
YFP  (A), untagged ERβ5 with ERα-YFP and ERβ5-YFP with untagged ERα (B) and 
untagged ERβ5 with ERβ-YFP and ERβ5-YFP with untagged ERβ (C) following E2 
treatment. No difference was observed (N=2). 
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4.3.5.2 Role of agonists and antagonists on the functional capacity of 
ERs in Ishikawa cells 
Further to the FRAP analyses, the functional activity of ERβ5 was compared with 
that of ERα, ERβ and ERβ2 using Ishikawa cells; the treatments tested were the same 
as those used for FRAP but luciferase activity was measured after 24 hours. 
Treatment of control, uninfected cells with E2 induced a 6X increase in luciferase 
activity compared with a DMSO control (Fig. 4.22A black column) consistent with 
endogenous expression of ERs in these cells (see Chapter 3). Overexpression of ERα, 
ERβ2 or ERβ5 did not increase luciferase activity. However, consistent with 
previous reports using T-47D cells (Lin et al., 2007), overexpression of ERβ 
attenuated the E2-mediated response. Incubation of cells with ICI 182,780 blocked 
all transcriptional activity of the ERE reporter construct in the Ishikawa cells (Fig. 
4.22B). In the same study, incubation with PPT™ induced a 3X increase in luciferase 
activity in comparison to DMSO treated cells in the Ishikawa cell line and 
overexpression of ERα in these cells suggested a trend towards a further increase in 
luciferase activity (albeit not significantly greater than the response observed in the 
uninfected Ishikawa cells) (Fig.4.22C). The DPN™-mediated effect on endogenous 
receptors of the Ishikawa cell line mirrored the response of the E2-treated cells with 
a 6X increase in luciferase activity in comparison to DMSO control cells. 
Overexpression of ERα, ERβ, ERβ2 and ERβ5 did not alter this response (Fig. 
4.22D). 
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Figure 4.22 Impact of natural and synthetic agonists with ERs on luciferase 
reporter activity in Ishikawa cells.  
Cells were infected with ERα (red), ERβ (blue), ERβ2 (yellow) or ERβ5 (green) and 
each with the 3x-ERE-Luc reporter. Treatment was with E2 10
-8
M (A), ICI 182,780 
(B), PPT™ 10
-8
M (C) or DPN (D) 10
-8
M for 24 hours prior to luciferase production 
reading. Fold difference is expressed relative to the vehicle-treated cell, each bar 
represents N=3±SEM and has been normalised to protein levels and compared to 
luciferase output following treatment in each case with a DMSO vehicle control.  
 
4.3.5.3 E2-mediated transcriptional response of ERα and ERβ5 after 
single or co-expression of receptors 
The impact of E2 treatment on ERE-mediated reporter gene activation was compared 
between cells infected with ERα or ERβ5 alone with those co-infected with both 
ERβ5 and ERα. This investigation was conducted in both Ishikawa and hTERT cells 
to elucidate the relevance of cell context on transcriptional activity. In Ishikawa cells 
overexpression of either ERα or ERβ5 resulted in an identical induction of luciferase 
activity to that in uninfected cells (Fig. 4.23). However, co-infection of cells with 
ERα and ERβ5 resulted in a significant increase in reporter gene expression 
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suggesting a cumulative effect of ERα and ERβ5 working together (Fig. 4.23A). 
However in hTERT cell line (Fig. 4.23B) co-expression had no significant impact 
when compared with that seen in uninfected cells although there was a trend for 
overexpression of ERβ5 alone to increase luciferase activity. 
 
 
Figure 4.23 Comparison of impact of E2 on luciferase activity in Ishikawa (A) and 
hTERT (B) cell contexts. 
Cells were infected with either ERα (red) or ERβ5 (green) or the combination of ERα 
and ERβ5 together in equal ratio (yellow). The cells were treated for 24 hours with 
E2 10
-8
M. Fold difference is expressed relative to the vehicle-treated cell, each bar 
represents N=3±SEM. 
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4.4 Discussion 
4.4.1 Protein expression of ERβ5 in the human endometrium 
Differential patterns of individual ER subtype mRNAs were demonstrated using 
extracts from the functional layer of normal pre-menopausal endometrial tissue 
obtained at different phases of the menstrual cycle. Consistent with previous studies, 
ERα mRNA levels decline with advancement of the cycle owing to the progesterone-
mediated down-regulation of the gene (Henderson et al., 2003). In line with results 
reported by Brandenberger and colleagues, overall expression of ERβ mRNA was 
detected at lower levels than that of ERα (Brandenberger et al., 1997). In spite of 
this, an inverse expression pattern of mRNAs encoding ERβ and its splice variant 
isoforms (ERβ2 and ERβ5) was detected with a trend toward increased expression 
during the secretory phase. While the mRNA expression of ERβ and ERβ2 has 
previously been described (Critchley et al., 2002), we believe that this is the first 
study that has examined the expression of ERβ5 mRNA in the normal endometrium.  
 
ERβ5 protein was immunolocalised to the nuclei of the glandular epithelial and 
stromal cells as well as the endothelial cell population at all phases of the cycle.    
Co-localisation of ERβ5 with ERα revealed that the reduced expression of the ESR1 
gene during the secretory phase of the cycle resulted in weak ERα immunostaining in 
sections of mid-late secretory phase endometrium while ERβ5 immunoexpression 
was ubiquitous and sustained at all stages. A previous study reported expression of 
ERβ in the endothelial cells (Critchley et al., 2001) and in the current study the 
detection of ERβ5 in these same cells supports the hypothesis that ERβ isoforms 
regulate E2-dependent action(s) within the endothelial cell population of the 
endometrium. 
 
Taken together, the sustained expression of ERβ and its isoforms ERβ2 and ERβ5 
when ERα declines (mid-late secretory phases of the cycle) and the widespread 
expression of ERβ and ERβ5 in all cell types of the functional layer of the 
endometrium suggests ERβ-dependent regulation of gene expression in response to 
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E2 levels may be important in the normal pre-menopausal endometrium during the 
secretory phase. 
 
In other studies, investigations of ERβ variant expression have revealed increased 
ERβ2 and ERβ5 mRNAs (Leygue et al., 1999b) and ERβ2 protein (Omoto et al., 
2002) in comparison with full length ERβ in breast cancer cell lines and pre-
menopausal breast tumour tissue. Park et al. demonstrated increased expression of 
ERβ5 mRNA in breast cancer of post-menopausal patient tissue (Park et al., 2006) 
irrespective of ERα being reported as the dominant subtype at the post-menopausal 
stage (Jarvinen et al., 2000). Further to this, numerous recent studies have reported 
on increased immunoexpression of ERβ5 as a feature of cancer cells in primary 
colorectal carcinomas (Wong et al., 2005), breast cancer (Shaaban et al., 2008) and 
endometrial carcinoma tissue (Collins et al., 2009). 
 
There are conflicting reports regarding the importance of ERβ as a therapeutic 
marker in breast cancer states. Fuqua et al. reported no correlation between ERβ 
expression and tumourigenesis (Fuqua et al., 2003). However, an epidemiological 
study by the same group implied that the high expression levels of ERβ and ERβ5 
mRNAs in ERα negative breast cancer tissues of African-Americans compared with 
the Caucasian population underlies the poor survival statistics for the African-
American patients (Poola et al., 2005b). Other studies have suggested that loss of 
ERβ protein may define a tumour phenotype with high metastatic capability 
(Jarvinen et al., 2000). In line with this view, there is accumulating evidence that the 
expression of ERβ in breast cancer tissue is associated with a favourable prognosis 
(Omoto et al., 2001) and disease free survival attributable to an inverse affiliation 
with the coactivator SRC-1 (Myers et al., 2004). A role for ERβ as a tumour 
suppressor agent has also been described (Treeck et al., 2009). 
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4.4.2 ERβ5 intranuclear mobility is not influenced by oestrogenic 
ligand but is responsive to anti-oestrogenic treatment 
A previous study has questioned the ability of the truncated splice variant of ERβ to 
form homodimers (Leung et al., 2006) originally claimed in the study by Moore et 
al. (Moore et al., 1998). However Leung et al. ascribed a functional role for the 
splice variants ERβ2, ERβ4 and ERβ5 in heterodimeric partnership with their 
cognate full length ERβ (Leung et al., 2006).  
 
In the present study FRAP analysis has revealed that ERβ5 is a highly mobile protein 
within the nucleus and shown that incubation with E2, PPT™ or DPN™ did not alter 
the rapid recovery times of ERβ5 upon photobleaching. These results are the first to 
examine ERβ5 intranuclear dynamics and are consistent with studies claiming that 
this truncated splice variant does not contain all the sequences that are required for a 
fully functional ligand binding pocket like that found in the full length wild type ERβ 
receptor. Interestingly, the anti-oestrogen ICI 182,780 had a significant impact on 
subnuclear mobility of ERβ5 in both the Ishikawa and hTERT cells. Furthermore 
incubation with ICI 182, 780 resulted in a distinct change in the nuclear distribution 
of ERβ5-YFP. These changes were ICI-dependent and there were no differences in 
cells that were exposed to E2 before or after ICI 182,780 treatment (data not 
presented).  
 
Stenoien et al., suggested ICI-mediated immobilisation of ERα was Helix 12-
dependent (Stenoien et al., 2001b). However, the ERβ5 splice variant lacks Helix 12 
so this would suggest a different mechanism. Unlike the receptor immobilisation that 
resulted from ICI 182,780 treatment of ERα and ERβ tagged constructs in the same 
cell contexts (Chapter 3, section 3.3.2.2), ICI 182,780 reduced the mobility of ERβ5 
in both the Ishikawa and hTERT cells. Furthermore, a significant increase in the half-
time (i.e. time taken to reach 50% of the final maximal recovery value YMAX) from 
7.27 seconds in control cells to 29.17 seconds in the hTERT cells was noted. 
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A recent study in MCF-7 and HeLa cells reported differences in the ERβ response to 
ICI 182,780 compared to ERα. For example, ERβ unlike ERα, retained mobility 
(albeit reduced) following exposure to ICI 182,780 and mutation studies also argue 
against a role for Helix 12 (Damdimopoulos et al., 2008). It has previously been 
suggested that the ICI-mediated degradation of ERα arises from disruption to 
dimerisation and nucleocytoplasmic shuttling caused by steric hindrance of the bulky 
side-chain of the compound itself (Dauvois et al., 1993b) and interruption of ERα 
cycling at the promoter site that results in direct targeting of the ERα to the ubiquitin 
proteasome pathway (UPP) (Reid et al., 2003). Hence, a plausible explanation for the 
discrepancy in the intranuclear response of ERβ5 compared with ERα and ERβ 
(Chapter 3, section 3.3.2.2) in response to ICI 182,780 is that the impact of the anti-
oestrogen on ERβ5 is independent of proteasomal regulation. 
4.4.3 Oestrogen exposure alters the intranuclear dynamics of 
endometrial cells co-infected with ERβ5-YFP and ERα in vitro 
Early studies using COS-1 cells demonstrated ligand-independent heterodimeric 
formations between ERα and ERβ based on the relative expression patterns of the 
two subtypes (Cowley et al., 1997, Pace et al., 1997). In these studies, mutation 
assays revealed that the DNA binding domain of ERα was sufficient to enable 
heterodimers to occur (Pace et al., 1997) and that the amino acids involved in 
homodimerisation of ERα were not identical to those required for heterodimerisation 
with ERβ (Cowley et al., 1997).  
 
In the current study, the co-expression of ERβ5-YFP with ERα resulted in a change 
in the intranuclear dynamics of ERβ5-YFP in response to E2. While the decrease in 
the mobility of ERβ5 in co-infected Ishikawa and hTERT cells was significant, a 
trend towards a decrease in mobility was observed from the results of E2 exposure 
on cells infected with ERβ5-YFP alone. While the capacity of ERβ splice variants to 
form homodimers has been questioned (Leung et al., 2006), gel shift mobility assays 
have suggested that ERβ isoforms are capable of forming partnerships with ERα 
(Moore et al., 1998) and between the ERβ isoforms themselves (Leung et al., 2006). 
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The results of the current study suggest that overexpression of ERα may result in 
stabilisation of ERα-ERβ5 heterodimers in response to E2-binding of ERα. This 
implies that the change in ERβ5-YFP intranuclear dynamics is occurring only in a 
milieu of high expression levels of ERα, suggesting a distinct expression profile 
context (mixed dimer) in which E2 can elicit an effect on ERβ5 by virtue of its 
binding to ERα. 
4.4.4 Oestrogen exposure effects the transcriptional capacity of 
endometrial cells co-infected with ERβ5 and ERα in vitro 
Many studies using HeLa and HEK293 cells have suggested a dominant negative 
role for ERβ in heterodimeric complexes with ERα in response to E2 (Ogawa et al., 
1998a, Pettersson et al., 2000, Hall et al., 2001, Li et al., 2004). In these studies, the 
interaction of the transactivation domains AF-1 and AF-2 within ERα has been 
suggested as the target for the repressive activity of ERβ repression (Pettersson et al., 
2000). Moreover, deletion studies have revealed that the AF-1 of ERβ is itself 
required to impart this inhibitory function (Gougelet et al., 2007). In the current 
study, E2 treatment reduced transcriptional activity in cells overexpressing ERβ 
while there was no discernable change in ERE-luciferase reporter gene activity in the 
Ishikawa cells infected with either ERα, ERβ2 or ERβ5 alone in response to 
treatment with E2, ICI 182,780, PPT™ and DPN™. This is presumably due to the 
masking of responses stemming from the high levels of endogenous receptor activity. 
 
Interestingly ERE-reporter activation in response to E2 treatment was higher in 
Ishikawa cells co-infected with ERα and ERβ5 than that in cells infected with ERα 
alone. A previous study reported that only one partner within a receptor heterodimer 
is required to be bound by E2 in order to induce transcriptional activity (Tremblay 
G.B. et al., 1999). As there was no receptor gene activation in MDA cells lacking 
endogenous receptor when they were infected with ERβ5 and treated with E2, one 
can conclude ERβ5 binding of E2 is not responsible for the enhanced transcriptional 
activity. Rather, the cumulative result observed in the Ishikawa cell line implies a 
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response to an ERβ5-ERα heterodimer where ERβ5 is imparting a positive influence 
on transcriptional activity after ERα binding to E2. 
4.5 Conclusion 
Investigation of the expression pattern of ERβ5 in the human endometrium revealed 
ubiquitous expression of this splice variant in the stromal and epithelial 
compartments of the tissue at significant levels throughout the course of the 
menstrual cycle. Despite the inability of ERβ5 to actively bind agonist, there remains 
a putative role for this splice variant in a) responding to pure antagonist (ICI 
182,780), b) functioning in a heterodimeric partnership, and c) imparting an effect on 
the functional capacity of the dimeric partner (e.g. ERα). In this study, the influence 
of cell treatments (agonist and antagonist) on the intranuclear dynamics of the ERβ5 
splice variant was examined. Although natural and synthetic agonists had no impact 
on ERβ5 mobility, a role for anti-oestrogenic regulation by ICI 182,780 was 
revealed. Stimulation with ICI 182,780 resulted in a significant decrease in the 
mobility of ERβ5-YFP molecules and this effect was not rescued by post-treatment 
with E2 at physiological concentration. This suggests a universal dominant inhibitory 
effect of ICI 182,780 on ER subtypes that is irrespective of a truncated C-terminal 
domain and impaired canonical ligand-binding capacity.  
Co-infection of ERβ5 with ERα had an impact on the E2-mediated transactivational 
activity in two endometrial cell lines (of adenocarcinoma and healthy patient origin) 
and ERE luciferase gene activity was upregulated when both ER isoforms were 
present in the Ishikawa cell line. While this effect was cell-dependent and not 
replicated in the hTERT cell line, the Ishikawa study revealed a cumulative effect 
when ERα and ERβ5 were infected together in comparison to the effect of either 
subtype infected independently. These results may have implications for the response 
of cancer tissues to oestrogenic ligands as previous data have implied overexpression 
of ERβ5 by cells in malignant tissue.   
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This chapter has explored the intranuclear dynamic response of ERβ5 in accordance 
with the canonical ligand-dependent mode of activation using a panel of ligands 
composed of natural and synthetic agonists. In the following chapter, the implication 
of an alternative ligand-independent mode of activation using GFs on ER dynamics 
and transcriptional activity is investigated. GFs have been implicated in the 
multifaceted maze of ER activation and as such pose as potential targets for 
controlling ER-dependent regulation of proliferation in human tissue. In particular, 
the influence of GFs on truncated ER variants lacking innate ligand-binding capacity 






Alternative modes of activation 
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5   Alternative modes of activation 
5.1 Introduction 
EGF, the derivative of the transmembrane precursor (prepro-EGF) transduces its 
effects through binding to its cognate receptor EGFR. Studies using a variation of the 
conventional FRAP technique; total internal reflection/FRAP have previously 
revealed a strong affinity of EGF for the EGFR in A431 cells in vitro (Hellen, 1991). 
The EGFR is a member of a receptor tyrosine kinase family of receptors that 
encompasses the HER proteins (HER1-4) (reviewed in Citri and Yarden, 2006). 
These proteins are reported to be differentially expressed in the endometrium over 
the course of the menstrual cycle (Srinivasan et al., 1999, Chobotova et al, 2005, 
Ejskjaer et al., 2005).  
 
A previous study demonstrated that treatment of ovariectomised mice with EGF had 
an impact on uterine function that mimicked the response to oestrogen treatment 
(Nelson et al., 1991). The results of this study prompted the investigation into ligand-
independent mechanisms of activation of ERs as well as the potential for cross-talk 
between E2 and EGF signalling pathways (reviewed in Smith, 1998, Levin, 2003). 
 
There is now an accumulating body of evidence establishing EGF-mediated tyrosine 
signalling as the key pathway inducing phosphorylation of residues on both ERα 
(Kato et al., 1995b, Joel et al., 1998b, Shah and Rowan, 2005, Chen et al., 1999, Cui 
et al., 2004, Rogatsky et al., 1999, Thomas et al., 2008, Weis et al., 1996) and ERβ 
(Tremblay A. et al., 1999, Tremblay and Giguere, 2001, Sanchez et al., 2007) that 
can transactivate the receptors independently of steroid ligands (Chapter 1, section 
1.4.2). In addition to direct phosphorylation of ERs in response to GF signalling, GFs 
have also been shown to induce expression of oestrogen-regulated target genes 
including PR (Stoica et al., 2000), pS2 (Martin et al., 2000b), and COX2 (Su et al., 
2009). 
 
The complex interplay of ligand-dependent and ligand-independent impacts on ER 
activity is also of importance from a clinical perspective. For example, bidirectional 
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cross-talk between MAPK and E2 signalling pathways augments ER activity in 
MCF-7 breast cancer cells and has been shown to result in accelerated tumour 
growth but without impacting on the sensitivity of anti-oestrogen treatment in severe 
combined immune-deficient (SCID) mice (Atanaskova et al., 2002). Conflicting 
studies have suggested that HER2-dependent signalling impacts on ERα activation  
as a result of MAP kinase activity and confers resistance to 4HT, disruption of 
corepressor activity (Kurokawa et al., 2000) or p38 signalling (Gutierrez et al., 
2005). Supporting studies have highlighted the MAPK-dependent phosphorylation of 
coregulators (e.g. amplified in breast cancer-1 (AIB1)/steroid receptor coactivator-3 
(SRC-3)) as a complementary process to ER-dependent protein phosphorylation/gene 
activation. Increased AIB1 coactivator expression in breast cancer cells has been 
positively correlated with overexpression of HER2 (Osborne et al., 2003) and HER3 
(Kirkegaard et al., 2007) and shown to be associated with 4HT resistance. 
 
The discrepancies in the results of the studies relating to 4HT resistance may stem 
from differences in the complex network of signalling cascades that target specific 
sites on the ER protein for phosphorylation. Disruption of GF-mediated tyrosine 
kinase signalling via ERα has been explored using various GF inhibitors in 
preclinical tumour mouse models (Knowlden et al., 2003, Nicholson et al., 2004) but 
without a sustained effect on actual tumour growth (Massarweh et al., 2006, Arpino 
et al., 2007). Notably, the anti-HER2 monoclonal antibody trastuzumab (Herceptin®) 
is widely employed in the clinical setting for treatment of HER2 positive breast 
cancers (Vogel et al., 2001) but has been linked with disease relapse (reviewed in 
Nahta and Esteva, 2006). Alternative compounds are being developed that target the 
multiple signalling pathways that converge at ERα and ERβ (Xia et al., 2002, Rusnak 
et al., 2001). For example Lapatimib serves as a dual inhibitor of both HER1 and 
HER2 transmembrane tyrosine kinase receptors (Spector et al., 2005). The available 
evidence therefore suggests that GF-dependent and E2-dependent activation of gene 
expression are not mutually exclusive but their cumulative effects result in a more 
potent ER response in target tissues (reviewed in Arpino et al., 2008). Combined 
Chapter 5     Alternative modes of activation 186 
treatment modalities targeting both systems independently may be the future of 
clinical therapy to combat ER activity in cancers.  
 
Irrespective of the mode of activation of ERα or ERβ, there is a growing body of 
evidence implicating the UPP as a primary regulator of ER subtype steady-state 
levels. Both ERα and ERβ are believed to undergo continual transient cycling on the 
DNA at specific promoter regions in both the unbound and ligand-bound state at 
approximate frequencies of 20 and 45 minutes respectively (Reid et al., 2003). The 
UPP acts on receptors at these responsive promoter sites to degrade DNA-bound 
receptor and ensure continuation of this cycle. 
 
Ubiquitylation is a well defined ordered process that involves three sequential 
enzymatic processes. In an energy-dependent reaction the 76 amino acid (8.6kDa) 
ubiquitin protein is activated by the ubiquitin-activator (Uba) enzyme 1 (E1). This 
results in the formation of a thioester bond between a specific cysteine residue of the 
E1 Uba and the carboxyl terminus of the ubiquitin protein itself. In this active state, 
ubiquitin is subsequently transferred to the cysteine residue of an ubiquitin-
conjugating (Ubc) enzyme (E2). The ligase enzymes (E3) serve as adaptor proteins 
in the final stage of the process and localise the ubiquitin to the Ɛ-amino group of 
the target substrate (e.g. ER subtype) (Jentsch, 1992, Ciechanover, 1994). 
 
Subsequent rounds of ubiquitylation ligate adjoining ubiquitin moieties at their lysine 
residues and signal the target protein for degradation by the 26S proteasome. Itself a 
multiplex protein, the 26S proteasome comprises a 19S regulatory cap in which the 
substrate becomes unfolded and directed into the 20S catalytic core barrel for 
degradation (Lipford and Deshaies, 2003). Studies using the proteasomal inhibitors 
MG132 and lactocystin have shown that disruption of the UPP results in abrogation 
of transcription and have implied that ubiquitinated ER is also necessary to mediate 
maximal transcriptional activation while the polyubiquitinated state is required to 
signal degradation of the receptors (Lonard et al., 2000). FRAP studies have 
demonstrated that the same proteasomal inhibitors render ERs dysfunctional and they 
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remain localised to inactive sites of the nuclear matrix (Stenoien et al., 2001b). 
Specific domains of ERα are targeted by ubiquitin and these regions have been 
shown to coincide with coactivator binding sites while coregulators (e.g. SRC-1, 
TIFII, RAC3, CBP) are also subject to proteasomal-mediated degradation (Reid et 
al., 2002). A number of the ubiquitin enzymes have themselves been shown to 
interact with nuclear receptors including SUG1/TRIP1 (Masuyama and Hiramatsu, 
2004), E2 Ubc9 (Poukka et al., 1999) and the E3s; Rsp5/RPF-1 (Imhof and 
McDonnell, 1996), E6 associated protein (E6-AP) (Nawaz et al., 1999). Taken 
together, these studies imply a central role for the UPP in ER turnover and 
maintenance of steady-state levels. 
 
5.1.1 Aims of the chapter 
Chapters 3 and 4 of this thesis have investigated ligand-dependent mediated effects 
on the intranuclear dynamics and functional capacity of ERα, ERβ and its cognate 
splice variants, ERβ2 and ERβ5. Conversely, the experiments described in this 
chapter sought to examine alternative modes of activation of the ER that were 
independent of oestrogenic ligands. In particular, this study investigated the 
functional activity of the ERβ splice variant, ERβ5, as a complement to studies on its 
expression in normal endometrium (Chapter 4). The impact of EGF on intranuclear 
mobility and transcriptional activity on ERs was investigated using FRAP and 
luciferase reporter assays and the impact of the UPP on ER kinetics and functional 
capacity was also explored. 
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5.2 Materials and Methods 
5.2.1 Taqman® qRT-PCR  
RNA was extracted from lysed cells using a Qiashredder™ spin column for cell 
homogenisation (section 2.5.1) and quantified using the Nanodrop® ND 1000 
(Labtech International, East Crawley, UK). Complementary DNA was prepared 
using random hexamers (section 2.5.4.1) and was used for the Taqman reaction 
protocol outlined in section 2.5.4.3. Taqman analysis of EGFR was conducted in 
triplicate using probes from the Roche Universal Probe Library™ and run on the 
ABI Prism 7900. Data output from the detection system was quantified in accordance 
with the 2-∆∆Ct  algorithm (section 2.5.4.4). Results are expressed as means and 
standard errors and statistical analysis was conducted using a Student’s t-test.  
5.2.2 Collection of endometrial tissue 
As detailed in Chapter 2, section 2.2.1, human endometrial tissue was obtained from 
different phases of the menstrual cycle following hysterectomy, hysteroscopy or 
laparoscopic sterilisation performed at the Royal Infirmary, Edinburgh, UK. The 
histological staging analysis was performed by an expert histologist as previously 
reported (Critchley et al., 2001, Critchley et al., 2002). All patients gave written 
informed consent prior to tissue recovery. 
5.2.3 Immunohistochemistry 
Immunohistochemistry was performed on paraffin embedded endometrial tissue to 
identify the location of the proteins of interest as outlined in section 2.4.1 
5.2.3.1 Non Fluorescent Immunohistochemistry (DAB) 
In brief, tissue was processed and sections mounted on glass slides as described in 
section 2.4.1.1. The sections were then dewaxed, rehydrated (2.4.1.2) and subjected 
to antigen retrieval by means of pressure cooking in citrate buffer (2.4.2). Three 
blocking steps were employed to prevent endogenous peroxidase activity, non-
specific binding of the secondary antibody and the formation of avidin-peroxidase 
complexes binding directly to the tissue where endogenous biotin is expressed as 
outlined in 2.4.3.1, 2.4.3.2 and 2.4.3.3 respectively. The sheep anti-EGFR primary 
antibody was incubated with the tissue overnight at 4°C (Table 2.1). A rabbit anti-
sheep biotinylated secondary antibody (Table 2.2) used and the signal was localised 
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using the chromogenic substance 3, 3’-diaminobenzidine (DAB, K3468; DAKO, 
Cambridge, UK) diluted in its substrate. The corresponding negative control sections 
were incubated with blocking serum alone to enable confirmation of antibody 
specificity. The primary and secondary antibodies used are listed in Table 5.1. 
 
Table 5.1 Summary of primary and secondary antibodies used for DAB 
immunodetection 
Target Raised in Dilution Retrieval Source 
EGFR/ErbB1  
(HER1) 
Sheep 1:100 Citrate Upstate1 
ErbB2  
(HER2) 
Mouse 1:75 Citrate Abcam2 
ErbB3  
(HER3) 
Mouse 1:75 Citrate Abcam2 
ErbB4  
(HER4) 
Mouse 1:40 Citrate Abcam2 
  
1Upstate Biotechnology Inc., New York, USA 
2Abcam plc, Cambridge, UK 
  
5.2.4 Western Immunoblotting 
Western analysis was performed using nuclear protein extracts (section 2.6.1) from 
Ishikawa and hTERT cells. The infected cells were lysed with 1X RIPA buffer 
(Chapter 2; section 2.6.2) and separated into cytoplasmic and nuclear fractions and 
quantified in accordance with the Biorad DC Protein Assay (section 2.6.3). Proteins 
were separated on polyacrylamide gels (section 2.7.2), electro-transferred to PVDF 
membrane (section 2.7.3), incubated with primary antibodies (section 2.7.4; Table 
5.2) and scanned for detection using the LI-COR™ infrared detection system 
(section 2.7.5). These membranes were immunoprobed using an anti-EGFR for 
verification of endogenous EGFR protein expression and with anti-MAPK and anti-
ERα and the phosphorylated states of each of these proteins respectively. 
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Table 5.2 Primary antibodies used for Western blotting 
Antigen Host Species  Dilution  Source 
EGFR/ErbB1 
(HER1) 
Rabbit 1:200 Santa Cruz1 
β-tubulin Mouse 1:600 Sigma2 
ERα Mouse 1:200 Vector3 
Phosphor-Ser118 
ERα 
Rabbit 1:1000 Cell Signaling4 
p42/44 MAPK Rabbit 1:1000 Cell Signaling4 
Phospho p42/44 
MAPK 
Mouse 1:2000 Cell Signaling4 
1Santa Cruz Biotechnology, CA, USA 
2Sigma-Aldrich, St. Louis, MO, USA 
3Vector Laboratories Ltd., Peterborough, UK 
4Cell Signaling Technology®, MA, USA. 
 
5.2.5 Cell treatments 
To establish the impact of EGF on ER phosphorylation status, receptor mobility and 
activity, serum-starved cells were incubated with EGF at a final concentration of    
10-7M. Some cells were incubated with the MAP kinase inhibitor PD98059 at a final 
concentration of 10-8M. Control treatments using a distilled H2O alone (vehicle 
control) were conducted and used to compare the effects of agonist and antagonist 
incubation. Treatments were included 1 hour prior to live-cell FRAP analyses and 24 
hours in advance of cell harvesting for luciferase assays. 
5.2.6 FRAP 
FRAP was conducted on a LSM 510 confocal inverted light scanning microscope 
(section 2.8.6). In brief, live cells were maintained in PBS buffered with 10mM 
HEPES in an enclosed chamber heated to 37°C (section 2.8.2). Cells expressing 
YFP-labelled ER subtypes were selected for bleaching on the basis of uniform 
distribution of levels of fluorescence. Three ROIs were of equal dimension were 
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chosen (section 2.8.5). Two pre-bleach images were captured at 3 second intervals 
followed by photobleaching owing to a series of focused pulsed iterations using the 
Argon 12 laser (488 and 514nm) laser at maximal power. Eight subsequent images 
were taken to establish recovery patterns using an attenuated laser (514nm set 
between 1-5% power) (section 2.8.6). Data collation and quantitation was conducted 
and subject to correction, normalisation and statistical evaluation as outlined (section 
2.8.7). 
5.2.7 Luciferase Gene Reporter Assay 
Luciferase reporter assays were carried out as described (section 2.9.1). Luciferase 
output was expressed as relative light units using the FLUOstar OPTIMA 
luminometer (BMG Labtech) were normalised against total protein content from 




5.3.1 The EGFR family of proteins are expressed in the human 
endometrium 
To investigate the correlation of growth factor-mediated signalling on ER function, 
the expression of the complete repertoire of HER family of proteins (HER1–HER4) 
was investigated in the endometrium. Using tissue sections recovered from the 
proliferative phase of the menstrual cycle, the expression patterns of HER1, HER2, 
HER3 and HER4 were investigated using specific antibodies. HER1 expression was 
extensive and localised to the stromal and epithelial compartments of the tissue 
(Fig.5.1A). HER2 protein localised to the cytoplasm of the glandular epithelial lining 
and there was very weak detection of HER4 in this same region (Fig 5.1B and D). 
The detection of HER3 was strongest in the glandular epithelial cells but was also 
present in the stromal compartment of the tissue (Fig. 5.1C). 
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Figure 5.1 EGF receptor (EGFR) family immunoexpression in the human 
endometrium.  
Immunodetection in the functional layer of the human endometrium from the 
proliferative phase. EGFR/ErbB1 (A), ErbB2 (B), ErbB3 (C) and ErbB4 (D). EGFR 
was detected in the glandular epithelial (g) and stromal (s) cells, ErbB2, ErbB3 and 
ErbB4 staining was localised to the epithelial cells. Insets are negative controls. 
Magnification X20 (A, C) and X40 (B, D); scale bar, 100µm. 
 
5.3.2 RNA and protein expression of EGFR in cell lines 
Quantitative real-time mRNA analysis revealed expression of the primary receptor of 
the HER family, HER1 in the MDA, Ishikawa and hTERT cell lines (Fig. 5.2). This 
data was important as it provided the platform to conduct further investigations on 
the impact of EGF on ER status and function. Total protein was also extracted from 
the MDA and Ishikawa cell lines and used to probe for expression of EGFR. 
Endogenous EGFR protein was detected at the correct molecular weight of ~170kDa 
in each of the three cell lines (Fig. 5.3). 
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Figure 5.2 Comparison of mRNA expression of endogenous EGFR in Ishikawa 





Figure 5.3 Determination of EGFR protein levels in the cell lines.  
This is a representative Western blot following total protein extraction and probing 
for EGFR endogenous protein expression in the MDA cells (Lane 1) and Ishikawa 
cell protein extracts (Lane 3 and 4). Membrane was probed for EGFR (green) and β-
tubulin loading control (red). 
 
5.3.3 EGF functions through activation of the MAPK pathway in 
endometrial cells 
The phosphorylation status of the members of the MAPK signalling cascade has 
been shown to be modified in response to EGF activation through the cognate 
transmembrane receptor EGFR (Miyamoto et al., 1996). To establish whether this 
was also the case in endometrial cells, Ishikawa cells maintained in a serum-free 
environment were incubated with EGF treatment for 10, 20 and 30 minutes. 
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Thereafter the cells were lysed and total protein was extracted and used on Western 
blots that were probed with antibodies directed against phosphorylated and 
unphosphorylated forms of the p42/p44 (extracellular signal-regulated kinases) ERK 
2 and ERK 1 proteins. Incubation with EGF induced phosphorylation of the MAPK 
proteins at each of the time-points and quantification of the band sizes revealed this 
was blocked when cells were pre-incubated with the MEK inhibitor PD98059 (Alessi 
et al., 1995) for 1 hour (Fig. 5.4, upper panel; Fig. 5.5).  
 
 
                     
Figure 5.4 Western analysis of MAPK and phospho-MAPK proteins in Ishikawa 
cells.  
Protein was extracted from Ishikawa cells following incubation with EGF and/or a 
MAPK inhibitor. Lane 1, dH2O; Lane 2, ERK1/2 inhibitor PD98059 treatment for 1 
hour; Lane 3, EGF 10
-7
M incubation for 10 minutes; Lane 4, PD98059 1 hour 
treatment followed EGF 10
-7
M for 10 minutes; Lane 5, EGF 10
-7
M incubation for 20 
minutes; Lane 6, PD98059 1 hour treatment followed EGF 10
-7
M for 20 minutes; 
Lane 7, EGF 10
-7
M incubation for 30 minutes; Lane 8, PD98059 1 hour treatment 
followed EGF 10
-7
M for 30 minutes. Membrane was incubated with an anti-p42/p44 
MAPK (green) and anti-phopho-p42/p44 MAPK (red). 
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Figure 5.5 Quantification of Western blots p44 (ERK1) (A) and p42 (ERK2) (B) 
after EGF stimulation for 10, 20 and 30 minute intervals (N=1). 
 
5.3.4 ERα is phosphorylated at the Ser118 residue in response to EGF-
mediated signalling. 
To determine if Ser118 was phosphorylated by EGF-mediated MAPK signalling in 
vitro, Ishikawa cells overexpressing ERα-YFP were maintained in serum-free media 
and then treated with EGF for 10, 20 or 30 minutes with or without the addition of 
the MEK inhibitor PD98059 for 1 hour. Total protein extracts were run on a Western 
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blot and probed with an antibody against total ERα (green bands) and an antibody 
directed against the phosphor-Ser118 residue of ERα (red bands) (Fig. 5.6). ERα-
YFP with a phosphorylated residue at Ser118 was detected in all nuclear extracts 
prepared from cells incubated with EGF treatment. Surprisingly the ERK1/2 inhibitor 





Figure 5.6 Western analysis of ERα and phosphorylated ERα at the Serine residue 
118 protein in Ishikawa cells.  
Protein was extracted from Ishikawa cells following EGF treatment: Lane 1, H2O; 
Lane 2, ERK1/2 inhibitor PD98059 for 1 hour; Lane 3, EGF 10
-7
M for 10 minutes; 
Lane 4, PD98059 for 1 hour followed EGF 10
-7
M for 10 minutes; Lane 5, EGF      
10
-7
M incubation for 20 minutes; Lane 6, PD98059 for 1 hour followed EGF 10
-7
M 
for 20 minutes; Lane 7, EGF 10
-7
M incubation for 30 minutes; Lane 8, PD98059 for 
1 hour followed EGF 10
-7
M for 30 minutes. Membrane was probed with an anti-ERα 
(red) and anti-phopho-Ser118 ERα (green). 
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Figure 5.7 Quantification of Western blot for the Ser118 phosphorylation of ERα-
YFP in Ishikawa cells (N=1). 
 
5.3.5 Intranuclear dynamics of ERs in response to incubation with EGF 
To investigate whether growth factor induced receptor phosphorylation could have 
an impact on intranuclear mobility of ERs in endometrial cells, Ishikawa cells were 
infected with fluorescently-labelled ER constructs, maintained in serum-free media, 
incubated with EGF over a range of time-points and assessed using FRAP analysis 
(Fig. 5.8). There was a significant effect on the recovery response of ERα-YFP 
molecules in response to EGF exposure for 10 minutes with a reduction in YMAX. 
However, this effect was not sustained following longer incubation periods with the 
growth factor (Fig. 5.9). 
 
Incubation with EGF also had a detectable impact on the mobility of ERβ-YFP 
molecules in Ishikawa cells (Fig. 5.10). Significant effects were determined on the 
recovery response rates in response to EGF stimulation at 10, 20 and 30 minute time 
intervals with a reduction in YMAX. No change in recovery capacity was detectable 
after 60 minutes of EGF treatment (Fig. 5.11). The impact of EGF-dependent 
signalling on the ERβ5 splice variant that lacks the ability to bind oestrogens was 
also investigated using Ishikawa cells infected with ERβ5-YFP. Notably, EGF 
treatment over a range of time-points from 10 to 90 minutes had a significant impact 
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on overall percentage recovery suggestive of a ligand-independent impact on ERβ5-
YFP mobility (Fig. 5.12).  
 
Figure 5.8 Qualitative FRAP assessment of ERα-YFP infected Ishikawa cells.  
Cells were treated with a dH2O vehicle control and EGF 10-7M over a range of 
time-points (10, 20, 30, 60 and 90 minutes).  
 
Figure 5.9 Quantitative analysis of intra-nuclear kinetics of ERα-YFP infected 
Ishikawa cells.  
Graphical depiction of impact of EGF treatment on the recovery rates of ERα-YFP 
over time into the bleached zone. This recovery is indicated by the point at which the 
YMAX is achieved. Recovery rates of ERα-infected cells are presented in response to 
EGF stimulation over a range of different time intervals (10, 20, 30, 60 and 90 
minutes) at a concentration of 10
-7
M. ** (P<0.01) denotes significance in variation 
of ligand treatments compared with the dH2O vehicle control as derived from the 
Student’s t-test (N≥8). 
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Figure 5.10 Qualitative FRAP assessment of ERβ-YFP infected Ishikawa cells.  
Cells were treated with a dH2O vehicle control and EGF 10-7M over a range of 
time-points (10, 20, 30 and 60 minutes). 
 
Figure 5.11 Quantitative analysis of intra-nuclear kinetics of ERβ-YFP infected 
Ishikawa cells. 
Impact of EGF treatment on the recovery rates of ERβ-YFP over time back into the 
bleached zone are denoted by the point at which the YMAX is achieved and a plateau 
is reached on the graph. Recovery rates of ERβ-infected Ishikawa cells are presented 
in response to EGF over a range of different time intervals (10, 20, 30 and 60 
minutes) at a concentration of 10
-7
M. Additional statistical parameters are presented 
in B. ** (P<0.01) and *(P<0.05) denotes significance in variation of ligand 
treatments compared with the dH2O vehicle control as derived from the Student’s      
t-test (N≥8). 
Chapter 5     Alternative modes of activation 200 
 
Figure 5.12 Qualitative FRAP assessment of ERβ5-YFP infected Ishikawa cells.  
Cells were treated with a dH2O vehicle control and EGF 10
-7
M over a range of time-
points (10, 20, 30, 60 and 90 minute intervals). 
 
 
Figure 5.13 Quantitative analysis of intra-nuclear kinetics of ERβ5-YFP infected 
Ishikawa cells.  
Graphical depiction of impact of EGF on the recovery rates of ERβ5 fluorophores 
over time back into the bleached zone. This recovery is denoted by the point at which 
the YMAX is achieved and a plateau is reached on the graph. Recovery rates of    
ERβ5-YFP are presented over a range of different time intervals (10, 20, 30, 60 and 
90 minutes) in response to EGF at a concentration of 10
-7
M. * (P<0.05) denotes 
significance in variation of ligand treatments compared with the dH2O vehicle 
control as derived from the Student’s t-test (N≥8). 
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The studies using ERβ5-YFP revealed that the impact of EGF on percentage 
recovery (YMAX) was sustained throughout the treatment period (10-90 minutes) (Fig. 
5.13), a result that was in marked contrast to that observed with ERα-YFP (Fig. 5.9) 
or full length ERβ-YFP (Fig. 5.11). As an extension of the ERβ5-YFP study, the 
impact of EGF-mediated signalling on the behaviour of putative ER heterodimers 
was examined using Ishikawa cells co-infected with ERβ5-YFP and ERα treated 
with EGF for 90 minutes.  
 
 
Figure 5.14 Qualitative FRAP assessment of ERβ5-YFP and ERα infected 
Ishikawa cells.  
Cells infected with ERβ5-YFP and untagged ERα were treated with a dH2O vehicle 
control and EGF 10
-7
M for 90 minutes. 
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Figure 5.15 Quantitative analysis of intra-nuclear kinetics of ERβ5-YFP and 
untagged ERα in Ishikawa cells.  
Graphical depiction of impact of EGF treatment on the recovery rates of ERβ5 
fluorophores over time back into the bleached zone. This recovery is denoted by the 
point at which the YMAX is achieved and a plateau is reached on the graph. Recovery 
rates of ERβ5-YFP are presented in response to EGF stimulation for 90 minutes at a 
concentration of 10
-7
M. *(P<0.05) denotes significance in variation of ligand 
treatments compared with the vehicle control as derived from the Student’s t-test 
(N≥8). 
 
5.3.6 EGF induces ligand-independent transactivation of ERs at the 
ERE. 
Having established that incubation of cells with EGF and putative activation of 
MAPK-dependent phosphorylation had a significant impact on the intranuclear 
dynamics of ERs, the effect of EGF treatment on ER transcriptional activity was 
examined. The effect of EGF incubation on uninfected, control Ishikawa cells and 
those infected with constructs expressing ERα, ERβ and ERβ5 was assessed 
following infection of all cells with the 3X-ERE-tk-luc adenoviral vector. Twenty-
four hours after infection with the adenoviral constructs and incubation in serum-free 
media, the cells were treated with either EGF 10-7M alone for a further 24 hours. All 
cells were then lysed and assayed for luciferase activity. Incubation with EGF 
stimulated reporter gene activity in control Ishikawa cells and this activity was not 
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significantly changed by overexpression of ERα, ERβ or ERβ5 (Fig.5.16) although 
there was a trend for activity to increase with ERα. Surprisingly the ERK1/2 inhibitor 
PD98059 did not abrogate the effect of EGF in this cell context and this may suggest 
the involvement of alternative ERK-independent signalling pathways in mediating 
the effect of EGF on ERE-dependent transcriptional activity (data not presented).  
 
 
Figure 5.16 Impact of growth factor (EGF) with ERs on luciferase reporter 
activity in Ishikawa cells.  
Cells were infected with ERα (red), ERβ (blue), ERβ2 (yellow) or ERβ5 (green) and 
each with the 3X-ERE-Luc reporter. Treatment was with EGF 10
-7
M for 24hours 
before luciferase production reading. Fold difference is expressed relative to the 
vehicle-treated cell, each bar represents N=3±SEM and has been normalised to 
protein levels and compared to luciferase output following treatment in each case 
with a H2O vehicle control. 
 
The impact of EGF stimulation on ER transcriptional activity was also examined in 
control, uninfected hTERT cells as well as cells that had been infected with ERα, 
ERβ and ERβ5. All cells were infected with the 3X-ERE-tk-luc construct, incubated 
in a serum-free environment for 24 hours and then exposed to either EGF 10-7M 
alone for a further 24 hours. The cells were lysed and assayed for luciferase activity. 
Reporter activity in the control cells was greater that that observed in the Ishikawa 
Chapter 5     Alternative modes of activation 204 
cell line and overexpression of individual ER subtypes had no significant impact on 
the endogenous response although there was a trend for overexpression of ERβ to 




Figure 5.17 Impact of growth factor (EGF) with ERs on luciferase reporter 
activity in hTERT cells.  
Cells were controls (black) or infected with ERα (red), ERβ (blue), ERβ2 (yellow) or 
ERβ5 (green) and each with the 3X-ERE-Luc reporter. Treatment was with EGF     
10
-7
M for 24hours before luciferase production reading. Fold difference is expressed 
relative to the vehicle-treated cell, each bar represents N=3±SEM and has been 
normalised to protein levels and compared to luciferase output following treatment 
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5.3.7 Impact of proteasome-dependent degradation on ER intranuclear 
dynamics 
Studies examining intranuclear mobility and receptor turnover have identified an 
important role for the ubiquitin proteasome pathway in ER transcriptional activity 
(Stenoien et al., 2001b). These studies have almost exclusively focused on the impact 
of receptor degradation on ERα (Reid et al., 2003) although a recent study has 
demonstrated that the proteasome also plays a key role in activity of ERβ (Picard et 
al., 2008). To date no studies have considered the impact of receptor turnover in the 
activity of human ERβ variants. A preliminary study was therefore undertaken to 
investigate the impact of a proteasome inhibitor on E2-induced intranuclear 
dynamics of YFP-labelled ERs infected in hTERT cells. 
 
Incubation of cells with the 26S proteasome inhibitor MG132 prior to addition of E2 
altered the mobility patterns of ERα-YFP (Fig. 5.18) and ERβ-YFP (Fig. 5.20) 
proteins in hTERT cells.  In line with previous results (Chapter 3) both receptors 
were highly mobile in cells treated with DMSO but incubation with the proteasome 
inhibitor for 2 hours followed by a further 1 hour with E2 resulted in a significant 
and sustained decrease in the mobility kinetics of both receptors; ERα-YFP (Fig. 
5.19) and ERβ-YFP (Fig. 5.21) that closely mirrored that seen with E2 alone. 
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Figure 5.18 Qualitative FRAP assessment of ERα-YFP infected hTERT cells.  
Cells were treated with either a DMSO vehicle control (left hand panel) or a 
combination of MG132 10
-6
M for 180 minutes with E2 10
-8
M for 60 minutes (right 
hand panel). 
 
Figure 5.19 Quantitative analysis of intra-nuclear kinetics of ERα-YFP infected 
hTERT cells.  
Graphical depiction of the recovery rates of ERα-YFP over time into the bleached 
zone. This recovery is denoted by the point at which the YMAX is achieved. Recovery 
rates of ERα-infected cells are presented in response to MG132 10
-6
M for 180 
minutes and E2 for 60 minutes at 10
-8
M. *** (P<0.001) denotes significance in 
variation of ligand treatments compared with the DMSO vehicle control using the 
Student’s t-test (N≥8). 
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Figure 5.20 Qualitative FRAP assessment of ERβ-YFP infected hTERT cells.  
Cells were treated with either a DMSO vehicle control (left hand panel) or a 
combination of MG132 10
-6
M for 180 minutes with E2 10
-8




Figure 5.21 Quantitative analysis of intra-nuclear kinetics of ERβ-YFP infected 
hTERT cells. 
Graphical depiction of the recovery rates of ERβ-YFP over time into the bleached 
zone. This recovery is denoted by the point at which the YMAX is achieved. Recovery 
rates of ERβ-infected cells were in response to MG132 10
-6
M for 180 minutes and E2 
for 60 minutes at 10
-8
M. ** (P<0.01) denotes significance in variation of treatments 
compared with the DMSO vehicle using the Student’s t-test (N≥8). 
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It has been previously suggested that the AF-1 domain of ERβ plays an essential role 
in marking the receptor for ubiquitination and subsequent degradation in the 26S 
proteasome (Picard et al., 2008). To test the importance of the AF-1 domain in 
regulating proteasomal degradation, two ERβ splice variants, ERβ2 and ERβ5 that 
contain an intact AF-1 domain but are truncated at their C terminus compared with 
the full length ERβ receptor were assessed using MG132 and E2 as above. Using this 
treatment regime there was no significant change in the intranuclear dynamics of 
either ERβ2-YFP (data not presented) or ERβ5-YFP (Fig. 5.22, Fig 5.23) in 
comparison to the same receptors incubated with DMSO (vehicle control). The 
response of putative ERα-ERβ5 heterodimers to proteasomal regulation was 
examined using hTERT cells treated with a combination of MG132 and E2 for 180 
minutes and 60 minutes respectively. Incubation of cells with MG132 and E2 
reduced the mobility of the ERβ5-YFP in comparison to DMSO-treated control cells 
(Fig. 5.24 and 5.25), a result that was in contrast to that obtained with ERβ5-YFP 
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Figure 5.22 Qualitative FRAP assessment of ERβ5-YFP infected hTERT cells. 
Cells were treated with either a DMSO vehicle control (left hand panel) or a 
combination of MG132 10
-6
M for 180 minutes with E2 10
-8




Figure 5.23 Quantitative analysis of intra-nuclear kinetics of ERβ5-YFP infected 
hTERT cells.  
Graphical depiction of the recovery rates of ERβ5-YFP over time into the bleached 
zone. This recovery is denoted by the point at which the YMAX is achieved. Recovery 
rates of ERβ5-infected cells are presented in response to MG132 10
-6
M for 180 
minutes and E2 for 60 minutes 10
-8
M. Significance in variation of ligand treatments 
was compared with the DMSO vehicle control using the Student’s t-test (N≥8). 
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Figure 5.24 Qualitative FRAP assessment of ERβ5-YFP and ERα infected hTERT 
cells.  
Cells were treated with either a DMSO vehicle control (left hand panel) or a 
combination of MG132 10
-6
M for 180 minutes with E2 10
-8
M for 60 minutes (right 
hand panel). 
 
Figure 5.25 Quantitative analysis of intra-nuclear kinetics of ERβ5-YFP and 
untagged ERα infected hTERT cells.   
 
Graphical depiction of impact of ligand treatment on the recovery rates of ERβ5-
YFP over time back into the bleached zone. This recovery is denoted by the point at 
which the YMAX is achieved and a plateau is reached on the graph. Recovery rates of 
ERβ5-YFP and ERα-infected hTERT cells are presented in response to MG132 10
-
6
M for 180 minutes and E2 for 60 minutes at a concentration of 10
-8
M. * (P<0.05) 
and *** (P<0.001) denotes significance in variation of ligand treatments compared 
with the DMSO vehicle control as derived from the Student’s t-test (N≥8). 
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5.3.8  ER activity is regulated by proteasomal function 
 
To further investigate the relationship between the turnover of ERα and ERβ5 and 
E2-mediated transcriptional activity, luciferase assays were conducted that examined 
the effects of the MG132 proteasome inhibitor on cells infected with ERα and ERβ5 
alone or in combination. Cells infected separately with ERα and ERβ5 adenoviral 
constructs and a 3X-ERE-tk-luc reporter construct were treated with a DMSO 
vehicle control, MG132 alone, E2 alone or a combination of MG132 for 1 hour 
followed by addition of E2. Luciferase activity was measured after 24 hours and 
normalised to total protein levels (Section 2.9).   
 
In Ishikawa cells, treatment with E2 alone induced reporter gene activity in line with 
expectations based on previous studies (Chapter 4) and when cells were treated with 
MG132 alone, there was no significant change in ERE-dependent luciferase gene 
expression compared to the vehicle control suggesting that the inhibitor did not have 
any direct impact on the reporter construct (Deroo and Archer, 2002). Addition of 
MG132 had no significant impact on E2-mediated reporter gene activation in the 
control Ishikawa cells. However following increased expression of ERα or ERβ5 
alone or in combination E2-driven reporter gene activity was significantly attenuated 
by addition of MG132 (Fig. 5.26). This result suggests a role for the 26S proteasome 
in maximising ligand-dependent activation of ERs in this cell context.  
 
The impact of inhibiting proteasomal degradation of the ER on reporter gene 
activation was also investigated in the hTERT cell line. As in the Ishikawa cells 
treatment of the cells with MG132 alone matched the DMSO vehicle response. 
Surprisingly incubation of cells with MG132 did not abrogate the E2-drived 
transcriptional response in cells infected with ERα or ERβ5 alone or in combination 
(Fig. 5.27). These results are in contrast to those acquired in the Ishikawa cell line 
and may reflect a cell context dependant reliance on proteasomal function in the 
Ishikawa cells. This result also suggests that the 26S proteasome does not exclusively 
determine the optimal transcriptional response of ERs in all cell types. 




Figure 5.26 Impact of transcriptional inhibitor (MG132) with ERs on luciferase 
reporter activity in Ishikawa cells. 
Cells were infected with ERα (red), ERβ5 (green), or both ERα and ERβ5 (yellow); 





M or a combination of MG132 for 1 hour followed by E2 10
-8
M for 24 
hours before luciferase activity was measured. Fold difference is expressed relative 
to the DMSO vehicle-treated cell, each bar represents N=3±SEM and has been 
normalised to protein levels. *** (P<0.001), ** (P<0.01) and *(P<0.05) denotes 
significance in variation of ligand treatments compared with the vehicle control as 
derived from one-way ANOVA and Tukey’s post-test comparing all pairs of data sets 
(N≥8). 
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Figure 5.27 Impact of transcriptional inhibitor (MG132) with ERs on luciferase 
reporter activity in hTERT cells.  
Cells were infected with ERα (red), ERβ5 (green), or both ERα and ERβ5 (yellow) 





M and a combination of MG132 for 1 hour prior to E2 
for 24 hours before luciferase activity was measured. Fold difference is expressed 
relative to the DMSO vehicle-treated cell, each bar represents N=3±SEM and has 
been normalised to protein levels. *** (P<0.001), ** (P<0.01) and *(P<0.05) 
denotes significance in variation of ligand treatments compared with the vehicle 
control as derived from one-way ANOVA and Tukey’s post-test comparing all pairs 
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5.4 Discussion 
In order to gain an understanding of the functional role of the truncated splice variant 
ERβ5 in endometrial cells, experiments in the current chapter have investigated 
alternative ligand-independent modes of activation of receptors. Two endometrial 
cell lines were employed in order to determine the impact of EGF-mediated MAPK 
signalling on activation of ERα and ERβ5. The impact of receptor turnover on 
receptor activity was also examined with regard to ERα and ERβ5 through disruption 
of the UPP. 
 
5.4.1 The EGF family of receptors are expressed in the human 
endometrium 
Immunohistochemistry documented the expression of the different members of the 
human epidermal growth factor family of receptors (HER family) in human 
endometrium recovered during the proliferative phase of the cycle. The HER family 
of transmembrane receptor tyrosine kinases (HER 1-4) is believed to have evolved 
from a single primordial tyrosine kinase into four different cell surface receptors 
through sequential gene fusion and duplication events (Citri and Yarden, 2006). 
Human HER1 and HER4 both bind a myriad of peptide growth factors including 
heparin-binding EGF (HB-EGF), betacullin (BCL) and epiregulin (EPI) among 
others (Harris et al., 2003). The accumulation of mutations over time has rendered 
HER2 and HER3 non-autonomous and these receptors are only functional in a 
heterodimeric partnership (Klapper et al., 1999, Guy et al., 1994). 
 
Immunohistochemical analysis revealed widespread immunoreactivity for HER 1 in 
both the stromal and glandular compartment of the healthy proliferative 
premenopausal endometrial tissue. HER2 positive staining was solely localised to the 
epithelial cells. HER3 positive cells were detected in both stromal and epithelial cells 
while HER4 staining was very weak and localised to the glandular epithelium. 
Previous studies have reported cycle-dependent regulation of HERs (Ejskjaer et al., 
2005) where HER4 expression has been determined to be greatest at the early and 
late secretory phases and may account for the weak staining observed at the 
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proliferative phase in this study (Srinivasan et al., 1999, Chobotova et al., 2005). A 
recent clinical study has described the prognostic value of HER4 due to its 
upregulation in endometrial cancer tissue (Ejskjær et al., 2007) compared to 
expression in the normal premenopausal endometrium where it is speculated that 
HER4 may be behaving as an inhibitor of proliferation (Ejskjaer et al., 2005). In this 
study, protein expression of HER1 was detected in the Ishikawa adenocarcinoma 
endometrial cell line and this cell line was therefore used for further experimental 
investigation. 
 
Amongst the numerous downstream response signalling pathways induced by the 
receptor kinase activity of the HER family is the activation of MAPK pathways 
(Wells, 1999). Early mouse studies implied a role for growth factor signalling in the 
activation of ERs that was independent of oestrogenic ligands (Nelson et al., 1991, 
Ignar-Trowbridge et al., 1992). EGF-mediated activation of MAPK signalling has 
been shown to result in the rapid phosphorylation of ERα in human cell lines in vitro 
(Kato et al., 1995b, Bunone et al., 1996). This study has localised the members of the 
HER family of receptors to site-specific cells of the endometrium and indicates a 
putative alternative mechanistic model for ligand-independent activation of the ERs. 
 
Phosphorylation of the p42/p44 (ERK2/ERK1) MAPKs in an Ishikawa cell line in a 
time-dependent manner in response to EGF exposure was demonstrated. The greatest 
accumulation of phosphorylated MAPK protein was observed ten minutes after EGF 
stimulation. This effect was specifically abrogated by treatment with the ERK 
inhibitor PD98059. ERα protein containing phospho-Ser118 residues was detected 
after EGF treatment in the same cell line (YFP-tagged and endogenous receptor). As 
ERα, ERβ and ERβ splice variants and HERs are all expressed in endometrial cells, 
further studies were conducted to examine the impact of EGF on receptor function. 
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5.4.2 EGF treatment has an impact on the intranuclear dynamics of ER 
subtypes in endometrial cells in vitro 
E2-induced nuclear redistribution of the full length ER subtypes (ERα and ERβ) was 
previously described (Chapter 3). Complementary studies described in this chapter 
have shown that EGF can also induce receptor redistribution. Notably, an EGF-
dependent redistribution of the truncated ERβ5 splice variant was also demonstrated 
in the endometrial adenocarcinoma Ishikawa cell line. This impact of EGF was time-
dependent with distinct time-courses of redistribution revealed for individual ER 
subtypes. These data are the first time that a growth factor-dependent change in 
ERβ5 activity has been demonstrated.  
 
Several studies have reported that the ER proteins have phosphorylation target sites 
clustered within the AF-1 region of their N-terminal domains. These kinase directed 
consensus sites have been defined in human ERα at serine residues 104, 106, 118 and 
167 (Thomas et al., 2008, Bunone et al., 1996, Ignar-Trowbridge et al., 1996, Kato et 
al., 1995a, Joel et al., 1998a) and mouse ERβ at serine residues 16, 106 and 124 
(Cheng and Hart, 2001, Tremblay A. et al., 1999). In addition, phosphorylation 
within the AF-1 domain of mouse ERβ is reported to facilitate recruitment of the 
coactivators SRC-1 and CREB binding protein (CBP) and activation of the receptor 
(Tremblay and Giguere, 2001). Binding of these regulatory proteins has also recently 
been implicated in enabling hypoxia inducible factor HIF-1α to activate ERβ under 
hypoxic conditions in HEK293 cells (Lim et al., 2009).  
 
It has been reported that EGF-induced phosphorylation of ERα at Ser118 residue 
occurs by 15 minutes post-EGF treatment in COS-1 cells (Kato et al., 1995d). In 
agreement with this, it was observed that EGF treatment stimulated nuclear 
redistribution of ERα-GFP in MCF-7 cells within 10 minutes, with maximal 
redistribution at 60 minutes after treatment (Takahashi et al., 2005). In the current 
studies, rapid nuclear redistribution was observed after EGF incubation with each of 
the ER subtypes (ERα, ERβ and ERβ5) when this was quantified in the Ishikawa cell 
line. Cells were maintained in serum-free media to prevent stimulation by growth 
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factors or steroids in the serum and to ensure the results observed were EGF-
dependent. Subnuclear distribution into a punctate state mirrored the changes 
observed following treatment of cells infected with ERα-YFP or ERβ-YFP after they 
were exposed to E2 (Chapter 3).  
 
In this study, ERβ5-YFP in cells maintained without serum was highly mobile and 
reached maximal recovery into the bleached zone (YMAX) in ~2.6 seconds which was 
slightly faster than ERα-YFP and ERβ-YFP (4.2, 5.8 seconds respectively). Using 
FRAP analyses, it was shown that incubation of cells with EGF leads to 
reorganisation of each of the tagged ERs within 10 minutes of the start of treatment. 
In Ishikawa cells this effect was sustained at 20 and 30 minutes post-EGF treatment 
in ERβ-YFP infected cells and additionally at 60 and 90 minute timepoints in the 
ERβ5-YFP infected cells. In addition to a decrease in the recovery rate of ERβ5 
molecules back into the bleached region (ROI I), a significant change in the half-time 
(i.e. the time taken to reach 50% of the maximal recovery (YMAX) was noted from 2.6 
seconds of the unliganded ERβ5-YFP to 5.3 seconds at 20 minutes post-EGF 
incubation. These novel results reveal that EGF can have an impact on the 
intranuclear kinetics of ERβ5, a receptor subtype that does not bind E2. 
 
5.4.3 EGF treatment has an effect on the transcriptional activity of ERs 
in vitro 
In Chapter 3, a correlation between the E2-dependent nuclear redistribution pattern 
and transcriptional activity was confirmed. This observation would be in agreement 
with the expectation that the ‘punctate’ appearance reflects DNA-bound associations 
that underlie activation of the transcriptional machinery. Other studies have 
suggested that nuclear redistribution and transcriptional activity are not linked as the 
punctate foci preclude polymerase II associations (Stenoien et al., 2001a). 
 
Earlier studies have demonstrated increased activity at a consensus ERE in ERα-
transfected HeLa cells (Bunone et al., 1996b, Hafner et al., 1996) and ER positive 
BG-1 human ovarian adenocarcinoma cells (Ignar-Trowbridge et al., 1996) in 
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response to EGF treatment. Analysis of the transcriptional activity of ERs using an 
ERE-luciferase reporter gene construct  in this study revealed an increase in the 
relative luciferase activity in comparison to the vehicle control by the endogenous 
receptors in both Ishikawa and hTERT cell lines (~1.5 and ~5.4 fold induction 
respectively). While there was no significant increase in transcriptional output 
derived from overexpression of ERα, ERβ or ERβ5 in the Ishikawa cell, a trend 
towards increased luciferase activity was observed in the ERα and ERβ5-infected 
cells. It has been suggested however that the EGF-mediated activity in Ishikawa cells 
is promoter-dependent (Gehm et al., 2000) and may involve a mechanism involving 
EGF-driven ER activity at alternative promoter regions such as AP-1 sites. 
 
5.4.4 Inhibition of the 26S proteome relayed effects on the intranuclear 
dynamics of ERs in vitro in endometrial cells 
Earlier studies have implicated proteasomal-mediated degradation through the UPP 
as an important regulator of ERα transcriptional activity in rats (Nirmala and 
Thampan, 1995) and mammalian cell cultures (Nawaz and O'Malley, 2004, Priesler-
Mashek, 2002). For example, it has been demonstrated that the inhibition of UPP-
directed turnover of ERα using the proteasomal inhibitor MG132 completely 
abolishes the intranuclear mobility of ERα in a number of human cell lines. These 
studies reported ERα immobilisation at the nuclear matrix in response to MG132 
both in the absence (Stenoien et al., 2001b, Reid et al., 2003) and presence of 
oestrogenic ligands (Reid et al., 2003). Consistent with a recent publication 
(Damdimopoulos et al., 2008), there were no differences between the ERα and ERβ 
responses to MG132 treatment in hTERT cells. In the current study, MG132 
combined with E2 treatment had a significant impact in reducing the mobility of ERα 
and ERβ in hTERT cells and an increased half-time of ~5.4 seconds was determined 
for the MG132/E2 treated ERα-infected cells in comparison with the vehicle control 
cells (T1/2 = 3.6 seconds). However, complete immobilisation of the receptors was 
not observed and there appeared to be no difference between receptor dynamics in 
cells treated with E2 and those treated with a combination of MG132 and E2. This 
discrepancy from results demonstrated in other reports may stem from the MG132 
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incubation time of 3 hours which falls short of the longer exposure times used in 
other studies (ranging from 3 to 10 hours) (reviewed in Hager et al., 2004). The 
results obtained in the presence of ligand were identical to those in hTERT cells 
treated with MG132 alone (data not shown) implicating a role of the for the 26S 
proteasome irrespective of the ligand bound/unbound status of the receptor. MG132 
treatment had no impact on ERβ2 (data not shown) or ERβ5-infected hTERT cells, 
indicating that these truncated variants are not completely regulated by proteasomal-
mediated clearance. However, co-infection of ERβ-YFP and ERα resulted in the 
reduced mobility of the ERβ5-YFP molecule and is suggestive of a susceptibility of 
ERβ5 to degradation when in a heterodimeric partnership. These intriguing 
observations merit further study. 
 
5.4.5 MG132-induced disruption of the ubiquitin protease pathway had 
an effect on activation of the ERE reporter gene 
MG132 treatment retarded the mobility of ERα and ERβ in both the presence and 
absence of ligand in hTERT cells (section 5.4.4). The accumulated population of ER 
in response to disruption of the UPP has been hypothesised as a dysfunctional pool 
of receptors (Stenoien et al., 2001b) that bind to the nuclear matrix and differs from 
the canonical ligand-bound receptor that are active at chromatin sites (Picard et al., 
2008). Further work has elucidated differences in the underlying mechanisms of 
UPP-mediated degradation based upon the ligand bound/unbound status of ERα at 
the pS2 promoter region (Reid et al., 2003) and the activity of ERβ (Tateishi et al., 
2006, Picard et al., 2008). 
 
Inhibition of UPP-mediated degradation by MG132 treatment for 24 hours in 
Ishikawa cells attenuated the E2-dependent transcriptional output by ERα and ERβ at 
the ERE. In other studies MG132 treatment has been shown to impair ERα-mediated 
transcription and the AF-1 domain has been implicated as a key component in 
regulating UPP-directed proteolysis of E2-bound ERα in transfected HeLa (Lonard et 
al., 2000) and HEK293 cells (Valley et al., 2005) and of ERβ also in HEK293 cells 
(Picard et al., 2008). This N terminal domain is intact in ERβ5 and is identical to that 
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of its homologue ERβ. In contrast to the insignificant effect of MG132 exposure (3 
hour timecourse) on the dynamics of ERβ5, the results of the luciferase reporter 
assay demonstrated a significant abrogation of transcriptional activity in ERα-
positive Ishikawa cells following infection with ERβ5 alone or in combination with 
ERα. These results are suggestive of a role for proteasomal degradation in 
maintaining steady-state ER levels (including ERβ5) and facilitating ongoing ER-
mediated transcription. However, this result was cell context dependent and was not 
replicated in the hTERT cell line where the E2-driven response was sustained even in 
the presence of MG132. This discrepancy may stem from a promoter-based effect as 
it has been previously published that MG132 can impart a deleterious effect on the 
luciferase enzyme itself in some cellular contexts (Deroo and Archer, 2002). 
Furthermore, Fan et al.. (Fan et al., 2004) demonstrated increased transactivation in 
response to E2 and MG132 combined treatment in MCF-7 cells and have dismissed a 
central role for the UPP in regulating ERα function. Taken together, these 
preliminary results examining the intranuclear dynamics and the transcriptional 
response to MG132 imply a salient role for the UPP in governing optimal activity of 
the ERs in a cell context dependent manner and merit further investigation.  
 
5.4.6 Conclusions 
The results presented in this chapter have examined a ligand-independent mode of 
receptor activation and the impact of proteasomal-degradation on regulation of ERs. 
It has been demonstrated that treatment of cells with EGF has an impact on receptor 
dynamics and transcriptional activity that conforms to distinct timeframes that are 
subtype dependent. For the first time it has been revealed that ERβ5 is also a putative 
candidate for EGF-induced post-translational modifications that impact on 
intranuclear dynamics and transcriptional activity. Ubiquitination of the ER via the 
UPP appears to be of importance to the regulation of ERα, ERβ and ERβ5 
transcriptional activity in a cell context-dependent manner. The results established a 
link between the proteasome and changes on the intranuclear dynamics of the full 
length ERα and ERβ subtypes. Further studies will be required to discern the reason 
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6 Final Discussion 
The oestrogen receptors are members of a ligand-regulated superfamily of 
transcription factors that mediate pleiotrophic biological effects (Hewitt and Korach, 
2002). Receptor dependent changes in gene expression are influenced by 
conformational changes in the 3D structure of the receptors, formation of homo- or 
hetero-dimers and the resulting association with coregulators and/or basal 
transcriptional factors at specific sequences within the promoter sequences of target 
genes (Tsai and O'Malley, 1994a, Brzozowski et al., 1997, Steinmetz et al., 2001) 
(reviewed in Nilsson et al., 2001). The advent of quantitative confocal microscopy 
methods such as FRAP and FRET in parallel with the development of fluorescently 
labelled receptor proteins have enabled investigators to study of behaviour of 
receptors including ERs in the nuclei of living cells (Stenoien et al., 2001a, Stenoien 
et al., 2001b, Tamrazi et al., 2003, Damdimopoulos et al., 2008, van Royen et al., 
2009). Much of the published research on the intranuclear dynamics of ERα (Stenoien 
et al., 2000, Stenoien et al., 2001b, Reid et al., 2003) and more recently, ERβ 
(Damdimopoulos et al., 2008) has utilised constructs in transiently transfected cell 
lines. Stenoien et al. specifically reported significant variation in the levels of 
fluorescent protein expressed between transiently transfected cells and made a point 
of only using low fluorescing cells that were just sufficiently bright for use in FRAP 
analyses (Stenoien et al., 2000, Stenoien et al., 2001b). In contrast, the studies 
described in this thesis utilised cell lines into which the receptor constructs were 
introduced using adenoviral constructs. This approach allowed us to carefully titrate 
the amount of fluorescent protein in each call so that the cell was not ‘overloaded’ 
with an excess of receptor protein allowing us to have confidence that the behaviour 
of the fluorescently-tagged receptors would recapitulate that of endogenous receptors. 
 
The primary objective of the work described in this thesis was to acquire a better 
understanding of what impact steroid ligands and growth factors have on the 
intranuclear dynamics and functional activity of human oestrogen receptors and to 
identify whether differences in responses occur between the full-length ‘wild type’ 
oestrogen receptors (ERα and ERβ) both of which have an intact oestrogen-binding 
pocket and AF-2 domain at their C-terminus. Parallel investigations were also carried 
out on two splice variant isoforms of human ERβ, ERβ2 and ERβ5 both of which 
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contain an intact DNA binding domain but lack an intact ligand binding pocket 
(Leung et al., 2006). One of the key techniques used in these studies was FRAP, a 
method that measures intracellular mobility (van Royen et al., 2007). An association 
between reduced mobility, interactions with euchromatin and changes in gene 
expression has been claimed for the PR (Arnett-Mansfield et al., 2004) and 
glucocorticoid receptor (reviewed in DeFranco and Guerrero, 2000) making this an 
attractive system with which to visualise the impact of steroid ligand-dependent and 
steroid-ligand independent activation on the ER subtypes. 
 
The specific aims of the studies described were: 1) to establish and optimise methods 
for measuring the intranuclear mobility of both full length ERα and ERβ and splice 
variant isoforms of human ERβ (ERβ2 and ERβ5); 2) to determine whether ERβ5 
may play a role in oestrogen responsiveness in the normal human endometrium; 3) to 
examine alternative ligand-independent modes of activation of ER with particular 
reference to the truncated ERβ5 splice variant. 
6.1 Relationship between nuclear dynamics of ER and transcriptional 
output 
Studies on the impact of ligand binding to either ERα and/or ERβ on the intranuclear 
dynamics of both homo- and hetero-dimeric conformations of the receptors were 
carried out in the three cell lines; MDA, Ishikawa and hTERT. Infection with ERα-
YFP adenoviral constructs resulted in homogeneous distribution of the fluorescent 
receptor within the nucleus of all three cell types. This was in contrast to their 
appearance following infection with ERβ-YFP that localised into discrete subnuclear 
foci in the cells.  The predisposition of ERβ-YFP to adopt this arrangement is 
suggestive of a higher affinity of this protein for specific regions within the nucleus 
even in the absence of ligand.   
 
Addition of E2 to ERα-YFP infected cells induced a rapid redistribution into a 
‘punctate’ arrangement of distinct focal points in all the cell lines examined. This is in 
agreement with previous studies that demonstrated a significant decrease in mobility 
and redistribution of full length ERα in human cell lines in response to E2 stimulation 
and suggests this is one aspect of the cascade of events associated with ligand-
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dependent activation of the receptor (Htun et al., 1999, Stenoien et al., 2001b, 
Maruvada et al., 2003).  
 
To date, there has been limited published data on the subnuclear dynamics of ERβ 
(Damdimopoulos et al., 2008) and while ERβ shares significant homology with ERα, 
the two receptors differ in tissue distribution and functionality. Like ERα-YFP, 
treatment of ERβ-YFP infected cells with E2 resulted in a further nuclear re-
organisation of the ERβ-YFP and a decrease in the mobility of the receptor within 
these foci. The decrease in mobility observed with both ERα-YFP and ERβ-YFP in 
response to E2 stimulation is suggestive of increased residence of the ERs DNA sites 
involved in transcriptional activation where they can associate with the enzymes and 
transcription factors required for formation of the pre-initiation complex. 
 
 
Figure 6.1 Morphological comparison of fluorescently-labelled ERα and ERβ in 
MDA cells between vehicle control versus E2-stimulated conditions.  
The uniform distribution of ERα-YFP contrasts with the predisposed fluorescent foci 
of ERβ-YFP infected MDA cells. Treatment with E2 yields a punctate effect that is 
mirrored by both ER subtypes (ERα and ERβ). 
 
The pure anti-oestrogen ICI 182,780 has been widely used to abrogate E2-induced 
activity. Association with this compound induces a distinct inhibitory conformation 
that prohibits AF-1 and AF-2 activity and coactivator association and promotes ERα 
turnover (Wakeling et al., 1991, Dauvois et al., 1993b). The studies in this thesis 
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revealed differences in the intranuclear mobility of ERα-YFP and ERβ-YFP in cells 
incubated with ICI 182,780; ERα-YFP became completely immobilised whereas a 
significant decrease in the mobility of ERβ-YFP was observed without complete 
immobilisation. 
 
Binding of ERα within the nuclear matrix has been shown to result in extensive 
chromatin unfolding, an effect that can occur independently of ligand binding (Nye et 
al., 2002). The decrease in mobility of both ERα-YFP and ERβ-YFP in this study in 
response to agonist is suggestive of ER-chromatin associations that may determine 
chromatin remodelling. The prediction is that should this occur at the site of an ERE it 
would provide a receptive context for coactivator recruitment and transcriptional 
initiation. A key observation from the current study was that while ICI 182,780 
treatment resulted in the immobilisation of ERα-YFP to the DNA template and caused 
a significant reduction in the ERβ-YFP mobility suggestive of DNA binding, this was 
not associated with activation of luciferase reporter gene suggesting that the ER-ICI 
182,780 conformation does not yield activity at the chromatin. 
 
Co-expression of ERα and ERβ in many cell contexts has been shown to result the 
formation of heterodimers (Pace et al., 1997, Tremblay G.B. et al., 1999); this 
conformation is reported as being favoured over that of ERβ homodimers (Cowley et 
al., 1997). FRET studies conducted in our lab have demonstrated close proximity of 
ERα-YFP and ERβ-CFP in response to E2, PPT™ and DPN™ treatments (Karen 
Tuzi, unpublished data) consistent with formation of heterodimers following binding 
of a range of ligands. In agreement with these results, FRAP analyses revealed 
changes in mobility of ER-YFP constructs when they were co-expressed with another 
untagged full length receptor (ERα or ERβ). Surprisingly, in cells co-expressing ERα 
and ERβ-YFP, there was no change in the subnuclear dynamics of the tagged receptor 
in response to stimulation with PPT™. Based on the FRET analyses that suggested 
heterodimerisation between these two subtypes, this result could suggest a dominant 
inhibitory role for ERβ-YFP in the ERα response to PPT™. This is consistent with 
other reported studies in mouse (Lindberg et al., 2003) and human cell lines (Strom et 
al., 2004, Chang et al., 2006, Papoutsi et al., 2009). Further experimental data 
including ChIP analyses are necessary to verify that this response reflects that of the 
ERβ/α heterodimer and not ERβ homodimers. 
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Subtype-specific agonists are designed by exploiting the different conformations that 
can arise at helix 12 of the ERs (Shang, 2006). This study examined the influence of 
the signature agonist-induced conformations of ERα-selective PPT™ and ERβ-
selective DPN™ on ERα-YFP and ERβ-YFP in MDA, Ishikawa and hTERT cell 
lines. The observations and results from the FRAP analyses using PPT™ and DPN™ 
were largely consistent across each of the cell lines investigated. PPT™ specifically 
caused a significant decrease in mobility of ERα-YFP that was not observed with 
ERβ-YFP infected cells. DPN™ appeared to exhibit specificity for ERβ-YFP infected 
cells with MDA cells. 
 
In order to establish whether changes in receptor distribution and mobility were 
paralleled by changes in the transcriptional activity of the receptors the same 
combinations of receptor homo- and hetero-dimers and ligands were tested using an  
assay system in which a luciferase reporter gene was under the control of three copies 
of a consensus ERE using a number of different cell lines including those that lacked 
endogenous receptors.  Previous investigators have suggested that changes in the 
subnuclear distribution of ERs reflect transcriptional activity because they are a 
consequence of active recruitment of coactivators such as SRC-1 (Stenoien et al., 
2000). Although we detected a clear parallel between reduced mobility following 
binding of E2 to either ERα or ERβ and increased expression of the ERE-dependent 
reporter gene, the results using the ERα and ERβ selective agonists PPT™ and 
DPN™ were more variable. PPT™ selectively activated transcription at the ERE in 
ERα-YFP infected MDA cells to the same extent as E2 but this was not recapitulated 
in ERβ-YFP infected MDA cells. This result correlated with the decrease in mobility 
of the ERα-YFP infected cells being associated with transcription initiation. In 
contrast, although DPN™ is reported to have a 70X higher binding affinity for ERβ 
over ERα (Meyers et al., 2001), incubation of cells with this agonist induced changes 
in the intranuclear mobility of both ERα-YFP and ERβ-YFP homodimers and ERα-
ERβ heterodimers. However, the reduction in ERα-YFP mobility did not result in a 
demonstrable change in transcriptional activity at the luciferase-tagged ERE. 
Treatment with DPN™ induced luciferase reporter activity in ERβ-YFP infected cells 
but not in those expressing ERα-YFP. These results suggest that subnuclear dynamics 
and transcriptional output are not inherently linked. There are a number of lines of 
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evidence that are in agreement with these observations; Carroll and Brown presented 
the results of ChIP on chip arrays that demonstrated an excess of binding sites in 
comparison to the estimated numbers of ER-regulated genes, suggesting that many of 
these sites may be redundant and not involved in a productive transcription complex 
(Carroll and Brown, 2006). A previous study demonstrated that the location of bound-
ERα excluded RNA polymerase II interaction, a transcriptional factor that is 
indispensable at the transcriptional start site (Stenoien et al., 2001b). While the FRAP 
data indicate efficient ERα-YFP-DPN™ binding that results in dissociation from the 
repressive hsp90 complex and marked by a decrease in ERα-YFP mobility, this 
observation alone does not signal optimal activity at the ERE-luciferase construct. A 
third potential/possible explanation is that DPN™ binding to ERα is sufficient to 
activate non-genomic activity through MAPK signalling (Lahm et al., 2008) and this 
is not addressed by the luciferase reporter system. Further investigation of this result 
could include examination of the phosphorylation status of the ERα in response to 
DPN™ to determine if changes in subnuclear mobility could be attributable to non-
genomic signalling by the ER.  
 
The results that have been presented indicate that receptor tethering at the DNA 
inferred by the observed decrease in nuclear mobility does not always mean that the 
receptor is actively engaged in transcription and underlines the necessity of forming a 
complete gene transcriptional apparatus including ERs as part of the pre-ininitiation 
complex in association with the transcriptional start site (Fig. 6.1).  This study has 
expanded our knowledge of ER subnuclear responses to ligand, demonstrating that 
ligand binding facilitates conformational changes that drive selective ER regulation. 
While changes in mobility are indicative of association with the DNA, binding of the 
ER alone is not always sufficient to orchestrate functional output at an ERE (Fig. 6.1). 
Additional studies with ERα and ERβ-specific antagonists in the presence or absence 
of their respective agonists PPT™ and DPN™ and examination of coregulator 
assembly at the DNA may enable further characterisation of the role of the complete 
protein complex that is required for activity at the preinitiation complex. 
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Figure 6.2 Summary of relationship between mobility and luciferase reporter 
activity in the current study.  
M (Mobile, rapid recovery into ROI within ~25 seconds) 
D (Dynamic, with reduced percentage recovery compared with control cells). 
 
6.2 A role for truncated ERβ splice variants 
Alternative splicing of exons within both the human ERα and ERβ genes results in the 
generation of multiple variant isoforms of both proteins (Moore et al., 1998, Palmieri 
et al., 2002, Speirs et al., 2004). In particular, the splice variants of human ERβ 
known as ERβ2 (or ERβcx; Ogawa et al., 1998c) and ERβ5 are derived from distinct 
coding sequences in place of ‘wild type’ exon 8 that results in translation of truncated 
variants lacking an intact LBD (Poola et al., 2002, Leung et al., 2006). This lab has 
previously documented the patterns of expression of ERα, ERβ1 and ERβ2 in normal 
human endometrium (Saunders and Critchley, 2002, Critchley et al., 2002). In the 
current study these results were complemented and extended by including analysis of 
the pattern of expression of ERβ5 that documented for the first time that this isoform 
is expressed in this tissue. A number of studies have reported that ERβ2 and ERβ5 
mRNAs have increased distribution in cancer pathologies (Fujimura et al., 2001, 
Skrzypczak et al., 2004, Esslimani-Sahla et al., 2005). This lab has documented 
expression in cancers of the endometrium (Collins et al., 2009) and in collaboration 
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with other groups has reported expression in the breast (Shaaban et al., 2008) and 
colon (Wong et al., 2005). This and other observations suggests that more accurate 
therapeutic targeting could be achieved through identification of the specific subtypes 
of ER isoforms that can mediate oestrogen receptor dependent changes in gene 
expression in endometrial and other reproductive tissue carcinomas (Taylor et al., 
2010).  
 
To date, there have been no published reports documenting the subnuclear mobility of 
either ERβ2 or ERβ5 splice variants in human cell lines. By comparing the 
intranuclear dynamics and transcriptional activity of these isoforms the current study 
reemphasised the importance of having an intact LBD in order to facilitate agonist-
driven changes in nuclear distribution. The ability of ERβ2 and ERβ5 to exist in 
homodimers has been challenged with a report suggesting that their sole activity is as 
a supporting role in a heterodimer with a full-length ERβ receptor (Leung et al., 
2006). The results in this thesis found that there was no change in receptor dynamics 
or luciferase reporter activity using MDA cells (lack endogenous receptor) infected 
with either ERβ2 or ERβ5 alone when incubated with E2. This finding is in agreement 
with molecular models that show the absence of a functional ligand binding pocket in 
these variants (Leung et al., 2006). 
 
FRAP analysis conducted using MDA cells co-expressing ERβ2-YFP and ERα 
revealed a change in the mobility of ERβ2-YFP that was both E2 and ERα dependent 
consistent with the formation of a hetero-dimer where ligand binding to one partner 
was sufficient to change the activity of the complex (Li et al., 2004). This result 
concurs with a previous report that revealed a dominant inhibitory influence of ERβ2 
on ERα transactivation at ERE and AP-1 sites in breast cancer cells (Zhao et al., 
2007). Co-expression of ERβ5-YFP with ERα resulted in an ERβ5-YFP decrease in 
mobility that was not observed in cells infected with ERβ5-YFP alone. This response 
implies a functional role for ERβ5 when in partnership with the full length ERα 
subtype. Furthermore, in a response that was cell context-dependent (Ishikawa 
endometrial adenocarcinoma cell line), co-expression of ERβ5 with ERα resulted in a 
luciferase transcriptional response that exceeded the luciferase reporter output of 
either subtype infected independently. 
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The novelty of these results lies in the finding that truncated variants that lack a 
competent ligand-binding domain can either a) form an inhibitory complex that blunts 
the ERα response to E2 (by ERβ2) or b) exploit the ligand binding capacity of ERα to 
yield a greater transcriptional effort in response to E2 (ERβ5). These studies are 
consistent with a putative role for the truncated splice variants in the regulation of 
their ‘parent’ counterparts and further expansion of this area should include ChIP 
array analyses to ascertain the binding sites for these functional heterodimers.  
6.3 Influence of growth factor signalling on ER functionality 
ERs have been shown to integrate signals from extracellular stimuli such as GFs 
(Hamelers and Steenbergh, 2003, Chen et al., 2009). The effects of EGF are mediated 
via MAPK signalling that can induce phosphorylation of ERα at serine 118 within the 
N-terminal AF-1-containing domain (Kato et al., 1995c). Treatment of cells with EGF 
has been shown to determine changes in nuclear redistribution of ERα in MCF-7 cells 
with a time-frame that is distinct from E2 (Takahashi et al., 2005). Nuclear re-
patterning was recapitulated in the current study using endometrial adenocarcinoma 
cells infected with ERα-YFP, ERβ-YFP and ERβ5-YFP. The preliminary results 
provided evidence for a temporal effect of EGF in reducing the mobility of these ERs 
in cells starved of endogenous ligand as early as ten minutes after addition of EGF. 
This is the first evidence of an activation mechanism for the truncated ERβ5 isoform. 
Studies have provided evidence for phosphorylation target sites at the N-terminus of 
full length mouse ERβ (Cheng and Hart, 2001, Tremblay G.B. et al., 1999). The AF-1 
domain of ERβ5 is intact and therefore provides a putative target site for ligand-
independent activation of the variant. The novel observation of a decrease in mobility 
of ERβ5 when cells were treated with EGF may be evidence for a putative activation 
mechanism of this receptor. It has been shown that EGF treatment of HeLa cells 
resulted in large scale chromatin modifications by ERα at a defined transcriptional 
start locus (prolactin enhancer/promoter reporter construct) (Berno et al., 2008). This 
report demonstrated chromatin decondensation after treatment with EGF that was 
similar to the response induced by treatment with E2 although over a longer time-
scale (ten minutes versus thirty minutes for E2 and EGF respectively) (Berno et al., 
2008). 
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The changes in nuclear redistribution did not cause a significant increase in 
transcriptional activity although a trend towards this effect was demonstrated. 
However, this result concurs with the previous data where it was demonstrated that 
chromatin association alone is insufficient to drive high rates of transcriptional 
efficiency. This study is in its infancy and has potential to be expanded by further 
examination of the distinct temporal effects of EGF treatment and investigation of the 
effect of IGF-dependent signalling. 
 
6.4 General Conclusions 
Oestrogen receptors can play a pivotal role in changing the behaviour of different cell 
types because they can regulate gene expression through a variety of mechanisms 
including both direct and indirect interactions with DNA, some of which involve 
different transcription factors (Nilsson et al., 2001). Changes in receptor activity may 
be induced either by direct binding of steroid ligands or as result of phosphorylation 
downstream of growth factor signalling cascades. Accordingly, the present study 
sought to examine the spatio-temporal effect of ligand-induced activity at the nuclear 
level. This involved examination of how ligand influenced ER behaviour and mobility 
in the nucleus and the influences that discriminate between signature ER subtype 
responses. In summary, the results described in this thesis elucidated differential ER 
subnuclear redistribution and mobility as a characteristic that distinguishes the 
different pharmacological compounds tested. This is a corollary of the signature 
conformational changes each compound induces at Helix 12 of the ER-LBD as 
revealed using site-specific fluorescence microscopy (Tamrazi et al., 2003). It also 
demonstrated how direct (E2) and indirect (EGF) modes of activation compare in 
terms of nuclear behaviour, association with the nuclear architecture and 
transcriptional output. Using quantitative confocal imaging and analysis, this study 
revealed a dynamic portrait of selective changes in ER subtype distribution and 
mobility that were dependent on the nature of the ligand and the co-existence of other 
ER isoforms, and largely coincident with transcriptional efficacy although the precise 
physiological relevance of changes to nuclear re-patterning remain elusive. 
Furthermore, this study indicated an active role for truncated ERβ splicing variants in 
partnership with full length receptors and provided evidence for a previously unshown 
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